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Abstract	
Background	Measures	 of	 right	 ventricular	 (RV)	 structure	 and	 function	 have	 significant	 prognostic	value.	The	right	ventricle	is	currently	assessed	by	global	measures,	or	point	surrogates,	which	 are	 insensitive	 to	 regional	 and	 directional	 changes.	 We	 aim	 to	 create	 a	 high-resolution	three-dimensional	RV	model	to	improve	understanding	of	its	structural	and	functional	 determinants.	 These	 may	 be	 particularly	 of	 interest	 in	 pulmonary	hypertension	(PH),	a	condition	in	which	RV	function	and	outcome	are	strongly	linked.	
Purpose	To	 investigate	 the	 feasibility	 and	 additional	 benefit	 of	 applying	 three-dimensional	phenotyping	 and	 contemporary	 statistical	 and	 genetic	 approaches	 to	 large	 patient	populations.		
Methods	Healthy	subjects	and	 incident	PH	patients	were	prospectively	recruited.	Using	a	semi-automated	 atlas-based	 segmentation	 algorithm,	 3D	 models	 characterising	 RV	 wall	position	 and	 displacement	 were	 developed,	 validated	 and	 compared	 with	anthropometric,	 physiological	 and	 genetic	 influences.	 Statistical	 techniques	 were	adapted	from	other	high-dimensional	approaches	to	deal	with	the	problems	of	multiple-testing,	contiguity,	sparsity	and	computational	burden.	
Results	1527	healthy	 subjects	 successfully	 completed	high-resolution	3D	CMR	and	automated	segmentation.	 Of	 these,	 927	 subjects	 underwent	 next-generation	 sequencing	 of	 the	sarcomeric	gene	 titin	and	947	subjects	 completed	genotyping	of	 common	variants	 for	
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genome-wide	association	study.	405	incident	PH	patients	were	recruited,	of	whom	256	completed	 phenotyping.	 3D	modelling	 demonstrated	 significant	 reductions	 in	 sample	size	compared	to	two-dimensional	approaches.	3D	analysis	demonstrated	that	RV	basal-freewall	 function	reflects	global	 functional	 changes	most	accurately	and	 that	a	 similar	region	 in	 PH	 patients	 provides	 stronger	 survival	 prediction	 than	 all	 anthropometric,	haemodynamic	and	functional	markers.	Vascular	stiffness,	titin	truncating	variants	and	common	variants	may	also	contribute	to	changes	in	RV	structure	and	function.	
Conclusions	High-resolution	 phenotyping	 coupled	 with	 computational	 analysis	 methods	 can	improve	 insights	 into	 the	 determinants	 of	 RV	 structure	 and	 function	 in	 both	 healthy	subjects	 and	 PH	 patients.	 Large,	 population-based	 approaches	 offer	 physiological	insights	relevant	to	clinical	care	in	selected	patient	groups.	
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Glossary	of	terms	and	abbreviations	
2D	 Two	dimensional	3D	 Three	dimensional	6MWD	 Six-minute	walk	distance	6MWT	 Six-minute	walk	test	AF	 Atrial	fibrillation	ANOVA	 Analysis	of	variance	AP	 Anterior-posterior	APAH	 Associated	(with	a	primary	disease)	pulmonary	arterial	hypertension	AUC	 Area	under	the	curve	b-SSFP	 Balanced	steady	state	free	precession	BMI	 Body	mass	index	BPM	 Beats	per	minute	BSA	 Body	surface	area	C	 Caucasian	CDCV	 Common	disease,	common	variant	CF	 Compression	factor	CI	 Cardiac	index	CMR	 Cardiac	magnetic	resonance	CO	 Cardiac	output	CTEPH	 Chronic	thromboembolic	pulmonary	hypertension	DCM	 Dilated	cardiomyopathy	DHP	 Digital	heart	project	DNA	 Deoxyribonucleic	acid	DNA	 Deoxyribonucleic	acid	DPAH	 Drug-associated	pulmonary	arterial	hypertension	ECG	 Electrocardiogram	
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EDCSR	 Early-diastolic	circumferential	strain	rate	EDLSR	 Early-diastolic	longitudinal	strain	rate	EDRSR	 Early-diastolic	radial	strain	rate	ENCODE	 Encyclopedia	of	DNA	elements	FC	 Functional	class	FDR	 False	discovery	rate	FHS	 Framingham	Heart	Study	FID	 Free	induction	decay	FOV	 Field	of	view	FWER	 Familywise	error	rate	GCS	 Global	circumferential	strain	GCSR	 Global	circumferential	strain	rate	GE	 Gradient	echo	GLM	 General	linear	model	GLS	 Global	longitudinal	strain	GLSR	 Global	longitudinal	strain	rate	GRAPPA	 Generalized	auto-calibrating	partially	parallel	acquisition		GRS	 Global	radial	strain	GRSR	 Global	radial	strain	rate	GWA	 Genome	wide	association	HC	 Heteroscedasticity	consistent	HIV	 Human	immunodeficiency	virus	HPAH	 Hereditary	pulmonary	arterial	hypertension	HR	 Heart	rate	HWE	 Hardy-Weinberg	equilibrium	ICC	 Intraclass	correlation	coefficient	IQR	 Inter-quartile	range	
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JHS	 Jackson	Heart	Study	K-space	 ‘raw	data	space’	where	the	digitized	MRI	signal	data	is	stored	LA	 Left	atrium	LASSO	 Least	absolute	shrinkage	and	selection	operator	LHD	 Left	heart	disease	LV	 Left	ventricular	LVSA	 Left	ventricular	short-axis	MAF	 Minor	allele	frequency	MET	 Metabolic	equivalents	ML	 Machine	learning	MPA	 Main	pulmonary	artery	MR	 Magnetic	resonance	MRI	 Magnetic	resonance	imaging	NEX	 Number	of	excitations	NGS	 Next	generation	sequencing	NMR	 Nuclear	magnetic	resonance	NTP	 Nucleoside	triphosphate	OLS	 Ordinary	least	squares	OR	 Odds	ratio	PA	 Pulmonary	artery	PAH	 Pulmonary	arterial	hypertension	PC	 Phase-contrast	PCA	 Principal	component	analysis	PCWP	 Pulmonary	capillary	wedge	pressure	PEA	 Pulmonary	endarterectomy	PEDSR	 Peak	early	diastolic	strain	rate	PEER	 Probabilistic	estimation	of	expression	residuals	
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PET	 Positron	emission	tomography	PH	 Pulmonary	hypertension	PPHN	 Persistent	pulmonary	hypertension	of	the	newborn	PPWV	 Pulmonary	pulse	wave	velocity	PVR	 Pulmonary	vascular	resistance	PWV	 Pulse	wave	velocity	QC	 Quality	control	QQ	 Quantile-quantile	plot	RA	 Right	atrium	RF	 Radiofrequency	RFT	 Random	fields	theory	RL	 Right-left	RNA	 Ribonucleic	acid	ROI	 Region	of	interest	RPA	 Right	pulmonary	artery	RV	 Right	ventricle	RVEDP	 Right	ventricular	end-diastolic	pressure	RVEDV	 Right	ventricular	end-diastolic	volume	RVEDVI	 Indexed	right	ventricular	end-diastolic	volume	RVEF	 Right	ventricular	ejection	fraction	RVESV	 Right	ventricular	end-systolic	volume	RVESVI	 Indexed	right	ventricular	end-systolic	volume	RVM	 Right	ventricular	mass	RVSV	 Right	ventricular	stroke	volume	RVSVI	 Indexed	right	ventricular	stroke	volume	SA	 South	Asian	SAR	 Specific	absorption	rate	
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SD	 Standard	deviation	SENSE	 Sensitivity	encoding	-	parallel	imaging	method	for	accelerating	image	acquisition	SFD	 Septum-freewall	displacement	SFD-F	 Fractional	septum-freewall	displacement	SNP	 Single	nucleotide	polymorphism	SNR	 Signal	to	noise	ratio	SPC	 Supervised	principal	component	analysis	SPM-O	 Optimised	single-point	marker	SSE	 Sum	of	squared	errors	SSM	 Statistical	shape	model	TAPSE	 Tricuspid	annular	plane	systolic	excursion	TAPSE-F	 Fractional	tricuspid	annular	plane	systolic	excursion	TE	 Echo	time	–	time	between	excitation	and	echo	TFCE	 Threshold-free	cluster	enhancement	TGF	 Transforming	growth	factor	TR	 Repetition	time	–	time	between	successive	excitation	pulses	TTN(tv)	 Titin	gene	(truncating	variant)	VENC	 Velocity	encoding	WES	 Whole	exome	sequencing	WGS	 Whole	genome	sequencing	WHO	 World	Health	Organisation	
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1. Introduction	The	 aim	 of	 this	 thesis	 is	 to	 contribute	 to	 our	 understanding	 of	 how	 anthropometric,	environmental	and	genetic	determinants	influence	right	ventricular	(RV)	structure	and	function.	The	novel	contributions	are	 three-fold.	Firstly,	we	develop	a	high-resolution,	three-dimensional	 (3D)	 RV	 phenotype	 to	 improve	 diagnostic	 sensitivity	 to	 influences	with	localised	or	asymmetric	effects.	Secondly,	we	apply	robust	statistical	and	machine	learning	 (ML)	 approaches	 to	 these	 datasets	 to	 optimise	 the	 extraction	 of	 clinically	meaningful	data.	Lastly,	to	add	to	our	understanding	of	the	influence	of	genotype	on	the	right	 ventricle,	 we	 apply	 next-generation	 sequencing	 and	 genome-wide	 association	techniques	to	large	population	groups.		
The	right	ventricle	 is	an	 important	prognostic	marker	across	a	broad	range	of	cardio-pulmonary	diseases	[1-16]	as	well	as	in	healthy	subjects	[17,	18].	This	finding	appears	to	be	independent	of	modality,	with	supportive	studies	in	echocardiography	[7,	19,	20],	computed	 tomography	 [12],	nuclear	 [6,	9,	13-15]	and	magnetic	 resonance	 imaging	 [5,	11]	 and	 right	 heart	 catheterisation	 [4,	 8,	 16].	 Understanding	 the	 determinants	 of	 RV	function	is	therefore	an	important	goal.	Although	several	influences	have	already	been	identified	 [21-24],	 current	 assessment	methods	 rely	 on	 global,	 volumetric	 changes	 to	the	 ventricle	 or	 point	 surrogates	 of	 global	 properties.	 Global	measures	 insensitive	 to	localised	 or	 asymmetric	 effects,	 and	 point	 surrogates	 require	 pre-selection,	 are	 often	chosen	 for	 convenience	 rather	 than	 relevance	 and	 cannot	 provide	 a	 comprehensive	description	of	RV	physiology.	A	broad	range	of	phenotypes	including	diastolic	function	and	 the	 interaction	 with	 the	 pulmonary	 vasculature	 may	 also	 be	 significant	 in	 RV	dysfunction	 [25-29].	 In	 the	 systemic	 circulation,	 such	parameters	 have	 been	 assessed	
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and	shown	significant	prognostic	benefit	[30-33],	though	assessing	these	parameters	in	the	 right	 ventricle	 has	 been	 difficult	 because	 of	 its	 complex	 shape	 and	 contractile	pattern	[34-36].	The	pulmonary	vasculature	has	also	received	less	attention	because	of	its	 short	 length,	 tortuous	 path	 and	 thin	 wall,	 which	 make	 non-invasive	 imaging	challenging.	
Although	 several	 imaging	 methods	 have	 been	 used	 to	 estimate	 RV	 structure	 and	function	 [37],	 cardiac	 magnetic	 resonance	 imaging	 (CMR)	 has	 emerged	 as	 the	 gold	standard	as	it	is	free	from	ionising	radiation,	unrestricted	by	acoustic	windows	and	able	to	capture	the	complex	three-dimensional	RV	shape	and	contractile	pattern	[18,	21,	24].	However,	advances	 in	engineering	and	sequence	development	within	MR	have	further	improved	 allowed	 “high-resolution”	 MR	 datasets,	 accelerating	 acquisition	 [37-39].	When	 coupled	 with	 automated	 segmentation	 algorithms	 these	 protocols	 can	 provide	high-resolution	 quantitative	 ventricular	 assessment.	 These	 approaches	 have	demonstrated	 increased	 statistical	 power	 and	 new	 physiological	 insights	 in	 the	 left	ventricle	 [39],	 though	 complex	 anatomy	 and	 low	 blood-to-tissue	 contrast	 has	 limited	progress	in	the	right	ventricle.	
These	approaches	provide	large	datasets	which	require	specific	statistical	approaches	if	signal	 is	 to	be	efficiently	extracted	from	noise	within	the	data.	The	use	of	quantitative	high-resolution	phenotyping	in	neuroimaging	has	led	to	statistical	approaches	designed	to	deal	with	problems	specific	to	large	datasets,	such	as	multiple	testing,	computational	workload,	 inter-dependence	 of	 effects	 and	 also	 to	 the	 broader	 development	 of	 “Big	Data”	 and	 ML	 [40].	 These	 approaches	 have	 already	 shown	 promise	 in	 classification	problems	 in	 medicine	 though	 their	 application	 to	 cardiovascular	 medicine	 has	 been	limited	to	date	[41].	
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We	 therefore	 aim	 to	 provide	novel	 insights	 into	RV	 structure	 and	 function	by	 linking	three	fields	which	individually	contribute	towards	more	sensitive	physiological	enquiry.	Firstly,	 we	 aim	 to	 apply	 high-resolution	 CMR	 to	 the	 right	 ventricle	 to	 provide	 gold-standard	imaging.	Coupling	this	with	optimised	segmentation	algorithms	allows	a	high-resolution	quantitative	model	of	the	right	ventricle	to	be	constructed.	Secondly,	we	aim	to	use	 innovative	statistical	approaches	established	in	other	contexts	to	accelerate	the	identification	of	patterns	of	structure	and	function	within	these	data	structures.	Thirdly,	we	aim	 to	 link	 these	 to	anthropometric,	 environmental	 and	genetic	determinants	and	understand	how	these	influence	the	phenotype.		
We	apply	these	techniques	to	two	population	groups.	A	group	of	1530	healthy	subjects	free	from	known	cardiovascular	disease	and	drug-treatment	influencing	cardiovascular	function	 provides	 a	 detailed	 understanding	 of	 the	 normal	 range	 of	 phenotypes.	Although	 population-based	 imaging	 studies	 of	 the	 right	 ventricle	 have	 already	 been	undertaken	[18,	21,	24],	this	is	the	largest	cohort	of	disease-free	subjects,	imaged	using	standard	and	high-resolution	CMR.	The	normal	variation	 in	volumetry	experienced	 in	this	population	has	the	potential	to	provide	additional	information	on	the	spectrum	of	normal	 phenotypes	 relevant	 to	 clinical	 CMR.	 In	 addition,	 3D	 approaches	 allow	more	subtle	 questions	 to	 be	 addressed.	 It	 is	 well	 understood,	 for	 example,	 that	 the	 right	ventricle	 has	 an	 asymmetrical	 structure,	 and	 unequal	 contributions	 to	 function	 from	longitudinal,	 radial	 and	 circumferential	 contraction	 [25]	 but	 it	 is	 unclear	 how	 these	components	 combine	 across	 the	 ventricle	 during	 reductions	 in	 global	 function.	Characterising	the	patterns	of	dysfunction	allows	imaging	to	inform	on	the	mechanisms	of	dysfunction	in	healthy	subjects	and	to	link	this	to	the	development	of	symptoms	and	disease.	
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The	second	population	group	consists	of	patients	with	pulmonary	hypertension	(PH),	a	condition	 characterised	 by	 raised	 afterload,	 in	 which	 prognosis	 is	 strongly	 linked	 to	adaptation	in	the	right	ventricle	[5,	42].	PH	is	a	heterogeneous	disease,	characterised	by	chronic	 raised	 afterload	 to	 which	 the	 right	 ventricle	 is	 exquisitely	 sensitive	 [35].	Although	non-invasive	 imaging	 is	central	 to	assessment	and	 follow-up	 in	 this	group,	a	number	 of	 unmet	 goals	 have	 been	 identified	 in	which	 the	 resolution	 of	 imaging	may	limit	our	 further	understanding	 [37].	 It	 is	clear	 than	chronic	pressure	overload	 is	met	with	 compensatory	 increases	 in	 contraction	 and	 hypertrophy,	 followed	 invariably	 by	reduced	 function,	 failure	 and	death.	However,	 current	markers	 of	 RV	 function	 offer	 a	global	summary	by	a	single	scale.	It	is	therefore	unsurprising	that	the	optimal	threshold	for	 dysfunction	 is	 unclear	 [5,	 6,	 43].	 High-resolution	 MR	 has	 the	 opportunity	 to	understand	 the	RV	 response	 to	pressure	 in	 far	greater	detail,	with	assurance	 that	 the	organ	 in	 question	 is	 undoubtedly	 clinically	 significant.	 This	 group	 is	 combined	 with	broad	 phenotyping,	 including	 haemodynamic,	 functional	 and	 anthropometric	 data,	provide	 further	 insight	 into	 how	 RV	 function	 is	 affected	 by	 haemodynamic	derangement.	
My	contribution	to	this	work	has	been	in	the	manual	segmentation,	implementation	and	validation	of	a	healthy-volunteer	atlas	with	Dr.	Antonio	de	Marvao	and	Dr.	Wenzhe	Shi,	as	 part	 of	 the	Digital	Heart	 Project	 coordinated	 and	 organised	 by	Dr.	Declan	O’Regan	and	Professor	Stuart	Cook.	I	have	used	statistical	techniques	developed	in	neuroimaging	and	from	other	areas	of	statistics	and	ML	and	coded	these	for	use	in	our	datasets	with	the	 guidance	 of	Dr.	 Tristan	 Fletcher.	 To	 extend	 this	work	 to	 pulmonary	 hypertension	patients,	 I	 have	 developed,	 implementation	 and	 validated	 a	 separate	 atlas	 with	 Dr.	Wenzhe	Shi	and	demonstrated	an	application	of	this	in	patients	with	Dr.	Geoff	Watson.	I	
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have	 scanned	 a	 small	 number	 of	 healthy	 volunteers	 and	 recruited	 and	 scanned	 PH	patients	with	the	help	of	the	Robert	Steiner	radiography	team	and	Dr.	Declan	O’Regan.	
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2. Background		Sir	William	Harvey	may	be	credited	with	the	first	recognition	of	the	importance	of	the	right	ventricle	in	De	Motu	Cordis:	“Thus	the	right	ventricle	may	be	said	to	be	made	for	the	 sake	 of	 transmitting	 blood	 through	 the	 lungs,	 not	 for	 nourishing	 them.”	 [44,	 45].	Although	 the	 left	 ventricle	 was	 for	 many	 years	 viewed	 as	 physiologically	 more	important	subsequent	work	has	confirmed	the	right	ventricle’s	prognostic	 importance	in	 heart	 failure	 [7],	 ischaemic	 cardiomyopathy	 [9],	 myocarditis	 [10]	 and	 pulmonary	hypertension	(PH)	[5].	
2.1. The	Right	Ventricle	
2.1.1. RV	Anatomy	The	heart	is	a	hollow,	muscular	organ	of	the	middle	mediastinum	orientated	obliquely	in	 the	 chest,	 divided	 into	 four	 chambers	 by	 an	 atrioventricular	 constriction	 and	 the	inter-ventricular	 septum.	 Surface	 grooves	 indicate	 these	 divisions:	 the	 atria	 are	separated	from	the	ventricles	by	the	coronary	sulcus	(the	atrioventricular	groove)	with	a	 hiatus	 anteriorly	 at	 the	 root	 of	 the	 pulmonary	 artery	 (PA).	 The	 atria	 are	 separated	posteriorly	by	the	inter-atrial	groove	though	this	is	scarcely	marked,	and	anteriorly	this	is	hidden	by	the	pulmonary	artery	and	aorta.	The	ventricles	are	separated	posteriorly	by	the	posterior	longitudinal	sulcus	on	the	diaphragmatic	surface	and	anteriorly	by	the	anterior	longitudinal	sulcus	on	the	sternocostal	surface,	extending	from	the	base	of	the	heart	to	a	notch,	the	incisura	apices	cordis	on	the	acute	margin	of	the	heart	just	to	the	right	of	the	apex	[46].		
Internally,	 the	 right	 ventricle	 is	 delimited	 by	 the	 tricuspid	 valve	 annulus	 and	 the	pulmonary	 valve	 and	 is	 anatomically	 divided	 into	 three	 components	 [47]:	 the	 inlet	
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(tricuspid	valve,	chordae	tendinae,	papillary	muscles),	the	trabeculated	myocardium	of	the	apex	and	the	outlet	region	(infundibulum).	These	regions	are	anatomically	divided	into	anterior,	lateral	and	inferior	walls	with	basal,	mid	and	apical	sub-regions	for	each	[48].	The	internal	surface	of	the	RV	has	three	prominent	muscular	bands:	the	parietal,	septomarginal	and	moderator	bands.	The	parietal	band,	or	conal	septum,	which	runs	on	to	 the	 parietal,	 or	 freewall	 of	 the	 right	 ventricle	 makes	 up	 the	 infundibular	 septum	together	 with	 the	 crista	 supraventricularis	 [49].	 The	 septomarginal	 band	 passes	inferiorly	along	the	RV	septum	and	gives	rise	to	the	moderator	band	which	attaches	to	the	anterior	papillary	muscle.	
The	 right	 ventricle	 is	 triangular	 in	 lateral	 view	 and	 crescentic	 in	 cross-section	 [48],	though	 the	 inter-ventricular	 septum,	 which	 is	 normally	 concave	 towards	 the	 left	ventricle,	may	change	position	 in	 response	 to	volume	or	pressure	overload.	 In	adults,	the	right	ventricle	has	greater	volume	but	one	sixth	of	the	mass	of	the	left	ventricle	[50].	
	
Figure	2.1.	Cardiac	anatomy:	anterior	view	
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Figure	2.2.	Cardiac	anatomy:	posterior	view	
2.1.2. RV	myofibrillar	architecture	and	contraction	RV	 myofibrils	 are	 divided	 into	 two	 layers.	 The	 superficial,	 circumferential	 layer	 is	roughly	 parallel	 to	 the	 atrioventricular	 groove	 before	 turning	 obliquely	 towards	 the	apex	 and	 joining	 the	 superficial	 left	 ventricular	 (LV)	 fibres	 [34,	 51].	 The	 deep,	longitudinal	 fibres	 diverge	 from	 the	 apex	 to	 the	 base	 [51]	 and	 provide	 the	 most	significant	contribution	to	contraction,	though	a	“bellows”	action	of	the	radial	 freewall	and	 traction	 on	 the	 left	 ventricle	 at	 the	 points	 of	 attachment	 also	 provide	 important	contributions	[35,	48].	
2.1.3. RV	haemodynamics	The	 right	 ventricle	 is	 coupled	 to	 a	 low-impedance,	 highly-distensible	 pulmonary	vascular	system.	The	pulmonary	arteries	have	low	vascular	resistance	and	pressure,	are	highly	distensible	and	have	a	lower	peripheral	pulse	wave	reflection	coefficient	than	the	systemic	 circulation	 [35,	 51,	 52].	 RV	 pressure	 tracings	 show	 an	 early	 peak,	 a	 rapidly	declining	 pressure	 and	 the	 continuation	 of	 flow	 at	 end-systole	 due	 to	 a	 negative	
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ventricular-arterial	 gradient,	 thought	 to	 be	 caused	 by	 the	momentum	 of	 blood	 in	 the	outflow	tract	[53].	
2.1.4. RV	function	RV	 function	 is	 sensitive	 to	 changes	 in	 contractility,	 afterload	 and	 preload	 but	 also	dysrhythmias	 [54],	 interventricular	 dyssynchrony	 [55],	 LV	 dysfunction	 and	 valvular	incompetence	 [51,	54,	56-58].	Compared	 to	 the	 left	ventricle,	 the	right	ventricle	has	a	shorter	period	of	isovolumetric	relaxation,	lower	peak	passive	(E)	and	active	(A)	filling	velocities,	a	lower	E:A	ratio,	and	is	more	compliant	[59,	60].	Ventricular	filling	is	longer	and	more	sensitive	to	respiratory	variation	and	pericardial	dynamics	[48,	51,	61].	
RV	 function	 is	 particularly	 sensitive	 to	 changes	 in	 afterload	 [1,	 62],	 the	 wall	 stress	developed	in	the	right	ventricle	in	response	to	ejection.	Although	afterload	is	commonly	equated	 with	 pulmonary	 vascular	 resistance	 (PVR),	 stiffening	 of	 the	 pulmonary	vasculature	 contributes	 over	 a	 third	 of	 RV	 workload	 in	 PH	 [63],	 and	 independently	predicts	RV	dysfunction	 and	mortality	 in	pulmonary	 arterial	 hypertension	 [64-66].	 In	the	general	population	vascular	stiffness	is	associated	with	elevated	PA	pressures	but	it	is	unclear	whether	this	has	a	significant	impact	on	RV	function.	
RV	preload,	defined	as	the	degree	of	myocytic	stretching	at	end-diastole,	is	also	affected	by	 several	 factors	 including	 vascular	 volume	 status,	 ventricular	 relaxation,	 chamber	compliance,	heart	 rate,	 atrial	dynamics,	LV	 filling	and	pericardial	 constraints	 [35,	67].	Preload	 increases	 myocyte	 contractility	 by	 the	 Frank-Starling	 mechanism,	 but	 may	ultimately	 result	 in	 LV	 compression	 and	 impairment	 of	 cardiac	 output	 through	ventricular	interdependence	[1].	
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Physical	activity	is	also	a	significant	influence	on	RV	morphology,	and	is	associated	with	greater	 RV	 end-diastolic	 volume	 (RVEDV)	 and	 mass	 (RVM)	 in	 both	 the	 general	population	 [24]	 and	 in	 elite	 athletes	 [68,	 69].	 Animal	 work	 support	 a	 causative	relationship,	with	intense	exercise	leading	to	increases	in	RV	mass	[70,	71],	perhaps	due	to	relative	increases	in	pulmonary,	compared	to	systemic,	pressures	[72-75].	The	long-term	 consequences	 of	 exercise	 on	 RV	 function	 are	 less	 clear	 however,	 with	 no	 effect	identified	 in	 the	 general	 population	 [24]	 and	mixed	 results	 in	 elite	 athletes	 [69,	 76].	Understanding	 the	effect	of	exercise	on	 the	right	ventricle	 is	significant	as	 less	benign	processes	 such	 as	 pulmonary	 vascular	 disease	 and	 RV	 pathology	 may	 also	 affect	 RV	function	and	benefit	from	prompt	treatment	[77-79].	
	
2.2. Pulmonary	Hypertension	PH	 is	 a	 heterogeneous	 disease	 defined	 by	 a	 resting	mean	PA	pressure	 of	 ≥25	mmHg.	One-year	 mortality	 varies	 by	 subtype	 but	 may	 exceed	 30%	 [80],	 and	 three-year	mortality	 is	 approximately	 50%	 [81].	 Several	 disease	 processes	may	 lead	 to	 elevated	pulmonary	pressure.	Pulmonary	arterial	vasoconstriction	may	occur	due	to	imbalances	in	 vasoactive	 hormones	 such	 as	 prostacyclin,	 nitric	 oxide	 and	 endothelin-1	 [82].	Vascular	destruction	and	hypoxic	vasoconstriction	may	lead	to	PH	in	lung	disease,	and	thromboembolism	 and	 left	 heart	 failure	 may	 cause	 elevated	 pulmonary	 pressures,	through	obstruction	and	raised	left	atrial	pressure	respectively.	
2.2.1. WHO	Classification	PH	 was	 first	 classified	 in	 1973	 [82,	 83]	 and	 the	 classification	 has	 been	 updated	 by	consensus	to	its	present	five	major	groups	[84]	(Table	2.1).	
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1 Pulmonary arteria l  hypertension 
• Idiopathic	PAH	
• Heritable	PAH	
• BMPR2	
• ALK-1,	ENG,	SMAD9,	CAV1,	KCNK3	
• Unknown	
• Drug	and	toxin	induced	
• Associated	with	
• Connective	tissue	disease	
• HIV	infection	
• Portal	hypertension	
• Congenital	heart	disease	
• Schistosomiasis	
	
1’ Pulmonary veno-occlusive disease and/or pulmonary capi l lary haemangiomatosis  
1’ ’  Persistent pulmonary hypertension of  the newborn (PPHN) 
2 Pulmonary hypertension due to left  heart  disease 
• Left	ventricular	systolic	dysfunction	
• Left	ventricular	diastolic	dysfunction	
• Valvular	disease	
• Congenital/acquired	left	heart	inflow/outflow	tract	obstruction	and	congenital	cardiomyopathies	
3 Pulmonary hypertension due to lung diseases and/or hypoxia 
• Chronic	obstructive	pulmonary	disease	
• Interstitial	lung	disease	
• Other	pulmonary	diseases	with	mixed	restrictive	and	obstructive	pattern	
• Sleep-disordered	breathing	
• Alveolar	hypoventilation	disorders	
• Chronic	exposure	to	high	altitude	
• Developmental	lung	diseases	
4 Chronic thromboembolic  pulmonary hypertension (CTEPH) 
5 Pulmonary hypertension with unclear mult ifactoria l  mechanisms 
• Haematologic	disorders:	chronic	haemolytic	anaemia,	myeloproliferative	disorders,	splenectomy	
• Systemic	disorders:	sarcoidosis,	pulmonary	histiocytosis,	lymphangioleiomyomatosis	
• Systemic	disorders:	glycogen	storage	disease,	Gaucher	disease,	thyroid	disorders	
• Others:	tumoral	obstruction,	fibrosing	mediastinitis,	chronic	renal	failure,	segmental	PH	
Table	2.1.	Updated	Classification	of	PH	
Reproduced from Simonneau et a l  [84]  	
Classification	is	important	as	treatment	and	prognosis	vary	by	subtype	[85],	though	this	may	be	difficult	in	patients	with	more	than	one	disease	process	[82].	
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2.2.2. The	Right	Ventricle	in	PH	Although	PH	is	defined	by	pulmonary	pressure,	survival	is	closely	linked	to	RV	function	[5,	25,	86-88].	The	initial	response	to	raised	afterload	is	an	increase	in	RV	contractility	with	 concentric	 remodelling,	 maintaining	 normal	 cardiac	 output	 and	 right	 atrial	pressure.	The	right	ventricle	is	said	to	be	“coupled”	to	the	pulmonary	arterial	circulation	[89].	Elevated	systolic	and	diastolic	RV	pressures	stretch	 the	ventricular	wall,	 causing	adaptive	 hypertrophy,	 protein	 synthesis	 and	 the	 addition	 of	 sarcomeres	 to	 the	cardiomyocyte	[90].	However,	with	time	the	RV	decompensates	and	contractility	fails	to	increase,	 or	 decreases	 with	 further	 increases	 in	 afterload.	 The	 precise	 cause	 of	ventricular	 decompensation	 is	 unclear	 though	 an	 imbalance	 in	 oxygen	 demand	 and	supply,	 causing	 myocytic	 and	 extracellular	 changes,	 has	 been	 implicated	 [90].	 RV	dilatation	 follows,	 increasing	 wall	 tension	 and	 myocardial	 oxygen	 demand	 while	decreasing	 RV	 perfusion,	 further	 impairing	 RV	 function.	 Increasing	 sympathetic	activation	 [91,	 92],	 oxidative	 and	 nitrosative	 stress,	 activation	 of	 the	 immune	 system	and	apoptosis	[90]	may	all	have	a	role	in	deteriorating	function.	Progressive	ventricular	dilatation	 causes	 tricuspid	 regurgitation	 adding	 volume-	 to	 pressure-overload,	 which	compounds	dilatation	and	further	increases	wall	tension.	
2.2.3. Imaging	in	PH	Although	right	heart	catheterisation	is	widely	used	for	haemodynamic	assessment,	it	is	an	 invasive	 procedure	 requiring	 appropriate	 expertise,	 with	 a	 small	 but	 recognised	morbidity	and	mortality	[93].	The	information	gathered	from	right	heart	catheterisation	may	not	influence	non-invasive	assessments	[94]	and	may	not	be	accurate	[95-97].	
Non-invasive	imaging	is	increasingly	important	in	the	diagnosis	and	management	of	PH	[37],	and	is	able	to	assess	the	pulmonary	vasculature	and	left	ventricle	simultaneously.	
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Echocardiography,	 computed	 tomography	 (CT),	 positron-emission	 tomography	 (PET)	and	CMR	have	 all	made	 significant	 contributions	 to	PH	management	 [98-103]	 though	freedom	from	acoustic	windows,	lack	of	ionisation	radiation	and	high	spatial	resolution	have	made	CMR	the	modality	of	choice	 [37,	38,	102,	104-106].	Changes	 in	ventricular	volume	as	measured	by	CMR	precede	clinical	signs	in	the	detection	of	right	heart	failure	[5,	103]	and	more	subtle	effects	may	be	detected	if	the	effects	of	age,	sex	and	race	are	accounted	 for	 [21,	 107].	 CMR’s	 high	 spatial	 resolution	 allows	 the	 3D	 structure	 of	 the	right	ventricle	to	be	appreciated	though	these	benefits	have	thus	far	only	translated	into	improved	reproducibility	of	global	volumetric	measures	[104].		
Assessment	of	RV	function	is	challenging	because	of	the	complex	geometry	and	motion	of	 the	 right	ventricle	 [34,	51].	Two	main	approaches	have	 therefore	been	 taken.	Most	commonly,	RV	function	is	measured	by	ejection	fraction	(RVEF),	though	assessment	 is	time-consuming,	has	higher	inter-observer	reproducibility	than	the	measurement	of	LV	ejection	 fraction	 and	 provides	 a	 global	 summary	 insensitive	 to	 regional	 effects.	Nonetheless	 RVEF	 has	 prognostic	 value	 before	 and	 during	 treatment	 of	 PH	 [5,	 108].	Alternatively	 RV	 function	 may	 be	 assessed	 by	 regional	 measures,	 most	 commonly	targeting	 the	 contributions	 of	 longitudinal	 and	 transverse	 motion	 since	 these	 are	thought	 to	 predominate	 [35].	 Tricuspid	 annular	 plane	 systolic	 excursion	 (TAPSE)	measures	 longitudinal	 function,	 which	 is	 the	 largest	 contributor	 to	 RV	 function	 in	normal	 subjects	 [109],	 though	 TAPSE	may	 be	 unreliable	 in	 the	 detection	 of	mild	 and	moderate	RV	dysfunction	[110],	in	specific	patient	groups	[111]	and	in	less	experienced	operators	 [112].	 Markers	 of	 transverse	 function	 have	 also	 been	 developed	 [26],	 and	may	 be	 more	 sensitive	 to	 early	 dysfunction,	 but	 are	 highly	 load	 dependent	 [113].	Regional	 surrogates	 of	 global	 function	 are	 problematic	 as	 some	 regions	 are	 easy	 to	
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measure,	 some	are	strongly	associated	with	global	 function	and	some	are	sensitive	 to	global	 dysfunction,	 but	 these	 three	 areas	 do	 not	 necessarily	 coincide	 [26]	 and	 may	change	 in	 disease	 [114].	 Furthermore,	 even	 in	 the	 normal	 right	 ventricle,	markers	 of	function	 show	 regional	 variation	 suggesting	 that	 single	 measures	 are	 unlikely	 to	provide	a	comprehensive	functional	assessment	[115].	
2.2.4. Further	challenges	in	imaging	the	cardiopulmonary	unit	in	PH	Although	imaging	is	seen	as	an	integral	part	of	the	assessment	of	both	treatment	naïve	PH	 patients	 and	 those	 in	 follow-up,	 several	 unmet	 needs	 have	 been	 identified	 [37].	These	 include	the	need	for	better	 indices	of	RV	contractility	and	the	development	and	validation	 of	 simple	 and	 reproducible	 imaging-based	 prediction	 scores	 in	 pulmonary	arterial	hypertension	(PAH).	We	suggest	that	novel	imaging	methods	may	be	beneficial	to	achieving	these	goals.		
2.3. Genetics,	genotyping	and	sequencing	The	 idea	 of	 heredity	 dates	 from	 Hippocrates	 and	 Aristotle	 in	 the	 fourth	 century	 BC	suggesting	 that	material	 from	 throughout	 the	body	 is	 passed	on	 to	 govern	 superficial	characteristics	in	combination	with	a	“fixed	essence”	characteristic	of	individual	species	[116].	During	the	eighteenth	century	the	increasing	emphasis	on	taxonomy	led	Charles	Darwin	 in	 animals,	 and	 Linnaeus	 in	 plants,	 to	 suggest	 that	 beneficial	 traits	 could	 be	passed	 on	 to	 future	 generations	 [117].	 From	 here,	 Gregor	 Mendel	 first	 described	“dominant”	and	“recessive”	traits	[118]	and	Friedrich	Miescher	in	1871	first	suggested	the	 substrate	 for	 this	process:	 a	phosphorus-rich	 component	 from	 leukocyte-nuclei	 in	pus,	which	he	named	“nuclein”,	later	renamed	nuclei	acid.	
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Mendel’s	 findings	were	 followed	 by	 Darwin	who	 discussed	many	 aspects	 of	 heredity	including	sexual	selection,	race	and	the	implications	of	evolution	for	society.	Galton	and	Karl	 Pearson	 attempted	 to	 build	 statistical	 models	 of	 heredity	 but	 the	 underlying	molecular	methods	 remained	 unclear	 until	 1944,	when	 Avery,	MacLeod	 and	McCarty	showed	 that	 deoxyribonucleic	 acid	 (DNA)	 was	 the	 carrier	 molecule	 for	 genetic	information.	 In	 1953	 James	Watson	 and	 Francis	 Crick	 proposed	 the	 structure	 of	 this	molecule,	 the	 double-helix.	 Genome	 sequencing	 followed,	 first	 of	 the	 fruit	 fly	 in	 1999	and	published	in	2003	[119]	and	latterly	of	the	human	genome.	By	26th	June	2003	this	too	was	sequenced,	with	the	“race”	between	the	publicly	funded	Human	Genome	Project	and	the	privately	owned	Celera	ending	in	a	tie	[120].	
DNA	is	a	polymer	of	nucleotides	each	consisting	of	deoxyribose,	a	 five-carbon	sugar,	a	nitrogen-containing	 base	 and	 a	 phosphate	 group.	 Four	 types	 of	 nucleotides	 exist,	differing	 only	 in	 the	 nitrogenous	 base	 attached:	 adenine	 (A)	 and	 guanine	 (G),	collectively	known	as	purines,	and	cytosine	(C)	and	thymine	(T),	known	as	pyrimidines.	The	 deoxyribose	 sugar	 forms	 the	 backbone	 of	 the	 DNA	 molecule	 with	 a	 phosphate	group	attached	at	the	5’	carbon,	which	links	to	the	3’	carbon	of	the	next	nucleotide.	Each	nitrogenous	 base	 attaches	 at	 the	 1’	 carbon	 in	 the	 deoxyribose	 chain.	 DNA	macrostructure	consists	of	two	paired	helices	in	which	bases	form	particular	pairings:	adenine	with	thymine	and	guanine	with	cytosine.	The	two	polynucleotide	chains	run	in	opposite	 directions	with	 each	 end	 of	 the	 DNA	molecule	 ending	 in	 a	 3’	 end	 (hydroxyl	group)	 from	 one	 strand	 and	 a	 5’	 end	 (phosphate	 group)	 from	 the	 other	 strand.	 Each	sequence	 of	 three	 nucleotides	 (a	 “codon”)	 provides	 a	 coding	 language	with	 43,	 or	 64,	possible	codons.	61	of	these	permutations	code	for	the	20	amino	acids	used	in	protein	synthesis	and	three	codons	cause	protein	synthesis	to	be	stopped	(“stop	codons”).	It	is	
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unclear	how	many	of	the	3	x	109	bases	are	important	in	human	biology,	with	estimates	varying	from	1-1.5%	to	80.4%	[121,	122].	Part	of	this	difficulty	relates	to	a	conceptual	change	in	the	definition	of	a	gene.	Wilhelm	Johannsen	in	1909,	based	on	Mendel’s	work,	is	attributed	with	the	first	use	of	the	word	“gene”	using	it	to	convey	the	idea	of	a	distinct	locus	“in	unique,	separate	and	thereby	independent	ways	[by	which]	many	characteristics	
of	the	organisms	are	specified”	[123].	Beadle	and	Tatum’s	discovery	that	gene	mutations	could	 lead	 to	 defects	 in	metabolic	 pathways	perpetuated	 the	 “one	 gene,	 one	 enzyme”	view,	which	later	became	“one	gene,	one	polypeptide”	[124,	125].	The	elucidation	of	the	3D	 structure	 of	 DNA	 and	 a	 fuller	 understanding	 of	 the	molecular	 processes	 between	nucleic	acid	to	protein	followed	[126,	127].	This	view	was	finally	broadened	by	cloning	and	 sequencing	 techniques	 of	 the	 1970s	which	 led	 to	 a	 huge	 amount	 of	 information	about	the	regulation	and	organisation	of	expression.	The	definition	of	a	gene	alluded	to	these	findings:	“a	DNA	segment	that	contributes	to	phenotype/function.	In	the	absence	of	
demonstrated	 function	 a	 gene	 may	 be	 characterised	 by	 sequence,	 transcription	 or	
homology”	[128].	Perhaps	the	largest	shift	in	our	approach	has	come	most	recently	with	the	Encyclopaedia	of	DNA	Elements	(ENCODE)	project	[129].	Here,	in	93%	of	the	bases	studied,	 80.4%	 were	 found	 to	 be	 involved	 in	 a	 biochemical	 RNA	 or	 chromatin-associated	event	[130].	The	ENCODE	consortium	has	made	several	new	contributions	to	the	understanding	of	genomic	activity	which	are	reviewed	elsewhere	[125],	but	include	the	 observations	 that	 regulation	 is	 more	 dispersed,	 that	 non-coding	 RNA	 genes	 are	more	 prevalent	 and	 that	 non-genic	 regions	 are	more	 conserved.	 These	 challenge	 our	current	views	on	what	constitutes	a	gene.		
In	 light	 of	 this	 change	 in	 perspective,	 Gerstein	 et	 al	 suggest	 that	 a	 gene	 should	 be	defined	by	three	aspects	[125].	Firstly,	it	should	be	a	genomic	sequence	of	either	DNA	or	
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RNA,	which	codes	for	a	functional	product	molecule	–	either	protein	or	RNA.	Secondly,	when	there	are	several	functional	products	sharing	overlapping	regions,	the	gene	is	the	
union	of	all	 the	overlapping	genomic	 sequences	 coding	 for	 them;	and	 thirdly,	 that	 the	union	is	coherent,	 that	 is,	 that	 it	 is	done	separately	for	final	protein	and	RNA	products	before	summation.	From	this,	they	offer	the	following	definition	of	a	gene:	“the	gene	is	a	
union	of	genomic	sequences	encoding	a	coherent	set	of	potentially	overlapping	functional	
products”	[125].	
The	 influence	 of	 genetic	 variants	 in	 the	 right	 ventricle	 is	 an	 unachieved,	 though	desirable	goal	given	the	prognostic	importance	of	RV	function	[5,	67,	131,	132]	and	the	evidence	 that	 cardiac	 phenotypes	 are	 highly	 heritable	 [133-135].	 Two	 investigative	approaches	have	been	suggested	which	address	this	question	differently.	
The	 “common	 disease,	 common	 variant”	 (CDCV)	 hypothesis	 suggests	 that	 disease	 is	caused	 by	 multiple	 common	 variants	 (>5%	 frequency	 in	 the	 population)	 which	individually	have	low	penetrance1	and	negligible	effects,	but	together	have	significantly	affect	the	phenotype	[136,	137].	The	CDCV	hypothesis	supports	the	use	of	genome-wide	association	(GWA)	studies,	 in	which	fast,	 low-cost	genotyping	allows	large	numbers	of	common	variants	to	be	sequenced	across	the	genome	with	the	aim	of	identifying	single-nucleotide	 polymorphisms	 (SNPs)	 associated	with	 complex	 disease.	 GWA	 studies	 use	linkage	disequilibrium,	the	non-random	association	of	alleles	at	differing	loci,	to	identify	common	 variants	 that	 influence	 complex	 medical	 traits.	 Although	 the	 number	 of	published	GWA	studies	has	steadily	 increased	(Error!	Reference	source	not	found.),	producing	a	large	number	of	new	loci	associated	with	cardiovascular	disease	[138],	the	
																																																								1Defined	as	the	probability	that	a	carrier	of	the	variant	expresses	the	disease.		
39	
common	 alleles	 identified	 account	 for	 only	 a	 small	 fraction	 of	 the	 total	 heritability	 of	these	disorders,	known	as	the	“missing	heritability”	problem	[139-144].	Several	reasons	have	been	suggested	to	explain	this	[136].	It	may	be	that	many	common	variants	exist	with	only	very	small	effects,	or	that	less	common	variation	(<5%	frequency),	epigenetic	and	 shared	 environmental	 effects	 are	 important.	 Even	 so,	 the	 attributable	 risk	 of	 the	identified	 common	 alleles	 to	 the	 population	 is	 still	 high	 simply	 because	 they	 are	common	[136].		
	
Figure	2.3.	Number	of	published	genome-wide	association	studies	
From National Human Genome Research Institute [138] 	
Missing	heritability	in	complex	disease	may	be	due	to	rare	variants	(≤0.01	minor	allele	frequency)	with	relatively	large	effects.	This	“common	disease,	rare	variant”	hypothesis	undoubtedly	 occurs	 in	 hypertrophic	 cardiomyopathy	 [145,	 146]	 and	 in	 other	cardiovascular	 phenomena	 such	 as	 syndromes	 of	 high-density	 lipoprotein	 deficiency	
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[147-149].	 However,	 rare	 variants	 are	 unlikely	 to	 solve	 all	 of	 the	missing	 heritability	problem	[136].	
DNA	sequencing	technology	is	less	than	fifty	years	old	but	has	influenced	a	wide	range	of	 sciences	 including	 archaeology,	 genetics,	 forensics	 and	 medicine	 [150].	 Four	categories	 of	methods	 can	 be	 identified:	 the	 Sanger	method	 and	 variants,	 the	Maxam	and	 Gilbert	 method	 and	 chemical	 variants,	 real-time	 detection	 of	 released	pyrophosphate	 (PPi)	and	single-molecule	sequencing	with	exonuclease.	More	recently	“next	 generation	 sequencing”	 (NGS)	methods	 have	 predominated.	 Sanger	 sequencing	and	NGS	are	most	relevant	to	current	methods	and	so	are	reviewed	here,	though	several	thorough	reviews	exist	of	all	techniques	[150,	151].	
Since	 development	 in	 the	 1970s,	 methods	 based	 on	 enzymatic	 polymerisation	developed	 by	 Sanger	 and	 Coulson	 have	 been	 central	 to	 DNA	 sequencing	 [152,	 153].	Sanger	 sequencing,	 also	 known	 as	 the	 “chain-termination”	 or	 “dideoxynucleotide”	method,	has	more	recently	been	superseded	by	NGS	for	large-scale,	automated	genome	analysis	but	remains	an	important	method	for	smaller-scale	projects,	validation	of	NGS	results	and	for	sequencing	long,	contiguous	DNA	sequence	reads.	
Sanger	 sequencing	 copies	 a	 single-stranded	 DNA	 template	 and	 requires	 DNA	 primer,	DNA	polymerase,	 normal	 deoxynucleotidetriphosphates	 (dNTPs)	 and	modified,	 chain-terminating,	di-deoxynucleotidetriphosphates	(ddNTPs)	to	achieve	this.	dNTPs	are	the	building	 blocks	 for	 replication	 and,	 unlike	 ddNTPs,	 have	 a	 hydroxyl	 group	 at	 the	 3’-terminal	 end,	 which	 forms	 a	 phosphodiester	 bond	 between	 nucleotides	 allowing	 the	chain	 to	 continue.	 ddNTPs	 lack	 a	 3’	 hydroxyl	 group	 halting	DNA	 polymerase	 activity.	The	DNA	sample	 is	divided	 into	 four	separate	sequencing	reactions	each	with	all	 four	types	of	dNTP	 (dATP,	dCTP,	dGTP	and	dTTP)	and	one,	 terminating,	 type	of	ddNTP	as	
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well	 as	 the	DNA	polymerase	 and	primer.	 In	 each	 reaction,	 replication	will	 continue	 if	dNTPs	 are	 included,	 or	 terminate	 if	 the	 ddNTP	 is	 included.	 Correctly	 balanced,	 the	competition	 between	 chain-extending	 (dNTP)	 and	 chain-terminating	 (ddNTP)	fragments	produces	a	range	of	nested	 fragment	 lengths	 indicating	the	positions	of	 the	ddNTP	in	the	sequence.	These	positions	can	then	be	 identified	by	heat-denaturing	the	fragments,	 high-resolution	 gel	 electrophoresis	 and	 automated	 reading.	 Since	 the	original	 publication	 of	 this	 method,	 Sanger	 sequencing	 has	 seen	 improvements	 in	fluorescence	 detection	 [154,	 155],	 enzymes	 [156,	 157],	 fluorescent	 dyes	 [158-160],	dynamic-coating	polymers	[161-165]	and	capillary	array	electrophoresis	[166]	though	the	underlying	method	remains	largely	unchanged.	
Challenges	of	the	Sanger	method	include	poor	quality	in	the	initial	bases	due	to	primer	binding	and	after	700-900	bases	as	single-base	pair	differences	in	length	are	difficult	to	resolve.	 Base-pair	 calling	 software	may	 provide	 estimates	 of	 quality	 helping	 to	 guard	against	this.		
First	published	 in	2005	[167],	NGS	has	allowed	much	more	rapid	sequencing	at	much	reduced	costs	allowing	genetic	questions	of	a	larger	scale	to	be	tackled	[168].	Although	considerable	 challenges	 remain	 in	 processing,	 analysing	 and	 interpreting	 the	 results,	the	 benefits	 of	NGS	 in	 healthcare	 [169,	 170]	 and	 specifically	 in	 cardiology	 [171,	 172]	have	been	highlighted.	
NGS	 involves	 template	 preparation,	 sequencing	 and	 imaging	 and	 data	 analysis	 [151].	The	 Illumina	 workflow	 is	 used	 as	 an	 example	 here.	 Template	 preparation	 aims	 to	produce	 a	 representative,	 non-biased	 source	 of	 nucleic	 acids	 from	 the	 extracted	 and	purified	 DNA	 [151].	 The	 DNA	 to	 be	 sequenced	 is	 fragmented	 and	 tagged	with	 short,	synthesized	 double-stranded	 DNA	 molecules,	 “adapters”,	 at	 both	 ends.	 Once	 the	
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adapters	have	been	 ligated,	additional	short	sections	of	DNA	are	added	 to	 the	ends	of	the	DNA.	These	include	“primers”,	which	are	short	sequences	which	serve	as	initiation	points	 for	DNA	replication,	and	regions	which	are	complementary	to	 the	binding	sites	on	the	surface	on	which	sequencing	will	be	based,	the	“flow	cell”.	Primers	are	necessary	as	 the	 DNA	 polymerases	 used	 in	 sequencing	 can	 only	 extend	 existing	 DNA,	 it	 cannot	initiate	a	complementary	strand.	The	complementary	sequences	allow	the	sequence	to	now	bind	to	the	flow	cell,	which	is	a	glass	surface	with	lanes.	Each	lane	is	a	lawn	coated	with	 two-types	 of	 oligonucleotides.	 DNA	 strands	 now	 bind	 to	 the	 first	 type	 of	oligonucleotides	 on	 the	 surface	 of	 a	 flow	 cell	 (“clustering”).	 The	 flow-cell	oligonucleotides	 are	 complementary	 to	 the	 adapter	 on	 one	 of	 the	 DNA	 strands.	 DNA	polymerase	 then	 creates	 a	 complementary	 strand	 to	 the	 hybridised	 fragment,	 after	which	the	double-stranded	molecule	 is	denatured	and	the	original	template	 is	washed	away.	 The	 strands	 are	 then	 amplified	 by	 bridge	 amplification,	 a	 process	 in	which	 the	strand	folds	over	and	the	adapter	region	on	the	other	end	of	the	strand	hybridises	to	a	second	 type	 of	 oligonucleotide	 on	 the	 flow-cell.	 Polymerises	 now	 generate	 the	complementary	 strand,	after	which	 the	 two	strands,	 still	 tethered	 to	 the	 flow-cell,	 are	de-natured.	This	process	is	then	repeated	many	times,	and	for	all	fragments	attached	to	the	 flow-cell,	 clonally	amplifying	 the	 strand.	The	 reverse	 strands	are	 then	washed	off,	leaving	only	a	large	number	of	forward-strands	attached	to	the	flow-cell	for	sequencing.		
Sequencing	 starts	 with	 the	 attachment	 of	 a	 primer	 to	 the	 strands,	 after	 which	fluorescently-labelled	 nucleotides	 are	 allowed	 to	 bind	 to	 the	 strand	 and	 will	 attach	based	on	 their	 fit	with	 the	complementary	strand.	Each	base	has	a	 terminator	so	 that	only	 one	 base	 is	 added.	 The	 successful	 binding	 of	 a	 nucleotide	 can	 be	 tracked	 by	 the	wavelength	of	the	fluorescent	signal	generated	in	response	to	an	external	light	source,	
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after	 which	 the	 fluorophore	 “label”	 is	 cleaved	 and	 the	 process	 repeated,	 adding	additional	nucleotides.	The	process	is	performed	in	all	the	identical	strands	in	a	cluster	resulting	in	a	very	large	number	of	simultaneous	reads.	This	process	is	then	sequenced	from	the	other	end	of	the	strand	and	the	sequence	fragments	aligned	with	the	reference	genome	 to	 identify	 variants,	 which	 would	 typically	 be	 then	 confirmed	 using	 Sanger	sequencing	[168].	
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Figure	2.4.	Next-generation	sequencing	workflow	
Sample preparation involves extraction, purification and denaturation of the DNA from the sample to be 
sequenced. Adapters, primers and sequences which are complementary to the flow cell oligonucleotides are 
added. Cluster generation: DNA are then amplified (“clustering”) attached to the flow cell (1). Clusters are 
generated by: (1) Attaching to oligonucleotide sequences on the flow cell, before a complementary strand is 
generated by DNA polymerase (3). The double-strand is then denatured and the original strand is detached (4) 
and washed away. The new strand then folds over and attaches to the second oligonucleotide type (5) and a 
DNA polymerase makes a complementary strand (“bridge amplification”). This results in two strands tethered to 
the flow cell (6). This process is repeated across the flow cell (7) many times before the reverse strands are 
cleaved and washed away (8). Sequencing by synthesis reads the strands by adding a primer and fluorescently-
tagged nucleotides which compete for the binding site based on the complementary strand nucleotide. The 
nucleotide which fits can be determined by reading the wavelength of the fluorescent signal produced in 
response to an external light source. This process is completed in cycles to read successive nucleotides from a 
large number of strands, first for forward and then backward read strands. Data analysis: sequences are 
aggregated across forwards and backwards reads and compared to a reference sequence for placement. Reads 
are sufficiently long for location to be apparent allowing the original sequence to be deduced and variants 
identified. 	
NGS	diagnostics	have	already	demonstrated	cost	savings	in	sequencing	the	BRCA1	and	BRCA2	 genes	 associated	 with	 breast	 cancer	 [173]	 and	 it	 has	 been	 suggested	 that	
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genetically	 heterogeneous	 conditions,	 including	 cardiomyopathies,	 may	 particularly	benefit	from	the	comprehensive,	lower-cost	approach	that	NGS	provides	[168].	
2.3.1. Approaches	to	genetic	studies	Candidate	gene	studies	have	been	a	popular	method	of	demonstrating	the	importance	of	a	gene	variant	with	disease.	Candidate	genes	are	 selected	based	on	 their	 relevance	 to	the	disease	mechanism	under	 investigation	[174]	and	selecting	polymorphisms	with	a	functional	 consequence	 either	 by	 affecting	 the	 protein	 product	 or	 be	 affecting	 gene	regulation	 [174,	 175].	 Finally	 the	 association	 of	 the	 variant	 with	 disease	 status	 is	assessed	in	cases	and	control	subjects.	This	approach	is	cheap	and	quick	to	perform,	has	had	 several	 successes	 in	 cardiovascular	medicine	 [176,	 177]	 and	 is	 a	 clinically	 useful	approach	 as	 it	 describes	 a	 diagnostic	 marker	 which	 may	 benefit	 personalised	approaches	based	on	genotype	[178].	
Based	 on	 observation	 of	 others	 [179],	Morgan	 first	 suggested	 that	 the	 inheritance	 of	traits	 was	 connected	 [180]	 and	 that	 this	 might	 be	 due	 to	 proximity	 on	 the	 same	chromosome	 [181].	 From	 this,	 Sturtevant	 developed	 linkage	 maps	 connecting	 the	distance	between	genes	with	the	chances	of	genetic	recombination	by	meiosis	[182]	and	linkage	analysis	of	pedigrees	which	allow	the	probability	of	seeing	two	markers	(either	phenotypic	 or	 genotypic)	 co-segregate	 purely	 by	 chance	 to	 be	 calculated	 [183].	 This	allows	phenotypic	markers	to	be	related	to	areas	of	the	genome.	
Linkage	studies	have	proved	most	successful	single-gene	disorders	(e.g.	cystic	fibrosis,	Huntingdon’s	 disease).	 In	 complex	 diseases,	 it	 may	 be	 difficult	 to	 narrow	 to	 a	 single	gene.	 Association	 studies	 have	 been	 used	 in	 this	 context,	 where	 the	 association	 of	 a	
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specific	 genetic	 variant	 with	 a	 disease	 has	 been	 examined,	 though	 this	 requires	knowledge	of	candidate	genes	and	therefore	the	underlying	biology	[184].		
Genome	 wide	 association	 (GWA)	 studies	 allow	 genome-wide	 investigation	 without	prior	hypothesis	facilitated	by	advances	in	sequencing	technology.	GWA	studies	assess	the	associations	between	several	hundreds	of	thousands	of	genetic	loci	across	the	whole	genome	 taken	 from	 cases	 and	 suitable	 controls	 to	 understand	 the	 genetic	 variants	associated	with	common	diseases.	GWA	studies	are	most	commonly	case-control	with	the	following	structure:	
1. Recruitment	of	a	large	number	(>1000)	of	patients	and	suitable	controls	2. DNA	 is	 isolated	 and	 purified,	 and	 a	 large	 number	 (typically	 >106)	 SNPs	throughout	the	genome	are	sequenced	[185]	3. Statistical	comparison	of	the	difference	in	the	allele	frequency	between	cases	and	the	controls,	reported	by	odds	ratio	with	chi-squared	significance	[186]	4. Correction	for	multiple	testing	5. Replication	of	the	associations	identified	in	an	independent	population	sample		
The	GWA	approach	provides	a	rapid	and	unbiased	assessment	of	associations,	unreliant	on	knowledge	of	mechanisms	or	disease	pedigrees.	Responsible	genes	can	be	identified	from	 significantly	 associated	 loci.	 This	 approach	 brings	 difficulties	 in	 controlling	 for	multiple	testing,	expense,	a	well-annotated	genome	and	the	need	for	a	large	number	of	subjects	 to	detect	small	effects	 [187].	Despite	 this,	GWA	studies	have	 identified	 loci	 in	diabetes	[188-195],	coronary	heart	disease	[196-201],	atrial	 fibrillation	[202-204]	and	cardiomyopathy	 [205,	 206],	 though	 statistical	methods	 are	 still	 in	 development	 [207,	208].	
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A	further	approach	to	genetic	studies	is	whole-exome	sequencing	(WES).	Although	the	human	genome	 comprises	 approximately	3	 x	109	bases,	 only	3	 x	107	 (1%,	30Mb)	 are	coding	sequences.	It	is	estimated	that	85%	of	disease-causing	mutations	originate	from	coding	and	functional	regions	of	the	genome	[209,	210],	supporting	the	use	of	WES.	The	first	published	 report	of	WES	was	 in	2009	 [211]	and	by	2014	more	 than	150	articles	had	 been	 published	 using	 WES	 for	 gene	 discovery	 [212].	 It	 is	 suggested	 that	 whole	genome	 sequencing	 (WGS)	 may	 improve	 on	 variant	 detection	 (approximately	 3%	 of	coding	variants	that	were	detected	by	WGS	were	not	detected	by	WES)	but	given	that	only	 1%	 of	 the	 genome	 is	 coding,	 sequencing	 and	 bioinformatics	 costs	 of	 WGS	 are	currently	prohibitive	[213].		
2.3.2. The	Genetics	of	Right	Ventricular	Development	and	Function	RV	development	 is	under	complex	genetic	control	and	therefore	provides	background	to	understanding	its	genetic	determinants	and	function	in	adult	life.	The	study	of	cardiac	development	 has	 traditionally	 used	 the	 model	 of	 chick	 embryo	 development	 and	Hamburger-Hamilton	stages	[214]	as	a	framework	[215].	The	use	of	chick	development	as	 a	 model	 allows	 intervention	 and	 therefore	 more	 precise	 understanding	 of	 the	mechanisms	involved.	The	model	is	relevant	to	human	cardiac	physiology	as	the	stages	of	 cardiac	 development	 occur	 in	 the	 same	 order	 as	 in	 humans,	 with	 imaging	 work	suggesting	 that	 chick	embryo	ventricular	 failure	 resembles	 that	of	humans	 [216].	The	following	 discussion	 therefore	 refers	 to	 Hamburger-Hamilton	 stages,	 with	 rough	equivalents	for	human	embryos	given	[217,	218].	
The	 early	 embryo	 is	 an	 ovoid	disc	with	 a	 primitive	 groove	 in	 the	 long-axis	 extending	from	 Henson’s	 node	 caudally	 and	 consists	 of	 three	 germ	 cell	 layers:	 endoderm,	ectoderm	and	mesoderm,	 from	which	 the	heart	 originates.	 The	 first	 differentiation	 of	
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progenitor	heart	cells	comes	as	mesenchymal	cells	which	migrate	through	the	primitive	streak	(Figure	2.5,	Stage	3)	to	create	separate	but	paired	left-	and	right-	heart	forming	regions,	before	migrating	cranially	(Stage	5).	Here	they	form	a	crescentic	group	of	cells,	the	 “primary	 heart	 field”	 which	 gives	 rise	 to	 the	 left	 ventricle	 and	 atria.	 A	 second,	poorly-defined	 region	 –	 the	 secondary	 or	 anterior	 heart	 field	 -	 forms	more	 medially	within	the	mesoderm	and	develops	into	the	right	ventricle	and	outflow	tract	[219-221].	
	
Figure	2.5.	Early	cardiogenesis	
Stages refer to the Hamburger-Hamilton system with approximate human embryonic stages in days given in 
brackets. Stage 3 (17) shows the mesenchymal cells migrating through the primitive streak in the midline 
forming lateralised heart forming regions Stage 5 (19) shows the cranial migration to form the primary and 
secondary heart fields at Stage 7 (20) before separating into dorsal and ventral splanchnic groups by which 
develop into the primitive heart tube by Stage 12 (22). 	
In	 mammals	 these	 cells	 divide	 into	 a	 dorsal	 somatic	 group	 and	 a	 ventral	 splanchnic	group	 which	 are	 influenced	 by	 signalling	 from	 the	 endoderm,	 the	 ectoderm	 and	 the	node	(Figure	2.6).		
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Figure	2.6.	Early	cardiac	signalling	
Schematic cross-section of the germ cell tri-layer of the developing embryo at Hamburger and Hamilton Stage 8 
showing the signalling pathways which induce splanchnic mesoderm to become cardiogenic. Arrows denote 
stimulation, bar-ends denote inhibition. The ectoderm, Hensen’s node, the notochord and areas within the 
mesoderm inhibit cardiogenesis. Figure re-drawn from Wagner al. [222] 	
Induction	 of	 the	 secondary	 heart	 field	 cells	 is	 controlled	 by	 FGF-8,	 BMP-2	 and	 Sonic	Hedgehog	 which	 act	 via	 cardiogenic	 transcription	 factors	 including	 Tbx1	 [21-23],	Nkx2.5	and	GATA4	(17,24,25).	The	tri-layer	structure	of	the	developing	heart	then	folds	ventrally,	bringing	the	heart	forming	regions	on	each	side	to	the	midline	to	form	a	fused	single	heart	tube.	
	
Figure	2.7.	Folding	of	the	germ-cell	trilayer	
Three cross-sectional diagrams showing the progressive folding of the germ-cell trilayer to form the primitive 
cardiac tube. Green indicates the ectoderm; Red, mesoderm; Purple, endoderm; Red dots, primitive aortae; Red 
sac, primitive cardiac tube. The heart-forming regions on each side of the midline are brought together under 
the yolk sac (which becomes the gut) forming a primitive cardiac tube.  	
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The	 primitive	 heart	 tube	 is	 fixed	 at	 both	 ends.	 At	 one	 end	 it	 is	 anchored	 by	 the	differentiating	arterial	trunks	and	at	the	other	by	venous	channels	which	drain	into	the	atria.	This	primitive	heart	tube	undergoes	a	complex	process	of	 looping	and	folding	to	create	the	normal	cardiac	morphology	(Figure	3).	With	growth,	the	embryonic	ventricle	bends	to	the	right	of	the	midline	anteriorly	to	the	developing	atria.	
	
Figure	2.8.	Embryonic	folding	of	the	primitive	cardiac	tube	
The primitive cardiac tube folds under genetic control at day 22 with the ventricles (V) folding to the right and in 
front of the atria (A). The embryonic ventricle is bent into a loop on the right side of the midline before moving 
back into the midline and covering the atrium and great veins. The sacculations expand behind the truncus 
arteriosus to form the left (LA) and right (RA) atria.  	
The	 folding	 process	 is	 under	 polygenic	 control	 and	 the	 TGF-beta	 related	 molecules	Nodal	 and	Lefty	 are	 central	 to	 left/right	 asymmetry	 [223-226]	 as	well	 as	other	 genes	involved	 in	chamber	 formation	such	as	HAND1	[227],	HAND2	[228],	Bop	[229],	Nodal	and	 GATA4	 [230-232].	 The	 cavity	 is	 then	 divided	 into	 four	 chambers	 by	 the	development	of	 three	 septae,	which	partition	 the	atria,	 the	ventricles	and	 the	 truncus	arteriosus,	finally	giving	rise	to	the	mature	cardiac	shape.		
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Genetic	 control	 of	 cardiac	 development	 is	 complex	 and	 multi-staged.	 However,	experimentation	 with	 knockout	 mice	 and	 the	 discovery	 of	 HAND1	 and	 HAND2	transcription	factors	has	led	to	the	idea	that	cardiac	chambers	form	under	the	influence	of	 separate	 patterns	 of	 gene	 expression.	 During	 development,	 cascades	 of	 different	transcription	 factors	 regulate	 chamber	 differentiation.	 Myocyte	 enhancer	 factor	 2C	regulates	 Bop,	 a	 key	 regulator	 of	 RV	 development.	 Similarly,	 GATA4,	 a	 key	 upstream	cardiac	development	regulator,	which	regulates	cardiomyocyte-specific	gene	expression	(e.g.	 alpha-myosin	 heavy	 chain),	 also	 induces	 HAND2	 expression,	 again	 a	 key	transcription	 factor	 governing	RV	 formation	 [229,	 230,	 233,	 234].	Gene	 expression	 in	the	 right	 ventricle	may	also	 change	 in	 response	 to	physiological	 disturbances	 such	 as	pressure-	and	volume-	overload.	These	are	associated	with	adaptive	remodelling	[232,	235-237]	which	sarcomeric	proteins	sense	and	adapt	to	[238,	239].	Pressure-overload	is	known	to	cause	a	variety	of	hypertrophic	and	functional	responses	in	the	wall	of	the	right	ventricle,	which	purely	mechanical	considerations	do	not	explain	[87,	240].	These	responses	may	be	under	genetic	control	[240].		
One	 of	 the	 key	molecules	 in	 sensing	 and	 determining	myocyte	 response	 to	 stretch	 is	titin.	Titin	is	a	giant	protein	approximately	1.9	μm	long	which	spans	the	Z-disk	to	the	M-line	 of	 the	 sarcomere.	Although	originally	 seen	 as	 purely	 structural	 protein,	 it	 is	 now	recognised	as	a	regulator	of	myocyte	stiffness	and	diastolic	filling.	Protein	binding	sites	are	clustered	in	sections	of	the	protein:	the	Z-disk,	I-band	and	M-line	and	in	particular	in	the	 I-band,	 which	 is	 central	 in	 titin	 sensing.	 Ligands	 of	 the	 I-band	 are	 produced	 in	response	to	a	diverse	range	of	metabolic,	ischaemic,	neuronal	and	stretch	insults	[241-245]	and	are	found	in	both	the	cytoplasm	and	nucleus,	where	they	affect	transcriptional	and	 cell	 cycle	 activity	 [246].	 This	 provides	 a	 bi-directional	 communication	 pathway	
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between	gene	expression	and	myocyte	function	[247].	Truncating	titin	variants	(TTNtv)	account	for	25%	of	familial	and	severe	DCM	[248].	However,	TTNtv	also	occur	in	~2%	of	healthy	subjects,	and	are	preferentially	localised	to	the	I-band	[176].	TTNtv	in	dilated	cardiomyopathy	 patients	 are	 more	 common,	 but	 affect	 other	 regions	 of	 the	 protein	[176].	Healthy	subjects	therefore	provide	the	ideal	substrate	for	examining	the	effects	of	I-band	disruption.	We	would	 expect	 from	 its	 role	 in	 signal	 transduction	 that	 it	would	alter	gene	expression	in	ways	which	might	lead	to	functional	changes	in	the	ventricles.	We	hypothesize	that	TTNtv	in	healthy	subjects	are	associated	with	subtle	RV	structural	and	 functional	 changes	 which	 three-dimensional	 high-resolution	 approaches	 may	 be	better	able	to	detect	detect	than	volumetry	[176].	
Although	 rare	 conditions	 provide	 some	 data	 on	 the	 genetic	 determinants	 of	 RV	structure	 and	 function	 [237,	 249],	 there	 remains	 a	 considerable	 gap	 in	 our	understanding	 in	this	area.	Common	variants	have	been	 implicated	 in	a	wide	range	of	cardiovascular	 diseases	 including	 diabetes	 [188-195],	 coronary	 heart	 disease	 [196-201],	LV	hypertrophy	 [250,	251],	hypertension	 [252-254],	atrial	 fibrillation	 [202-204]	and	 dilated	 cardiomyopathy	 [205,	 206].	 Given	 the	 breadth	 of	 data	 supporting	 the	prognostic	 importance	of	RV	structure	[17,	18]	and	function	[1-16,	19,	20,	94,	98-100,	255]	and	the	evidence	that	gene	expression	and	cardiac	development	and	function	are	closely	 linked,	 it	 is	 surprising	 that	 this	 approach	 has	 not	 been	 applied	 to	 the	 right	ventricle.		
GWA	studies	have	been	criticised	for	the	low	level	of	replication	of	initial	findings	[256-258].	 This	 results	 from	 multiple	 factors	 including	 false	 positive	 associations,	underpowered	 replication	 studies,	 heterogeneity	 of	 study	 populations,	 different	phenotyping	 methods,	 different	 genotyping	 arrays,	 different	 population	 SNP	
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frequencies,	confounding	from	population	stratification	and	from	environmental	effects.	The	problem	is	most	evident	in	the	study	of	complex	traits	and	diseases	where	multiple	environmental,	 epigenetic	 and	 genetic	 factors	 are	 likely	 to	 contribute	 to	 a	 measured	phenotype,	making	the	dissection	of	specific	genetic	influences	very	problematic.	
GWA	studies	suffer	from	a	huge	burden	of	multiple-testing,	posed	by	the	association	of	different	 traits	 with	 104–105	 SNPs.	 This	 had	 stimulated	 a	 drive	 to	 revisit	 statistical	methods.	 Frequentist	 statistical	 approaches	 have	 been	 criticised	 for	 assuming	 the	independence	of	SNPs,	and	for	difficulties	in	correction	of	the	multiple	testing	problem.	The	 Bonferroni	 approach	 reduces	 study	 power	 significantly	 and	 the	 false-discovery	approach	commits	to	false	positives	which	is	undesirable	[259].	Rapid	developments	in	computational	power	have	allowed	permutation	approaches	to	become	feasible	offering	an	unbiased	approach	to	significance	 testing.	Bayesian	approaches	offer	 the	chance	 to	incorporate	prior	information	to	estimates	and	have	already	shown	promise	[260,	261].	A	genome-wide	approach	to	variant	association	with	right	structure	and	function,	using	recent	 developments	 in	 high-dimensional	 statistics,	 high-resolution	 phenotyping	 and	careful	population	selection	is	therefore	a	worthwhile	and	desirable	goal.	
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2.4. Cardiovascular	Magnetic	Resonance	Cardiovascular	 magnetic	 resonance	 imaging	 (CMR)	 has	 rapidly	 become	 the	 gold-standard	 of	 RV	 imaging	 [37]	 despite	 the	 technical	 challenges	 of	 obtaining	 high-resolution	tissue-characterisation	of	a	moving	organ.		
2.4.1. History,	principles	and	techniques	of	Magnetic	Resonance	Imaging	Nuclear	 Magnetic	 Resonance	 (NMR)	 is	 a	 technique	 which	 uses	 the	 observation	 that	nuclei	 with	 a	 magnetic	 moment	 absorb	 electromagnetic	 energy	 at	 a	 characteristic	frequency,	when	exposed	to	an	external	magnetic	 field.	This	energy	is	then	re-emitted	and	detected	by	the	electrical	current	it	induces.	NMR	relies	on	a	fundamental	property	of	atomic	and	subatomic	particles:	spin.	Neutrons,	protons	(and	therefore	the	hydrogen	nucleus)	and	electrons	all	have	spin	of	a	half.	Hydrogen	nuclei	are	the	excitation	target	for	human	MRI	since	they	are	plentiful	in	water	(H2O)	and	fat	(CnH2nO2).		
Spin	 is	 significant	 because	 a	 non-zero	 value	 indicates	 a	 tendency	 to	 interact	 with	 a	constant	 magnetic	 field	 (B0).	 The	 number	 of	 spin	 states	 observable	 for	 a	 particle	 is	discrete	and	given	by	2I	+	1,	where	I	is	the	spin	value.	Protons	therefore	have	2(½)+1	=	2	spin	states,	which	are	classically	represented	by	up-	and	down-	arrows	or	the	terms	“spin-up”	or	parallel,	and	“spin-down”	or	anti-parallel.	By	applying	an	external	magnetic	field,	 the	 discrete	 nature	 of	 spin-states	 can	 be	 observed	 macroscopically.	 Stern	 and	Gerlach’s	first	observed	this	in	1922	when	they	passed	silver	atoms	(spin	-½)	through	a	magnetic	 field	 and	 found	 they	 projected	 to	 two	 discrete	 points,	 deflected	 by	 a	 force	proportional	 to	 the	 field	 strength.	 Peter	 Zeeman	 noted	 that	 discrete	 spin	 states	 had	discrete	energy	differences	and	quantified	the	energy	difference	between	spin	states	as:	
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	 Δ𝐸 =  𝛾 . ℎ .𝐵!	 (2.1)	
However,	objects	consist	of	large	numbers	of	spins,	spread	across	high-	and	low-	energy	states	 balancing	 a	 tendency	 to	 occupy	 the	 lowest	 energy	 states	with	 random	 thermal	motion.	A	small	excess	of	particles	exist	in	the	low	energy	(spin-up)	state	compared	to	the	high	energy	(spin-down)	state,	and	the	ratio	of	these	two	is	given	by	the	Boltzmann	factor,	which	depends	on	the	ratio	of	magnetic	to	thermal	energy:	
	 𝐵𝑜𝑙𝑡𝑧𝑚𝑎𝑛𝑛 𝑓𝑎𝑐𝑡𝑜𝑟:  𝑒!!!ℏ!!! 	 (2.2)	
𝛾	=	Gyromagnetic	constant,	B0	=	field	strength,	ℏ	=	Planck’s	constant	divided	by	2𝜋.	kB	=	Boltzmann	constant.,	T	=	temperature	in	Kelvin.	
This	can	be	thought	of	as	the	exponential	of	the	magnetic	energy	divided	by	the	thermal	energy.	At	room	temperature	in	the	earth’s	weak	magnetic	field,	thermal	energy	is	much	greater	than	magnetic	energy,	so	the	population	in	the	lower	energy	state	only	slightly	exceeds	 that	 of	 the	 higher	 energy	 state	 and	 the	 net	magnetisation	 (M0)	 only	 slightly	favours	the	spin-up	direction.	However,	this	spin	excess	can	be	increased	by	applying	a	stronger	magnetic	field	and	is	important	in	generating	the	magnetic	resonance	signal.	
The	physics	of	NMR	is	based	in	quantum	mechanics	since	the	energy	levels	of	spins	are	discrete.	 However,	 the	 behaviour	 of	 large	 groups	 of	 spins	 can	 be	 modelled	 using	classical	 physics	 and	 wave-mechanics	 and	 it	 is	 convenient	 to	 visualise	 many	 of	 the	properties	 exhibited	 by	 spins	 in	 this	 way.	 One	 such	 property	 is	 “precession”.	 When	placed	 in	 a	magnetic	 field	 (B0),	 spins	precess	 around	 the	magnetisation	direction	at	 a	frequency	given	by	the	Larmor	equation:	
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	 𝑓! =  𝛾𝐵!	 (2.3)		
The	precession	 frequency	 is	 therefore	proportional	 to	both	 the	 field	 strength	 and	 the	gyromagnetic	 constant,	 which	 is	 a	 characteristic	 of	 the	 nuclei	 involved.	 Initially	 the	spins	precess	out	of	phase,	causing	the	transverse	components	of	magnetisation	(Mxy)	to	cancel	 each	 other	 out,	 i.e.	 Mxy=0.	 The	 longitudinal	 component	 of	 the	 spins’	magnetisation	 (Mz)	 is	 also	 almost	 entirely	 cancelled	 out	 between	 the	 lower	 (spin-up)	and	 upper	 (spin-down)	 energy	 states,	 though	 the	 small	 excess	 in	 the	 lower,	 spin-up,	energy	direction	creates	a	net	longitudinal	magnetisation	parallel	to	the	magnetic	field.	The	 spin	excess	 can	be	 increased	by	 lowering	 the	 temperature	or	 increasing	 the	 field	strength,	 though	 only	 the	 latter	 is	 practical	 to	 do	 to	 any	 significant	 degree	 when	scanning	humans.	
Stern	and	Gerlach’s	discovery	of	quantal	spin	states	was	developed	by	Isidor	Rabi	into	a	precise	 beam	 method,	 showing	 that	 individual	 nuclear	 spin	 states	 and	 magnetic	moments	 could	be	measured	by	generating	electromagnetic	waves	at	 the	appropriate	Larmor	frequency.	He	received	the	Nobel	Prize	for	Physics	in	1944	for	his	work.	Around	the	same	time,	Felix	Bloch	and	Edward	Purcell	 independently	discovered	“resonance”,	in	which	nuclei	placed	in	a	magnetic	field	absorb	energy	from	a	second	magnetic	field,	B1,	 at	 a	 predictable	 frequency,	 re-emitting	 it	 in	 agreement	with	 the	 Larmor	 equation.	They	were	jointly	awarded	the	Nobel	prize	for	Physics	in	1952	for	this	work	[262,	263].	The	addition	of	a	second	magnetic	field	causes	M0	to	deviate	from	the	B0	direction	to	an	angle	α,	the	flip	angle,	which	is	given	by:	
	 𝛼 =  𝛾 .𝐵! . 𝑡!	 (2.4)	
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If	M0	reaches	the	horizontal	plane,	then	the	radiofrequency	(RF)	pulse	is	known	as	a	900	pulse.	A	B1	pulse	of	twice	this	duration	is	a	1800	pulse.	After	the	B1	has	been	turned	off,	the	 magnetisation	 in	 the	 transverse	 plane	 gradually	 reduces.	 This	 occurs	 as	 spins	interact	with	each	other,	creating	slightly	higher	or	lower	local	magnetic	fields	than	the	main	 field,	 and	 so	 changing	 their	 precessional	 frequencies	 in	 accordance	 with	 the	Larmor	 equation	 and	 de-phasing.	 These	 spin-spin	 interactions	 lead	 to	 an	 exponential	reduction	in	Mxy	with	the	time	constant	T2.	In	practice,	field	inhomogeneities	compound	the	 de-phasing	 causing	 Mxy	 to	 rapidly	 decrease	 to	 zero	 with	 time	 constant	 T2*.	Simultaneously,	although	more	slowly,	the	Mz	regenerates	with	time	constant	T1.	While	Mxy	is	greater	than	zero,	being	an	oscillating	magnetic	field,	it	is	able	to	induce	a	voltage	in	 signal	 detection	 coils	 surrounding	 the	 magnet	 also	 at	 the	 Larmor	 frequency.	 This	signal	is	known	as	the	free	induction	decay.		
During	 the	 1950s,	 Erwin	 Hahn	 developed	 pulsed	 B1	 fields	 which	 created	 transient	oscillations	 in	 the	 received	 signal	 at	 set	 time	 intervals,	 the	 “repetition	 time”	 (TR).	However,	the	ability	to	localise	a	signal	was	lacking.	In	1973,	Paul	Lauterbur	and	Peter	Mansfield	 independently	 described	 the	 use	 of	 additional	 magnetic	 field	 gradients	 to	distort	 the	magnetic	 field	 in	 predictable	ways,	making	 resonant	 frequencies	 spatially	specific,	 for	 which	 they	 were	 both	 awarded	 the	 2003	 Nobel	 Prize	 in	 Physiology	 or	Medicine.	 Three	 sets	 of	 gradient	 coils	 are	 now	 typically	 used,	 creating	 gradient	 fields	whose	z-component	varies	in	the	x-,	y-	and	z-	directions.	
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Figure	2.9.	Effect	of	gradient	fields	on	B0	
The gradient coils only affect B0 in the z-direction, causing different field strengths in the direction indicated. 
The overall B0 field remains in the z-direction. 	
The	gradient	 fields	–	slice-selecting,	phase-encoding	and	frequency-encoding	–	encode	spatial	 position	 in	 different	 ways	 and	 are	 briefly	 applied	 after	 the	 RF	 pulse.	 The	sequence	of	gradient	pulses	applied	is	shown	by	pulse	sequence	diagrams	with	separate	lines	for	each	pulse	and	the	induced	signal	at	the	bottom	of	the	diagram.	The	B0	field	is	constant	and	not	shown.		
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Figure	2.10.	Basic	gradient-echo	pulse	sequence	
Amplitude is shown vertically, time is shown horizontally. Each pulse is shown on a separate line. GSS / GPE / GFE 
are the slice-selecting, phase- and frequency-encoding gradients respectively, with the signal produced shown 
on the bottom line. The RF pulse is initially applied simultaneously with GSS, restricting excitations to a single 
“slab”. GSS includes a negative component (C) which compensates for the de-phasing of the positive component 
(B) of the GSS (the RF pulse is considered to act at its centre in time, so the gradient moment of GSS, area C, is 
only half its area, or: area C = area A). Next GPE is applied orthogonal to GSS, followed by GFE. GFE is preceded by a 
pre-phasing gradient (D) of opposite polarity to the main GFE to create maximal phasing, and thus signal, by the 
middle of GFE (i.e. between E and F). The whole sequence has to be repeated to apply a different phase-
encoding gradient and thus gather a different line of k-space. The time taking for one excitation is TR. 	
The	 slice-selecting	gradient	alters	 the	B0	 in	a	 specified	plane,	 so	 that	only	 these	 spins	will	resonate	in	response	to	the	appropriate	RF	pulse.	The	gradient	is	typically	a	narrow	bandwidth	RF	pulse	limiting	the	effects	to	only	a	narrow	“slice”	of	spins.	The	thickness	of	the	slice	depends	on	the	pitch	of	the	slice-selecting	gradient	over	the	volume	and	the	
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bandwidth	 of	 the	 RF	 pulse.	 Steeper	 gradients	 limit	 the	 excitation	 frequency	 to	 a	narrower	width	of	tissue.	By	Fourier	analysis,	a	narrower	RF	bandwidth	is	created	by	a	
longer	RF	pulse	prolonging	TR	and	therefore	acquisition	time.		
	
Figure	2.11.	Slice	selection	
Left: shows an oblong-shaped volume from which a slice is selectively excited. Here, the slice is perpendicular to 
the B0 direction, implying the slice-selecting gradient is parallel to B0, though slice selection can occur in any 
x/y/z plane. Right: shows how the selected slice thickness is reduced by increasing the GSS from red to blue. 
Phase- and frequency- encoding provide further spatial localisation within this slab. 	
The	 phase-encoding	 gradient	 is	 briefly	 applied	 orthogonal	 to	 the	 slice-selecting	gradient,	 changing	 the	 frequency	 of	 the	 spins	 proportional	 to	 the	 additional	 field	strength.	Although	the	effect	on	precession	frequency	is	short-lived,	a	phase	offset	from	0	 to	 3600	 in	 the	 direction	 of	 the	 gradient	 remains,	 repeating	 at	 a	 spatial	 frequency	decided	 by	 the	 steepness	 of	 the	 phase-encoding	 gradient.	 If	 the	 phase	 offset	 cycles	several	times	and	spins	are	evenly	placed	along	the	phase-encoding	direction,	then	the	magnetisation	of	every	spin	will	be	cancelled	out	by	a	corresponding	spin	further	along	the	 phase-encoding	 direction	 precessing	 1800	 out	 of	 phase	 (Figure	 2.12).	However,	 if	the	 spins	 in	 the	 tissue	 are	 spaced	 at	 distances	 coinciding	 with	 the	 same	 precession	
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phase,	 and	 the	 opposing	 phases	 are	 absent,	 then	 particular	 phases	 will	 be	 well-represented	resulting	in	a	high	signal	for	this	spatial	frequency.	
Images	usually	consist	of	features	covering	a	range	of	spatial	frequencies,	so	a	range	of	phase-encoding	gradients	must	be	applied	in	the	phase-encoding	direction.	Each	phase-encoding	 gradient	 must	 be	 tested	 in	 a	 separate	 excitation,	 collecting	 the	 signal	 and	deducing	 the	 contribution	 of	 that	 particular	 spatial	 frequency	 to	 the	 image.	 Once	 the	range	 of	 spatial	 frequencies	 has	 been	 interrogated,	 the	 amplitudes	 at	 each	 spatial	frequency	can	be	converted	from	a	spatial	frequency	distribution	back	into	an	image	by	a	 Fourier	 transform.	 Phase-encoding	 is	 thus	 time-consuming:	 a	 256-pixel	 image	requires	 256	 excitations,	 taking	 256	 x	 TR	ms.	 It	 is	 perfectly	 possible	 to	 encode	 spin	position	 orthogonal	 to	 the	 phase-encoding	 direction	 using	 a	 second	 phase-encoding	gradient	 (and	 this	approach	 is	used	 in	3D	 imaging)	but	 it	 is	quicker	 to	use	a	different	method,	frequency-encoding.		
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Figure	2.12.	Phase-encoding	
Phase-encoding identifies spins at spatial frequencies which coincide with the spatial frequency of the phase 
offsets. The top row shows the phase-encoding direction. The second row shows the phase differences created 
by a gradient pulse in the phase-encoding direction. The phase-offsets repeat at a wavelength of λ3. The third 
row shows spins (light blue dots) which are close together, λ1 apart. If this row of spins is excited by the phase-
encoding pulse shown, many of the spins will be at conflicting phases and cancel out, producing only a small 
total signal.  The fourth row shows spins (dark blue dots) further apart, λ2, with gaps in between. Since λ2 is 
similar to λ3, if this row of spins is excited they will be in the same phase, with spins cancelling out their effects, 
and produce a large combined signal. Each phase-encoding pulse tests for a single spatial frequency in the 
subject, so constructing an image consisting of features which span a range of spatial frequencies is slower than 
frequency encoding, in which all spatial frequencies can be coded in single RF pulse. 	
Frequency	 encoding	 applies	 a	 continuous	 gradient	 in	 a	 direction	 orthogonal	 to	 the	phase-encoding	 direction.	 This	 results	 in	 a	 gradated	 field	 strength	 in	 the	 frequency-encoding	direction	which,	by	altering	precession	 frequency	has	a	cumulative	effect	on	phase.	 At	 time	 zero,	 spins	 will	 be	 in	 phase	 and	 a	 spatial	 frequency	 of	 zero	 will	 be	encoded,	 steadily	 encoding	 higher	 spatial	 frequencies	 in	 the	 image	 as	 the	 cumulative	phase	shift	builds.	It	is	therefore	possible	to	collect	data	on	all	spatial	frequencies	in	the	subject	in	the	frequency-encoding	direction	from	a	single	pulse.	Since	the	results	are	a	
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scalar	value,	it	is	only	possible	to	use	frequency	encoding	in	one	direction	as	it	is	unable	to	differentiate	between	values	obtained	from	orthogonal	directions.	
In	 1975,	 Richard	 Ernst	 described	 how	 Fourier	 transforms,	 a	method	 of	 decomposing	any	periodic	function	into	simpler	parts	[264],	could	link	phase	and	frequency	methods	to	the	reconstruction	of	two-dimensional	(2D)	images	from	short,	intense	pulses	rather	than	the	slow,	sweeping	waves	used	previously.	This	increased	imaging	sensitivity	by	as	much	a	hundred	fold	[265]	and	led	to	the	concept	of	k-space,	the	Fourier	transform	of	the	image	data	[266-268].	Although	Fourier	analysis	is	often	described	as	a	method	of	deconstructing	an	amplitude	vs	time	function,	it	can	equally	be	used	to	deconstruct	an	amplitude	 vs	 position	 function.	 Image	 data	 can	 therefore	 be	 re-configured	 on	 axes	 of	spatial	 frequencies	 in	 the	x-,	y-	and	z-	directions,	with	axes	of	kx,	ky	and	kz	and	bright	areas	representing	dominant	spatial	 frequencies.	K-space	 is	usually	square	and	evenly	space	 to	 speed	 up	 acquisition	 and	 processing.	 K	 is	 inversely	 proportional	 to	 the	wavelength	 and	 is	 therefore	 the	 number	 of	 cycles	 per	 unit	 distance,	 with	 units	 of	2π/distance.	The	following	MR	brain	image	shows	the	contributions	of	different	spatial	frequencies,	or	equivalently	different	points	in	k-space,	to	the	original	image:	
(a) (b) (c) 
	
Figure	2.13.	Three	different	k-space	datasets	with	the	corresponding	images	
(a) Shows a brain MR image (right) with its k-space transform on (left). (b) Shows the same brain image with the 
high spatial frequencies removed from k-space and the image. The signal in k-space is confined to the centre 
causing the image to become blurry. (c) Shows the same image with the low frequencies removed. Now 
consisting of mainly high frequencies, the image has sharp edges and details with few general contours. This 
corresponds to a gap in the centre of k-space [269]. 
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 The	spacing	of	points	in	k-space	(Δk)	and	the	distance	from	the	centre	of	k-space	to	the	edge	 (kmax)	 relate	 to	 the	 size	of	 the	 field	of	 view	 (FOV)	 and	 the	pixel	 size	 in	 the	FOV.	Consecutive	 lines	 in	 k-space	 represent	 consecutive,	 integer	 spatial	 frequencies,	generated	from	the	Fourier	transform	of	the	image.	
	
Figure	2.14.	K-space	
The difference in spatial frequency between lines in k-space is equal to one divided by the field of view. This 
result follows directly from the form of the Fourier transform which uses consecutive integer multiples of the 
complex oscillators. (Figure based on: Elster A. Questions and Answers in MRI. www.mri-q.com/field-of-view-
fov.html. Accessed 18th May 2015). 	
So	the	difference	in	spatial	frequency	between	consecutive	points	in	k-space	(Δk)	is:	
Δ𝑘	 = 𝑛 + 1𝐹𝑂𝑉 − 𝑛𝐹𝑂𝑉	 (2.5)	
	 = 1𝐹𝑂𝑉	 (2.6)	
This	 relationship	 is	 shown	 in	 the	 following	 two	 images,	where	 doubling	 Δk	 in	 the	 y-direction	halves	the	field	of	view	in	this	direction.	
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(a) (b) 
	 	
Figure	2.15.	The	relationship	between	Δk	and	field	of	view	
Increasing Δk in the y-direction reduces the FOV from the original (a) to the reduced (b) dimensions. 	
A	second	important,	but	counter-intuitive,	relationship	in	k-space	is	that	pixel	size	(Δw)	in	 the	 original	 image	 is	 inversely	 proportional	 to	 the	 range	 of	 spatial	 frequencies	sampled	 in	 k-space	 (kFOV).	 This	 follows	 from	 the	 statement	 that	 the	 smallest	differentiable	 distance,	 the	 pixel,	 is	 equal	 to	 the	 distance	 between	 the	 peaks	 of	 the	highest	 frequency	 wave.	 i.e.	 the	 width	 of	 a	 pixel	 =	 the	 wavelength	 of	 the	 highest	frequency	wave	in	k-space.	So	in	“image	space”,	the	size	of	the	pixels,	Δw,	is	FOV/N,	and	in	 k-space,	 the	 spatial	 wavelength	 =	 FOV	 /	 N.	 Spatial	 frequency	 (k)	 =	 1/spatial	wavelength,	so	kFOV	=	N/FOV.	From	this	it	follows	that	the	Δw	is	equal	to	1/ΔkFOV.	In	the	following	example	(Figure	2.16)	the	range	of	k-space	sampled	(kFOV)	has	been	reduced	from	the	original	image	(a).	This	proportionally	increases	Δw	leading	to	a	blurry	image	in	(b).	
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(a) (b) 
	 	
Figure	2.16.	The	relationship	between	the	range	of	k-space	sampled	and	pixel	size	
Reduction in the sampling space proportionally increases pixel size and so leads to a blurry image. 
 A	 final	 concept	which	 is	 crucial	 in	MRI	 is	maximising	 the	 useful	 signal,	 in	 the	 face	 of	influences	 which	 degrade	 the	 signal,	 “noise”,	 due	 to	 imperfections	 in	 the	 MR	 system	such	 as	 field	 inhomogeneities,	 RF	 coil	 thermal	 noise	 or	 non-linearities	 in	 the	 signal	amplifiers,	 or	 due	 to	 image	 processing	 or	 patient-related	 factors	 such	 as	 movement	during	scanning.	More	precisely,	the	signal-to-noise	ratio	(SNR)	is	expressed	in	relation	to	the	region	of	interest	(ROI)	as:	
𝑆𝑁𝑅 =  𝑆𝑖𝑔𝑛𝑎𝑙 𝑖𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦 𝑖𝑛 𝑡ℎ𝑒 𝑅𝑂𝐼𝑆𝑡𝑎𝑛𝑑𝑎𝑟𝑑 𝑑𝑒𝑣𝑖𝑎𝑡𝑖𝑜𝑛 𝑜𝑓 𝑡ℎ𝑒 𝑠𝑖𝑔𝑛𝑎𝑙 𝑖𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦 𝑜𝑢𝑡𝑠𝑖𝑑𝑒 𝑡ℎ𝑒 𝑅𝑂𝐼	 (2.7)	
SNR	 can	 be	 increased	 by	 changing	 scanning	 parameters	 such	 as	 increasing	 slice	thickness,	TR	or	the	field	of	view,	decreasing	receiver	bandwidth,	TE	or	the	matrix	size	(in	 either	 the	 frequency	 or	 phase-	 encoding	 directions)	 or	 by	 increasing	 the	 field	strength	 or	 using	 local	 coils.	 	 Acceleration	 techniques	 such	 as	 partial-Fourier	 and	fractional	echo	imaging	reduce	SNR.		
These	technological	advances	were	met	with	several	published	reports	of	MR	imaging	of	the	wrist	 [270],	 chest	 [271]	 and	 head	 [272]	with	 reductions	 in	 imaging	 time	 further	stimulating	interest.	The	first	commercial	clinical	scanner	–	the	“Neptune”	0.15T	-	was	
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installed	 at	 Hammersmith	 Hospital,	 London	 and	 by	 1984,	 the	 first	 “high-field”	 1.5T	scanner	had	been	installed	by	General	Electric.		
A	 modern	 scanner	 combines	 many	 of	 these	 developments	 although	 the	 exact	 set-up	varies	 depending	 on	 the	 type	 of	 scanning	 performed.	 Typical	 components	 are	 a	 B0	magnet	 cooled	 by	 liquid	 helium	 to	 create	 superconductivity,	 RF	 coils	 which	 transmit	and	receive	RF	pulses	typically	surrounding	the	whole	body	or	the	area	of	interest,	and	gradient	coils	which	produce	gradient	fields	in	three	directions.	A	Faraday	cage	shields	the	scanner	from	electromagnetic	radiation	and	a	computer	system	controls	the	scanner	and	 archives	 images.	 ECG	 and	 other	 physiological	monitoring	 allow	 the	 subject	 to	 be	monitored	from	the	console.	
(a) (b) 
	 	
Figure	2.17.	Typical	MR	set-up	
(a) Shows the relative positions of the main magnet, RF and gradient coils. (b) Shows the standard orientation of 
standard x/y/z directions with the B0 field parallel to the z-direction. Re-drawn from: Ridgway, JP. [273] 
 
2.4.2. Cardiac	Magnetic	Resonance	Cardiac	 magnetic	 resonance	 imaging	 (CMR)	 brings	 additional	 challenges	 in	 avoiding	image	 degradation	 due	 to	 cardiac	 and	 respiratory	 motion.	 Artefacts	 (features	 in	 an	image	 which	 misrepresent	 the	 object	 in	 the	 field	 of	 view)	 may	 be	 due	 to	 field	inhomogeneities	and	digital	imaging,	but	respiratory	and	cardiac	motion	are	additional	
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causes	 of	 motion	 artefact	 in	 CMR	 especially	 in	 patients	 with	 respiratory	 or	 cardiac	disease.	Fast	acquisition	compromises	spatial	resolution	and	signal	to	noise	ratio	(SNR)	to	unacceptable	levels,	so	other	solutions	are	commonly	used.	
Respiratory	motion	 is	most	effectively	avoided	by	breath-holding	 though	 if	 this	 is	not	possible,	signal	can	be	acquired	from	several	breaths	at	set	points	in	the	cycle	(“gating”)	or	throughout	breathing	using	respiratory	compensation	or	navigator	echoes	[274].	For	cardiac	 motion,	 gating	 is	 used	 based	 on	 the	 peripheral	 pulse	 or	 more	 commonly	 an	electrocardiogram	 (ECG)	 and	 may	 be	 prospective	 or	 retrospective	 depending	 on	whether	the	signal	is	gathered	after,	or	before,	the	gating	[275-277].	
In	prospective	gating,	software	detects	the	ventricular	depolarisation	spikes	in	the	ECG	(the	QRS	complex)	and	delivers	a	synchronisation	pulse	via	a	pulse-frequency	controller	to	RF	and	gradient	coils	(Figure	2.18).	The	pulses	are	delivered	at	the	same,	set	point	in	the	cardiac	cycle,	creating	one	line	of	k-space	each	time.	The	TR	interval	of	the	sequence	must	 therefore	 be	 a	 multiple	 of	 the	 length	 of	 the	 cardiac	 cycle	 and	 is	 therefore	dependent	on	the	heart	rate.	Scan	time	is	long	by	this	method,	and	proportional	to	TR	interval	and	the	number	of	lines	of	k-space.	
Retrospective	 gating	 is	 more	 common	 and	 more	 efficient,	 acquiring	 and	 matching	imaging	and	ECG	data	continuously	over	5-6	cycles.	During	acquisition,	if	the	length	of	a	cardiac	 cycle	 is	 outside	 acceptable	 limits	 then	 a	 cardiac	 cycle	 is	 excluded,	 and	 the	breath-hold	 extended,	 which	 can	 be	 problematic	 when	 imaging	 patients	 with	dysrhythmias.	In	this	instance,	prospective	gating	may	be	preferred.		
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Figure	2.18.	ECG	gating	set-up	
Figure re-drawn from Plein, S. [278].  
2.4.3. MR	Signal	types	The	MR	signal	is	an	induced	current	in	the	receiver	coils	caused	by	Mxy	in	response	to	the	RF	pulses.	The	induced	signal	occurs	as	the	net	magnetisation	precesses	around	the	z-axis,	 oscillating	 at	 the	 Larmor	 frequency	 but	 decaying	 gradually	 as	 the	 transverse	components	 of	 M	 (Mxy)	 de-phase	 due	 to	 magnetic	 field	 inhomogeneities	 and	 T2	mechanisms,	collectively	known	as	T2*	decay.	With	this	basic	model,	we	describe	 four	types	of	MR	signal.		
If	no	further	RF	pulses	are	added	the	induced	signal	follows	a	sine	wave	at	the	Larmor	frequency,	with	superimposed	damping	of	the	form	sin	ω0t	.	exp(-t/T2*).	This	is	known	as	 free	 induction	decay	(FID).	Gradient	echo	(GE)	 is	an	extension	of	FID.	 It	consists	of	applying	an	additional,	gradient	field	immediately	after	the	RF	pulse	causing	accelerated	de-phasing.	This	 is	 followed	by	 a	 further	 gradient	 field	of	 opposite	polarity	which	 re-
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phases	 the	 spins.	 However,	 as	with	 the	 FID,	 the	 envelope	 of	 decay	 due	 to	 T2	 and	 T2*	processes	 is	 unaffected	 so	 the	 amplitude	 of	 the	 overall	 signal	 is	 still	 reduced.	 GE	sequences	require	only	a	single	pair	of	de-phasing/re-phasing	gradient	pulses,	often	at	a	low	flip	angle	allowing	quick	repetition	(TR	<10ms)	and	fast	scanning	and	are	therefore	popular	in	CMR.	However,	SNR	may	be	poor	as	the	low	TR	prevents	sufficient	recovery	of	the	Mxy.		
(a) (b) 
	 	
Figure	2.19.	Free	induction	decay	and	gradient	echo	signals	
(a) Induced signal from a single transverse pulse. The signal oscillates at the Larmor frequency (black) but 
following an amplitude envelope (red) dictated by T2
* decay due to field inhomogeneities and de-phasing. (b) 
Gradient echo signal trace showing the rapidly de-phasing signal followed by re-phasing to an equal, but 
opposite polarity pulse (black trace) under the envelope of decaying T2 and T2* processes (red trace). 	
Erwin	Hahn	in	1949	first	described	the	“spin	echo”	(SE)	sequence,	in	which	a	900	pulse	is	followed	by	a	1800	pulse.	The	initial	900	pulse	creates	transverse	magnetisation	which	decays	 with	 T2*	 time	 constant.	 After	 a	 time	 interval	 TE/2,	 the	 1800	 pulse	 causes	 a	reversal	 of	 the	 precession	 direction	 and	 by	 time	 TE,	 the	 spins	 have	 re-phased.	 Field	inhomogeneities	are	well-tolerated	in	this	pulse	sequence	provided	they	do	not	change	during	 the	pulse	sequence,	and	signal	 is	only	susceptible	 to	 losses	by	T2	and	diffusion	effects.	 The	 sequence	 is	 however	 comparatively	 slow,	 with	 long	 TRs,	 as	 transverse	
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magnetisation	must	achieve	full	relaxation	to	equilibrium	before	the	next	RF	pulse.	TE	also	 needs	 to	 be	 relatively	 long	 to	 improve	 T2	 contrast.	 The	 specific	 absorption	 rate	(SAR)	 –	 the	 amount	 of	 energy	 deposited	 in	 the	 patient	 –	 is	 also	 high	with	 SE	 as	 it	 is	proportional	 to	 the	 square	 of	 B0,	 the	 square	 of	 the	 flip	 angle	 and	 the	 fraction	 of	 the	scanning	time	during	which	the	gradient	is	on	(“duty	cycle”).	GE	and	SE	sequences	are	compared	in	Table	2.2.	
	 Spin	echo	 Gradient	echo	Basic	pulse	sequence	 RF	pulse	+		900	gradient	pulse	+		1800	gradient	pulse	
RF	pulse	+		Low	flip	angle	gradient	pulse	+	Reversing	gradient	pulse	Acquisition	speed	 Slow,	because:	TR	must	be	long	to	allow	Mxy	to	return	to	zero	TE	must	be	long	to	improve	T2	contrast	
Fast,	because	TR	is	short	
Affected	by	field	inhomogeneities?	 No	 Yes	Specific	absorption	rate2	 High	 Low	
Table	2.2.	Comparison	of	spin	echo	and	gradient	echo	pulse	sequences		
During	the	1980s,	Rob	Hawkes	and	Bill	Moore	developed	a	modification	of	GE	based	on	several	successive	RF	pulses,	leading	to	a	steady	magnetisation	state.	Although	initially	impractical	because	of	poor	image	quality,	improvements	in	field	homogeneity	and	fast																																																									2	Proportional	to	the	square	of	the	flip	angle	
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switching	 gradients	 allowed	 the	benefits	 of	 short	TR	 and	 fast	 image	 acquisition	 to	be	realised	 [279].	 A	 form	 of	 steady-state	 free	 precession,	 “balanced”	 steady-state	 free	precession	(b-SSFP)	 is	now	the	most	commonly	used	sequence	in	CMR.	After	a	typical	excitation	RF	pulse,	the	net	magnetisation	vector	is	rotated	so	that	precession	occurs	at	the	flip	angle,	α,	but	also	de-phased	in	this	precession	by	gradient	pulses	or	other	field	inhomogeneities.	 Balanced	 SSFP	 is	 characterised	 by	 a	 net	 de-phasing	 during	 the	 TR	interval	 of	 zero	 [280],	 achieved	 by	 providing	 a	 compensatory	 and	 opposite	 polarity	gradient-pulse	for	each	gradient-pulse.		
Contrast	in	b-SSFP	is	given	by	the	square	root	of	the	T2:T1	ratio	of	tissue	which	is	high	in	fluid	 and	 fat,	 and	 low	 in	 muscle.	 High	 SNR	 and	 blood	 inflow	 enhancement	 effects	improve	 differentiation	 between	 ventricular	 wall	 and	 blood	 pool	 necessary	 for	volumetric	 analysis.	 This	 is	 a	 key	 analysis	 in	 clinical	 analysis.	 b-SSFP	 is,	 however,	sensitive	 to	 field	 inhomogeneities	 which	 can	 produce	 dark-banding	 artefacts,	 though	short	TRs	and	the	use	of	dynamic	shimming	by	shim	coils	reduces	this.	
MR	imaging	can	also	be	used	to	measure	blood	flow.	Two	main	classes	of	methods	are	described.	Those	that	rely	on	the	endogenous	contrast	provided	by	moving	spins	(time-of-flight	and	phase-contrast	methods)	and	those	which	use	exogenous	contrast	agents,	such	as	gadolinium	compounds.	Phase-contrast	 (PC)	 imaging	uses	differences	 in	 spin-phase	to	encode	speed,	making	use	of	a	phenomenon	which	is	the	cause	of	artefacts	in	other	 situations.	 Phase-shifts	 commonly	 occur	with	 any	 briefly-applied	 gradient	 field,	such	as	the	frequency-encoding	and	slice-selecting	fields	used	for	localisation.	Exposing	the	 spin	 to	 a	 field	 of	 equal	 but	 opposing	 polarity,	 for	 the	 same	 length	 of	 time	 either	before	or	after	 the	original	 field,	 then	balances	 the	phase	shifts	caused	by	 these	 fields	(Figure	2.20,	black	arrow).	The	balancing	field	relies	on	the	assumption	that	the	spins	
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do	not	move,	parallel	 to	 the	gradient,	between	 the	 two	exposures.	PC	 imaging	applies	two	gradient	fields	in	the	same	way,	one	exactly	opposing	the	other.	If	spins	move	in	the	gradient	 direction	 between	 the	 two	 exposures	 then	 they	will	 be	 exposed	 to	 different	field	strengths	(Figure	2.20,	red	arrow)	and	be	left	with	a	residual	phase	shift,	reducing	signal,	which	can	be	calibrated	to	calculate	the	speed	of	the	spin,	in	the	direction	of	the	gradient	[281].	
To	 allow	 fast	 acquisition,	 GE	 sequences	 are	 commonly	 used.	 However,	 these	 are	susceptible	 to	 field	 inhomogeneities	 which	 themselves	 lead	 to	 phase	 changes,	 so	 the	bipolar	gradient	sequence	described	above	is	typically	repeated	with	reverse	polarities.	The	 two	resultant	phase	 images	are	 then	subtracted,	on	 the	assumption	 that	 the	 field	inhomogeneities	will	 remain	 the	 same	 and	 are	 therefore	 removed.	 Finally,	 to	 remove	the	effects	of	background	random	phase-shifts	occurring	in	low	intensity	spins	(e.g.	air)	the	phase	image	is	multiplied	by	a	magnitude	image	[282,	283].	
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Figure	2.20.	Phase-contrast	imaging	creates	phase-shifts	in	moving	spins	
The vertical and horizontal axes show time and spatial position, respectively. The arrows show the phase of two 
spins over time. One spin is moving (red), one is not (black). In the upper half of the diagram, spins are exposed 
to a gradient pulse causing a phase-shift to develop. In the lower half of the diagram, spins are exposed to a 
gradient pulse of equal duration and size but of opposite polarity causing the phase-shift in the stationary spin 
to be exactly removed. However, the moving spin is exposed to a different field strength in the second pulse 
compared to the first, resulting in a net phase-shift. This can be calibrated to the speed of the spin in the 
direction parallel to the gradient. To compensate for field inhomogeneities, a second pair of bipolar gradients is 
typically applied and the results subtracted from each other. To remove the effects of random, low-amplitude 
spins, the result is then multiplied by a magnitude image. These processes are not shown here. 	
The	highest	phase-change	discernible	is	1800,	which	is	calibrated	to	the	highest	velocity	needed	 to	 be	 encoded	 by	 the	 image	 (the	 velocity	 encoding	 value,	 “VENC”).	 Spin	velocities	above	the	VENC	will	cause	higher	phase	changes	but	be	confused	with	spins	moving	 in	 the	 opposite	 direction	 which	 result	 in	 the	 same	 phase	 difference.	 For	example,	 if	 the	VENC	is	set	at	100cm/s	a	spin	moving	at	125cm/s	will	 lead	to	a	phase	change	of	2250	(1800	x	125/100)	which	cannot	be	distinguished	from	a	phase	change	of	-1350	 corresponding	 to	 a	 spin	 moving	 at	 75cm/s	 in	 the	 opposite	 direction.	 This	
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property,	 “aliasing”,	 can	 be	 avoided	 by	 setting	 the	 VENC	 high	 enough	 to	 cover	 the	anticipated	range	of	blood	velocities.	
Phase-contrast	 imaging	 can	 be	 performed	 as	 a	 cine	 image	 to	 show	 flow	 across	 the	cardiac	cycle.	For	accurate	estimation,	it	should	be	done	exactly	parallel	to	the	direction	of	flow	by	alignment	in	two	orthogonal	views.	The	relationship	between	the	velocity	of	the	spins	in	the	gradient	direction	and	the	phase	shift	is	given	by:	
𝑃ℎ𝑎𝑠𝑒 𝑠ℎ𝑖𝑓𝑡 𝑟𝑎𝑑𝑖𝑎𝑛𝑠 =  𝛾 .𝑉𝑒𝑙𝑜𝑐𝑖𝑡𝑦 .∆𝑀!	 (2.8)	
where	𝛾 =	gyromagnetic	ratio,	∆𝑀!	=	difference	in	the	first	moment	of	the	gradient	field	(which	is	equal	to	the	gradient	pulse	x	the	duration	of	the	pulse	squared)	between	the	first	bipolar	pulse	and	the	second.	
Several	 potential	 sources	 of	 error	 exist	 in	 phase-contrast	 imaging	 [284].	 Flow	measurements	 are	 based	 on	 results	 from	 phantoms	 and	 lack	 an	 in	 vivo	 reference	standard.	Discrepancies	between	PA	and	aortic	flow	have	been	measured	at	5%	for	free-breathing	 cine	 gradient-echo	 sequences	 with	 prospective	 gating	 [285],	 and	 3%	 for	breath-hold	 FastCine	 PC	 [284]	 with	 retrospective	 gating	 sequences.	 Phase	 contrast	methods	 correlate	 well	 with	 Doppler	 ultrasound	 and	 reasonably	 with	 invasive	 flow	measurements	based	on	thermodilution	[286,	287].	Sources	of	error	include	setting	the	VENC	too	low,	leading	to	aliasing,	or	too	high	which	may	underestimate	flow	[285,	288].	Systematic	phase-errors	such	as	deviation	of	the	imaging	plane,	inadequate	temporal	or	spatial	 resolution,	 or	 phase-offset	 errors	 due	 to	 field	 inhomogeneities	 or	 gradient	imbalances	 affect	 stationary	 and	 moving	 spins	 alike.	 Accurately	 applied	 background	subtraction	may	compensate	for	this	[289].	
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Flow	 in	 the	 pulmonary	 vessels	 can	 be	 quantified	 using	 validated	 software	 (ART-FUN,	Inserm,	Paris,	Figure	1)[290]	[290,	291].	The	PC	images	are	uploaded,	and	after	manual	identification	 of	 the	 vessel	 of	 interest,	 automatic	 segmentation	 provides	 vessel	 area,	flow	velocity	and	flow	over	the	cardiac	cycle.	By	measuring	the	flow	at	two	points	in	the	same	vascular	tree,	the	time	delay	in	flow	initiation	over	systole	can	be	measured.	This	“transit	time	“corresponds	to	the	time	taken	for	the	systolic	pulse	to	travel	between	the	two	points	and	is	most	reproducible	using	several	measured	flow	values	between	10%	and	 90%	of	 the	 normalised	 flow	 (see	 Chapter	 9).	 The	 distance	 this	 pulse	 travels,	 the	path	 length,	 can	 be	 defined	 on	 the	 anatomical	 images	 using	 the	 same	 software.	 A	 3D	fitted	 Bezier	 curve	 is	 created	 which	 runs	 through	 the	 centre	 of	 the	 vessel,	 from	 the	proximal	 point	 at	 which	 flow	 was	 measured,	 to	 the	 distal	 point.	 From	 these	 two	measurements,	 the	 pulse	 wave	 velocity	 (PWV)	 in	 the	 pulmonary	 vessels	 can	 be	calculated.		
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Figure	2.21.	Flow	vs	time	in	the	main	and	right	pulmonary	arteries	
Normalized flow during the cardiac cycle can be obtained from phase-contrast imaging in the (a) main and right 
pulmonary arteries, with the relationship of scanning planes (b) illustrated on a pulmonary angiographic image. 
Transit time is measured from the upslope of the curve between the points shown. 	
2.4.4. Parallel	Imaging	Parallel	 imaging	 is	 a	 method	 of	 reducing	 the	 time	 needed	 to	 acquire	 an	 image,	shortening	 breath-holds	 and	 so	 avoiding	 motion	 artefacts	 and	 improving	 temporal	resolution.	 This	 is	 an	 important	 consideration	 in	 CMR	 and	 particularly	 in	 dyspnoeic	patients	where	breath-holds	may	be	difficult.	Reductions	in	scan	time	also	limit	energy	deposition	and	SAR,	which	may	be	 important	 at	higher	 field	 strengths.	 It	 is	discussed	here	 in	 relation	 to	 the	 Cartesian	 field	 for	 simplicity,	 though	 similarly	 principles	 have	been	applied	to	radial,	spiral	or	PROPELLER	trajectories	[292].	
Parallel	imaging	acquires	a	reduced	amount	of	k-space	data	from	which	the	full	image	is	reconstructed.	We	consider	acquisition	 time,	TA,	 in	relation	 to	2D	 imaging,	 though	 the	
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same	 principles	 apply	 to	 3D	 imaging	methods.	 K-space	 data	 are	 read	 in	 line	 by	 line,	giving	the	total	acquisition	time	as:	
	 𝑇! =  𝑇𝑅 × 𝑁!" 	 (2.9)	
TA	indicates	acquisition	time,	TR,	repetition	time;	NPE,	number	of	phase-encoding	lines	in	the	phase-encoding	direction.		
Reductions	 in	the	 imaging	time	can	be	achieved	by	reducing	the	TR,	or	the	number	of	lines	 of	 k-space	 acquired.	 Reducing	 the	 TR	 reduces	 the	 image	 contrast	 in	 some	sequences	(e.g.	SE)	but	not	 in	others	(e.g.	GE,	b-SSFP).	However	reductions	 in	TR	may	also	need	 increased	power	to	run	the	gradient	coils,	cause	 increased	peripheral	nerve	stimulation	 [293-295],	and	 lead	 to	 increases	 in	 the	SAR	[296].	Another	approach	 is	 to	reduce	NPE.	Theoretically	this	can	be	done	by	either	reducing	the	number	of	lines	of	k-space	 (kFOV)	 or	 increasing	 the	 width	 between	 the	 lines	 (Δk).	 Reducing	 kFOV	proportionally	increases	the	size	of	the	pixels,	Δw,	reducing	resolution	and	so	impairing	clinical	 interpretation.	 A	 preferable	 option	 is	 to	 remove	 some	 k-space	 lines,	 which	reduces	the	FOV	and	may	cause	aliasing	but	retains	image	resolution.	This	approach	has	successfully	 been	 used	 by	 several	 parallel	 imaging	 methods	 which	 share	 several	common	 characteristics	 [297]:	 K-space	 is	 under-sampled	 in	 the	 phase-encoding	direction.	 The	 degree	 to	which	 this	 happens	 is	 the	 acceleration	 factor.	 If	 the	 Nyquist	criterion	 is	 exceeded	 then	 aliasing	 will	 occur.	 Data	 are	 then	 acquired	 using	 several	independent	receiver	coils	sensitive	to	the	volume	nearest	the	coil,	rather	than	a	single	coil	(Figure	2.22).	This	gives	spatial	specificity	by	knowledge	of	the	position	of	the	coil,	as	well	as	the	signal	it	receives.	The	under-sampled	data	are	then	combined	allowing	for	the	specific	sensitivities	of	the	coils	and	aliasing	in	the	reconstructed	image.	
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(a) (b) 
	
Figure	2.22.	Parallel	Imaging 
(a) Images obtained from eight independent receiver coils can be combined to form a single image with uniform 
sensitivity, using knowledge of their position and sensitivities. (b) Linear array where parallel processing is not 
possible in the horizontal direction because coil sensitivity is homogeneous, but is possible in the vertical 
direction because coil sensitivity varies allowing spatial specificity. 
 Algorithms	can	be	divided	 into	 those	which	work	with	 the	aliased	 image	 (e.g.	 SENSE)	and	those	which	reconstruct	the	k-space	data	(e.g.	GRAPPA).	
Sensitivity	 Encoding	 (SENSE)	 [298]	 combines	 a	 map	 of	 coil	 sensitivities	 in	 different	parts	 of	 the	 image	 space,	 obtained	 using	 a	 reference	 scan	 before	 clinical	 scanning	 to	determine	 coil	 sensitivity	 profiles,	with	 the	 signal	 values	 at	 each	 pixel	 obtained	 from	each	 coil.	 By	 combining	 these	 data	 the	 real	 pixel	 values	 can	 be	 obtained	 and	 aliasing	removed.	 SNR	 is	 slightly	 reduced	 depending	 on	 the	 acceleration	 factor	 and	 the	 coil	geometry3.	 Generalized	 Autocalibrating	 Partially	 Parallel	 Acquisition	 (GRAPPA)	 [299]	takes	a	different	approach	and	regenerates	the	phase-encoding	lines	not	sampled	in	k-space	using	a	convolution	kernel.	This	approach	may	be	more	robust	in	images	of	 low	
																																																								3	The	SNR	reduction	in	parallel	imaging,	SNRPI,	is	given	by:	𝑆𝑁𝑅!" =  !"#! !	,	where	SNR	is	the	 non-parallel	 signal-to-noise	 ratio,	 g	 is	 the	 coil	 geometry	 factor	 and	 R	 is	 the	acceleration	factor.	
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signal	 where	 an	 accurate	 coil	 sensitivity	 map	 is	 hard	 to	 obtain	 [297].	 SNR	 is	 also	reduced	in	a	GRAPPA-reconstructed	image	depending	on	the	degree	of	acceleration,	R,	and	spatially	varying	noise	characteristics,	measured	by	the	GRAPPA	g-factor	[300].	
The	 benefits	 of	 parallel	 imaging	 protocols	 have	 been	 seen	 in	 many	 cardiovascular	applications.	Reduced	imaging	time	allows	increased	frame	rates	for	cine	imaging	[301],	allowing	studies	of	regional	wall,	valve	and	cardiac	dysfunction	[302].	Improvements	in	spatial	and	temporal	resolution	improve	the	accuracy	of	assessments	of	cardiac	function	[303,	304]	and	myocardial	perfusion	[305,	306],	which	are	important	in	many	diseases	including	hypertrophic	cardiomyopathy	[307]	and	ischaemic	heart	disease	[308].		
A	 further	 technique	which	 is	 combined	with	 parallel	 imaging	 to	 speed-up	 acquisition	times	is	“partial-Fourier”,	“halfscan”	or	“half	NEX”.	This	technique	exploits	the	fact	that	spin	density	in	the	image	field	is	real-valued,	which	implies	that	the	Fourier	transform	of	 the	data	will	be	a	Hermitian	 function,	 i.e.	 the	complex	conjugate	of	 the	data	will	be	equal	to	the	negative	of	the	original	data.	
	 𝑓 −𝑥 =  𝑓(𝑥)	 (2.10)	
In	 k-space	 this	 is	 equivalent	 to	 saying	 that	 there	 is	 1800	 rotational	 symmetry	 in	 the	phase-encoding	direction.	Field	imperfections	mean	that	slightly	more	than	50%	of	the	data	actually	need	to	be	acquired.	Acquisition	is	still	much	faster	and	spatial	resolution	is	unaffected,	though	SNR	is	reduced	by	about	30%.	
Conventional	 CMR	 cine	 images	 consist	 of	 short-axis	 sections	 spaced	10mm	apart	 and	thus	 long-axis	 resolution	 is	poor.	 Slice	 thickness	 is	usually	 less	 than	10mm,	 striking	a	balance	 between	 avoiding	 exciting	 neighbouring	 tissue	 while	 still	 providing	comprehensive	coverage	[309],	though	as	a	consequence	localised	regional	effects	may	
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be	missed.	Each	slice	requires	a	separate	breath-hold,	which	is	fatiguing	for	patients	and	may	 lead	 to	 poor	 breath-hold	 compliance,	 slice	 mis-registration	 and	 analysis	 errors	[310,	311].	
3D-CMR	allows	the	whole	ventricle	to	be	isotropically	sampled	and	reformatted	in	any	orientation.	Acquiring	 the	whole	volume	of	 interest	 in	a	 single	breath-hold	avoids	 the	problems	 of	 slice	 misalignment,	 though	 until	 recently	 acquisition	 times	 were	prohibitively	 long.	 Technical	 improvements	 in	 gradients,	 coil	 design	 and	 high-acceleration	 factor	 parallel	 imaging	 have	 reduced	 acquisition	 time	 to	 20-30s.	 Pulse	sequences	 for	 3D-CMR	phase-encode	 in	 two	directions,	 and	 frequency-encode	 in	 one.	These	 approaches	 often	 use	 parallel	 imaging	 (SENSE),	 partial-Fourier	 or	 k-space	temporal	 correlations	 to	 reduce	 acquisition	 time	 [312].	 Since	 the	 whole	 volume	 is	excited	 continuously,	 3D	 approaches	 have	 comparatively	 high	 SNR	 which	 makes	 3D	imaging	 less	 susceptible	 to	 the	 reductions	 in	 SNR	 caused	 by	 SENSE	 [313].	 However,	breath-holds	 are	 longer	 and	movements	 artefacts	 affect	 the	whole	 image	 field	 rather	than	just	the	slice	under	acquisition.		
The	accuracy	of	3D	and	2D	manual	volumetry	are	similar	using	b-SSFP	sequences,	and	scanning	 times	 are	 lower	with	 3D	 [312,	 314-324],	 though	 SNR	 is	 lower	 in-plane.	 3D-CMR	is	an	exciting	development	for	RV	assessment	where	subtle,	regional	changes	may	precede	global,	volumetric	changes	and	it	promises	to	be	an	important	tool	in	achieving	more	sensitive	prognostic	methods	[37].	
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(a) (b) 
	
Figure	2.23.	2D	b-SSFP	of	a	PH	patient	
(a) Short-axis view with high “in-plane” resolution; (b) Long-axis view with low long-axis resolution. 
	
(a)	 (b)	
	
Figure	2.24.	3D	b-SSFP	of	a	PH	patient	
(a) Short-axis view and (b) Long-axis view with high resolution in both directions. 
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2.4.5. Cardiac	Magnetic	Resonance	of	the	Right	Ventricle	CMR’s	 excellent	 visualisation	 of	 the	 right	 ventricle	 with	 highly	 reproducible	quantification	 of	 mass	 and	 volume	 measurements	 [104,	 325]	 have	 led	 it	 to	 quickly	become	the	gold	standard	for	the	assessment	of	RV	structure	and	function	[326,	327].	Freedom	 from	 acoustic	 windows,	 low	 operator-dependency	 and	 a	 lack	 of	 ionising	effects	extend	this	role	 to	 follow-up	examinations	and	although	breath-holding	can	be	problematic,	the	development	of	fast-imaging	techniques	has	allowed	CMR	of	the	right	ventricle	to	be	used	in	all	but	the	most	dyspnoeic	patients.	
Volumetric	 analysis	 for	 both	 ventricles	 is	 done	 at	 ventricular	 end-diastolic	 and	 end-systolic	frames.	In	normal	ventricular	contraction,	RV	end-systole	is	later	than	LV	end-systole	 [328]	but	 in	normal	 subjects	 the	difference	 in	 the	 choice	of	 frame	 for	 left	 and	right	 ventricle	 is	 at	 most	 one	 frame	 (25	 frames/cycle	 [329])	 and	with	 no	 significant	effect	on	RV	end-systolic	volume	(RVESV)	[329,	330].		
Including	 trabeculae	 and	 papillary	 muscles	 in	 the	 blood	 pool	 in	 healthy	 volunteers	affects	 volumetric	 estimations	 though	 the	 differences	 are	 small	 with	 varying	significance	[331,	332].	Including	these	structures	in	the	blood	pool	can	be	motivated	by	higher	 reproducibility	 [332-334]	and	reduced	analysis	 time	 [331]	but	 the	widespread	use	 of	 b-SSFP	 has	 improved	 tissue/blood	 delineation	 and	 semi-automated	 valve	tracking	allows	fast	and	highly	reproducible	analysis	[104].	Excluding	these	structures	from	 the	 blood	 pool	 allows	 variations	 in	 papillary	 and	 trabecular	 anatomy	 to	 be	measured	 which	 may	 be	 significant	 in	 the	 right	 ventricle	 [255,	 335]	 and	 these	approaches	 have	been	used	 in	 similar	 population-based	 studies	 of	 healthy	 volunteers	[336].		
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Several	 studies	 have	 presented	 normal	 ranges	 for	 RV	 volume	 and	 function	 [21,	 336-338],	although	only	three	use	the	b-SSFP	sequence	which	is	now	the	most	common	in	clinical	practice	 [336-338].	Of	 these	 three	studies,	only	one	excluded	papillary	muscle	mass	from	the	blood	pool	[336].	These	results	are	therefore	used	for	comparison	(Table	2.3,	Table	2.4).	
	 Men	 Women	
Parameter	 <60	years	 ≥	60	years	 <60	years	 ≥60	years	
RVEDV	(ml)	 169±25	(119,219)	 153±25	(103,203)	 133±22	(89,177)	 114±22	(70,158)	
RVEDVI	(ml/m2)	 87±12	(63,111)	 77±12	(53,101)	 78±9	(60,96)	 66±9	(48,84)	
RVESV	(ml)	 62±15	(32,92)	 48±15	(18,78)	 49±13	(23,75)	 35±13	(9,61)	
RVESVI	(ml.m-2)	 32±7	(18,46)	 24±7	(10,38)	 28±7	(14,42)	 20±7	(6,34)	
RVSV	(ml)	 107±17	(73,141)	 105±17	(71,139)	 85±13	(59,111)	 80±13	(54,106)	
RVSVI	(ml.m-2)	 55±8	(39,71)	 53±8	(37,69)	 50±6	(38,62)	 46±6	(34,58)	
RVEF	(%)	 64±7	(50,78)	 69±7	(55,83)	 64±6	(52,76)	 70±6	(58,82)	
RVM	(g)	 68±14	(40,96)	 63±14	(35,91)	 50±11	(28,72)	 44±11	(22,66)	
RVM	(g/m2)	 35±7	(21,49)	 32±7	(18,46)	 30±5	(20,40)	 25±5	(15,35)	
Table	2.3.	Normal	right	ventricular	volumetric	parameters	by	age	and	gender	
From Kawel-Boehm et al [339]. Values are mean ± SD (lower/upper limits*); I indicates values indexed to body 
surface area; RVEDV, right ventricular end-diastolic volume; RVESV, right ventricular end-systolic volume; RVSV, 
right ventricular stroke volume; RVEF, right ventricular ejection fraction; SD, standard deviation. *calculated as 
two standard deviations from the mean. 
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Age	(years)	 20-29	 30-39	 40-49	 50-59	 60-69	 70-79	
Males 
RVEDV	(ml)	 177	(127,	227)	 171	(121,	221)	 160	(116,	216)	 160	(111,210)	 155	(105,	205)	 150	(100,200)	
RVESV	(ml)	 68	(38,	98)	 64	(34,	94)	 59	(29,	89)	 55	(25,	85)	 50	(20,80)	 46	(16,	76)	
RVSV	(ml)	 108	(74,	143)	 108	(74,	142)	 107	(73,	141)	 106	(72,	140)	 105	(71,	139)	 104	(70,	138)	
RVEF	(%)	 61	(48,	74)	 63	(50,	76)	 65	(52,	77)	 66	(53,	79)	 68	(55,	81)	 70	(57,	83)	
RVEDVI	(ml/m2)	 91	(68,	114)	 88	(65,	111)	 85	(62,	108)	 82	(59,	105)	 79	(56,	101)	 75	(52,	98)	
RVESVI	(ml/m2)	 35	(21,	50)	 33	(18,	47)	 30	(16,	45)	 28	(13,	42)	 25	(11,	40)	 23	(8,	37)	
RVSVI	(ml/m2)	 56	(40,	72)	 55	(39,	71)	 55	(39,	71)	 54	(38,	70)	 53	(37,	69)	 52	(36,	69)	
Females 
RVEDV	(ml)	 142	(100,	184)	 136	(94,	178)	 130	(87,	172)	 124	(81,	166)	 117	(75,	160)	 111	(69,	153)	
RVESV	(ml)	 55	(29,	82)	 51	(25,	77)	 46	(20,	72)	 42	(20,	72)	 37	(11,	63)	 32	(6,	58)	
RVSV	(ml)	 87	(61,	112)	 85	(59,	111)	 84	(58,	109)	 82	(56,	108)	 80	(55,	106)	 79	(53,	105)	
RVEF	(%)	 61	(49,	73)	 63	(51,	75)	 65	(53,	77)	 67	(55,	79)	 69	(57,	81)	 71	(59,	83)	
RVEDVI	(ml/m2)	 84	(65,	102)	 80	(61,	98)	 76	(57,	94)	 72	(53,	90)	 68	(49,	86)	 64	(45,	82)	
RVESVI	(ml/m2)	 32	(20,	45)	 30	(17,	43)	 27	(14,	40)	 24	(11,	37)	 21	(8,	34)	 19	(6,	32)	
RVSVI	(ml/m2)	 51	(39,	63)	 50	(38,	62)	 49	(37,	61)	 48	(36,	60)	 46	(34,	58)	 45	(33,	57)	
Table	2.4.	Normal	volumetric	ranges	for	the	right	ventricle	by	age	
Normal volumetric ranges for the right ventricle, from Maceira et al [336] 
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CMR	 has	 firmly	 established	 itself	 in	 PH	 since	 it	was	 first	 used	 in	 1985	 [340].	 This	 is	unsurprising	since	RV	hypertrophy,	contractile	changes	[341]	and	right	atrial	dilatation	[2,	 100]	 are	 common	 in	 PH	 and	 well-appreciated	 by	 CMR.	 CMR	 can	 also	 assess	 the	effects	of	PH	outside	the	right	ventricle.	 In	the	 left	heart,	RV	dilatation	may	reduce	LV	preload	and	cardiac	output.	In	the	medium	and	large	pulmonary	vessels,	dilatation	and	thickening	 of	 the	 arterial	 media	 may	 occur	 with	 deposition	 of	 mucopolysaccharide	ground	substance	altering	the	structure	of	 the	vessel	 increasing	vascular	stiffness	[38,	342].	CMR	can	simultaneously	assess	LV	volumetry	and	pulse	wave	velocity	by	phase-contrast	imaging,	lending	insight	to	both	of	these	sets	of	pathological	changes.	
CMR	may	be	used	in	the	diagnosis	or	follow-up	of	PH	and	definitive	protocols	have	not	been	 established.	 In	 accordance	 with	 international	 guidelines	 on	 CMR	 tomographic	imaging,	 the	 heart	 is	 oriented	 using	 the	 long-axis	 of	 the	 left	 ventricle.	 Short-axis	 and	vertical	long-axis	planes	are	imaged	at	900	to	this.		
Although	scanning	practices	 for	CMR	 in	PH	vary,	Bradlow’s	approach	(Table	2.5	 [38])	provides	 an	 excellent	 template.	A	minimum	dataset	 includes	biventricular	 volumes	 at	end-diastole	and	end-systole	from	consecutive,	contiguous,	short-axis	slices	from	which	stroke	 volume	and	 ejection	 fraction	 are	 calculated.	Biventricular	mass	 is	measured	 at	end-diastole.	 Volumetry	 may	 be	 performed	 in	 other	 planes	 [343,	 344]	 which	 may	improve	 reproducibility	 and	 inter-ventricular	 agreement	 [343,	 344].	 However,	 these	approaches	have	not	been	widely	adopted,	preventing	comparison	with	other	cohorts	[21,	 336].	 No	 consensus	 approach	 exists	 on	 whether	 volumetry	 should	 include	 the	septum,	 papillary	 muscles	 or	 trabeculae,	 or	 how	 end-systole	 is	 defined.	 This	 is	particularly	 significant	 in	 PH,	where	 position	 of	 the	 septum	may	 change	 dramatically	
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near	 end-systole,	 making	 decisions	 on	 phase-assessment	 highly	 significant	 in	volumetric	analysis.	
Quantitative	methods	aim	to	summarise	global	ventricular	function	or	use	the	function	at	pre-defined	anatomical	points	such	as	the	lateral	tricuspid	annulus	or	the	RV	freewall	as	surrogates	of	global	 function	[26,	110].	However,	surrogate	markers	of	RV	function	are	problematic.	Some	regions	are	easy	to	measure,	some	are	strongly	associated	with	ventricular	function	and	some	are	sensitive	to	dysfunction,	but	these	three	areas	do	not	necessarily	 coincide	 [26]	 and	may	 change	 in	 disease	 [114].	 Furthermore,	 even	 in	 the	normal	 ventricle,	 markers	 of	 function	 show	 regional	 variation	 suggesting	 that	 single	measures	are	unlikely	to	provide	a	comprehensive	assessment	of	function	[115].	
Flow	 imaging	of	 the	pulmonary	arteries	may	be	used	 to	estimate	stroke	volume	or	 to	exclude	thromboembolic	disease	or	shunt,	though	additional	anatomical,	cine	and	flow	imaging	may	be	necessary	[38,	345].	Contrast	imaging	with	gadolinium	has	been	shown	to	 identify	 enhancement	 in	 the	 RV	 insertion	 points	 [346-348]	 which	 may	 represent	fibrosis	[349]	and	therefore	substrate	for	ventricular	arrhythmias	[348],	though	it	may	also	 represent	 the	 pooling	 of	 gadolinium	 in	 an	 area	 where	 normal	 myocardial	architecture	has	been	altered	by	pressure-overload	[38].		
CMR	may	also	be	able	 to	provide	 insight	 into	 the	 structure	of	 the	pulmonary	arteries	and	 thus	 vascular	 degeneration.	 Arterial	 stiffness	 in	 the	 systemic	 circulation	 is	 an	important	 marker	 of	 cardiovascular	 events	 [350],	 LV	 hypertrophy	 [351],	 dilatation	[352]	and	dysfunction	[353].	It	is	possible	to	measure	arterial	stiffness	in	the	pulmonary	circulation,	though	fewer	data	exist	[354].	Increases	in	PA	stiffness	have	been	noted	in	PH	 [355,	 356]	 and	 animal	 and	 theoretical	 models	 suggest	 that	 vascular	 stiffness	 has	adverse	 effects	 on	 the	 right	 ventricle	 [357-360].	 Separating	 the	 effects	 of	 pulmonary	
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vascular	resistance	and	PA	stiffness	on	the	right	ventricle	is	difficult	however,	since	all	measures	 are	 likely	 to	 be	 abnormal	 and	 causation	 is	 difficult	 to	 establish.	 Although	clinical	 trials	 in	 patients	 with	 early-stage	 disease	 are	 desirable	 [361],	 time	 from	symptom-onset	to	diagnosis	remains	high	in	PH	[362]	and	the	structure	and	function	of	the	 right	 ventricle	 are	 abnormal	 even	 at	 first	 presentation	 [363].	 Work	 in	 healthy	subjects	 may	 therefore	 provide	 a	 better	 population	 to	 study	 the	 effects	 of	 arterial	stiffness	on	the	right	ventricle.	
The	 approval	 of	 imaging	 as	 a	 surrogate	 endpoint	 for	 drug	 studies	 is	 timely	 for	 CMR	[364,	365].	Several	studies	report	the	beneficial	effects	of	both	medical	 [366-369]	and	surgical	 [370-374]	 therapies	 on	 RV	 structure	 and	 function	 and	 two	 therapies	 have	already	been	 trialled	using	RV	mass	as	an	 study	end-point	 [368,	375],	 though	RVM	 is	complex	since	it	is	unclear	whether	an	increase	or	a	decrease	in	RV	mass	is	desirable.	
The	excellent	 inter-study	 reproducibility	of	CMR	[376],	non-ionising	and	non-invasive	approach	make	 it	 an	appealing	 study	marker.	CMR	also	provides	mechanistic	 insights	which	 are	 not	 provided	 by	 the	 current	 trial	 surrogate	marker	 for	 pulmonary	 arterial	hypertension,	the	six-minute	walk	test.	
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Insight	 CMR	Method	 Reference	
Early	changes	PA	stiffens	before	PA	pressure	increases	at	rest	 Distensibility	of	PA	 [377]	
Ventricular	Remodelling	and	Dysfunction	LV	mass	is	lower	in	patients	with	chronic	thromboembolic	disease	by	normalises	post-pulmonary	endarterectomy	 LV	mass	 [378]	Interventricular	dyssynchrony	and	septal	bowing	in	PAH	is	due	to	slower	contraction	for	the	RV	than	LV	 Tagging	 [379]	
Cardiac	ischaemia	Both	ventricles	display	attenuated	vasoreactivity	proportional	to	mPAP	 Adenosine	Stress	Perfusion	 [380]	
RV	metabolism	Bosentan	improves	RV	energetics	 31P-NMR	spectroscopy	 [381]	
Ventricular-arterial	Decoupling	in	PH	Disconnect	occurs	since	increases	in	arterial	load	are	far	greater	than	those	in	contractility		 Volumes	combined	with	invasively	derived	pressure	loops/pressures	 [89,	382]	
Changes	with	Exercise	Stroke	volume	in	PAH	fails	to	augment	–	increases	in	cardiac	output	are	mediated	by	heart	rate	alone	 Bicycle	exercise	 [383]	
Inaccuracy	of	Catheter-Laboratory	Measurements	Pulmonary	vascular	resistance	derived	from	the	Fick	method	is	inaccurate	in	conditions	of	vasodilatation	 Flow	combined	with	invasively	derived	pressure	 [384]	
Table	2.5.	Mechanistic	insights	from	CMR	in	PH	
Figure from Bradlow et al. [38] 	
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Non-invasive	 imaging	 is	 important	 in	 the	diagnosis	 and	management	of	 patients	with	PH	though	there	is	a	need	for	more	detailed	information	to	be	extracted	from	imaging.	In	 particular,	 the	 use	 of	 imaging	 in	 understanding	 pathophysiology,	 the	 modulatory	effects	 of	 genetic	 factors	 on	 RV	 adaptation	 and	 imaging-based	 biomarkers	 for	prognostic	 stratification	 [37].	 	 We	 propose	 approaches	 which	 may	 be	 useful	 in	addressing	these	unmet	needs.	
2.4.6. Atlas-Based	Segmentation	of	Magnetic	Resonance	Images	Although	CMR	has	achieved	an	unrivalled	position	in	the	non-invasive	assessment	of	the	right	heart,	many	of	the	unmet	goals	are	not	achievable	with	standard	CMR	approaches	[37].	2D,	volumetric	approaches	are	unable	to	identify	regional	changes	in	structure	and	function	 which	 may	 long	 precede	 macroscopic	 changes	 in	 mass	 and	 volume.	Furthermore,	 the	 response	 to	 chronic	 raised	 afterload	 includes	 an	 initial	 increase	 in	contractility,	 with	 ventricular	 hypertrophy	 encroaching	 on	 cavity	 size,	 before	progressing	to	ventricular	dilatation	and	dysfunction.	Volumetric	markers	therefore	do	not	 deteriorate	 monotonically,	 preventing	 single	 thresholds	 of	 dysfunction	 to	 be	determined.	 Calculation	 of	 RV	 volumes	 is	 time-consuming,	 unstandardized	 and	confounded	by	intra-	and	inter-	observer	variability	[112,	338,	385].	
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Figure	2.25.	Schematic	of	volumetric	and	contractile	changes	with	clinical	progression	
Horizontal and vertical axes show clinical deterioration and quantitative assessment, respectively. Axes not to 
scale. Neither volumetric nor contractile markers monotonically deteriorate with clinical progression making 
identifying a threshold in one-dimensional metrics difficult. 
		Constructing	 a	 3D	 model	 of	 the	 ventricle	 (“segmentation”)	 allows	 global	 parameters	such	as	volume	and	mass	to	be	calculated	[386],	and	local	parameters	such	as	regional	wall	motion	[387]	and	timing	[388]	to	be	measured	as	well.	Other	datasets	such	as	late	gadolinium	 enhancement	 can	 also	 be	 overlaid	 [389-391].	 This	 process	 is	 extremely	laborious	 to	 perform	manually	 but	 its	 automation	 allows	 the	 benefits	 of	 quantitative,	reproducible	phenotyping	at	high-resolution.	Automated	segmentation	of	brain	images	has	been	highly	successful	[392-396],	though	cardiac	and	respiratory	motion	has	made	translating	 these	 approaches	 to	 cardiac	 imaging	 difficult.	 Despite	 this,	 computational	approaches	 to	 understanding	 LV	 structure	 and	 function	 have	 been	 successful	 [388,	397].		
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Segmentation	 techniques	 can	 be	 categorised	 according	 to	 whether	 the	 algorithm	 is	provided	with	prior	 information	about	the	target	or	not.	Methods	based	purely	on	the	appearances	of	 the	 image	aim	to	delineate	 the	 target	organ	by	 image	 features	such	as	thresholds,	 edge-based	 techniques	 or	 pixel	 classification	 and	 offer	 limited	 success.	Models	which	use	higher-level	information	such	as	deformable	models	or	active	shape	or	active	appearance	model	(ASM/AAM)	are	more	successful.	Finally,	atlas	models	offer	large	 numbers	 of	 manually-annotated	 images	 [398].	 Atlas-based	 methods	 produce	better	results	but	are	costly	 in	 time	and	expertise	 to	produce	depending	on	 the	detail	and	 number	 of	 variations	 provided.	 In	 Petitjean’s	 2011	 review	 [398],	 image-based	methods	 were	 most	 commonly	 used	 for	 automated	 segmentation	 of	 the	 ventricles,	though	 techniques	segmenting	 the	 left	ventricle	were	 three	 times	more	common	 than	those	attempting	to	segment	the	right	ventricle	(left/right,	n=67/21).	
(a)	 (b)	
	 	
Figure	2.26.	Summary	of	published	methods	of	cardiac	MR	segmentation	
(a) Shows the predominance of algorithms segmenting the left ventricle over algorithms segmenting the right 
ventricle. (b) Shows the range of approaches used for each ventricle. Atlas-based approaches are uncommon 
but are more commonly used for RV segmentation. This is unsurprising given the RV’s complex shape and 
comparatively poor tissue/blood contrast. 
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Given	the	complex	geometry	and	thin	walls	of	 the	right	ventricle,	with	 trabeculae	and	papillary	 muscles	 within	 the	 blood	 pool,	 it	 is	 unsurprising	 that	 few	 examples	 of	 RV	segmentation	 are	 published	 and	 those	 that	 do	 are	more	 likely	 to	 use	 prior	 data	 (RV:	9/21,	43%,	LV:	21/67,	31%).	A	detailed	review	of	all	segmentation	methods	is	beyond	the	scope	of	this	discussion	and	already	available	elsewhere	[398],	but	a	brief	overview	of	 segmentation	 using	 prior	 information	 focusing	 on	 atlas-based	 techniques	 is	 given	below,	as	these	are	the	most	relevant	to	RV	segmentation.	
Many	 approaches	 to	 ventricular	 segmentation	 have	 been	 described	 of	 which	 a	proportion	 use	 prior	 information	 to	 guide	 the	 segmentation	 algorithm	 [398].	 Prior	information	includes	landmarks,	contours	or	annotations	of	the	whole	target	(“atlases”),	manually	added	to	example	images.	The	complexity	of	the	right	ventricle	and	the	poor	image	contrast	between	the	trabeculae,	papillary	muscles,	thin	wall	and	blood	pool	has	led	to	a	variety	of	segmentation	approaches.	Whole-ventricle	atlases	are	common	in	this	as	although	laborious,	they	provide	the	most	complete	information	[36].		
In	 cardiac	 imaging,	 a	 segmentation	 algorithm	 aims	 to	 replicate	 the	 endocardial	 and	epicardial	contours	of	a	specified	chamber	at	given	phases	of	the	cardiac	cycle.	For	the	right	ventricle,	segmentation	at	end-systole	and	end-diastole	allows	global	and	regional	parameters	to	be	derived.	The	following	describes	a	workflow	which	is	shared	by	many	methods	and	provides	an	overview,	although	the	precise	details	vary	in	each	approach.	
To	reduce	computational	burden,	imaging	data	distant	to	the	heart	is	typically	removed	and	the	cardiac	phases	of	interest	are	identified.	Several	methods	are	used	to	crop	the	image	to	the	heart,	including	identifying	regions	of	high	variance	over	time,	training	an	algorithm	 to	 learn	 the	 appearance	 of	 the	 heart	 using	 positive	 and	negative	 examples,	and	using	 the	planning	 information	provided	by	 the	radiographer	when	acquiring	 the	
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images.	Further	spatial	refinement	can	be	made	by	 landmarks	placed	manually	by	the	user	 at	 agreed	 anatomical	 points.	 Electrocardiogram	 gating	 allows	 the	 images	 to	 be	consistently	 related	 to	 the	 phases	 of	 the	 cardiac	 cycle,	 and	 the	 end-diastolic	 image	 is	typically	 presented	 first.	 By	 identifying	 the	 “most-different”	 image,	 as	 quantified	 by	greyscale-differences	 between	 the	 images,	 end-systole	 can	 be	 identified.	 Algorithms	may	pre-smooth	 these	 differences,	 to	 guard	 against	 single-frame	 artefacts	 influencing	this	process	[399].		
The	use	of	several	manual	atlases	improves	segmentation	accuracy	when	compared	to	single-atlas	 segmentation	 [400-403]	 by	 representing	 a	 greater	 range	 of	 biological	variability,	 and	 by	 averaging	 results	 from	 several	 atlases	 and	 thus	 reducing	 the	influence	of	 sporadic	errors	 in	 segmentation	 [404].	These	data	may	be	contained	 in	a	large	number	 (10-1000)	of	discrete	manually-annotated	segmentation	examples	 [399,	405-407],	 or	 by	 summarising	 the	 information	 using	 a	 dimensionality	 reduction	technique	such	as	principal	component	analysis	[408,	409].	A	further	nuance	is	the	pre-selection	of	a	subset	of	atlases	at	this	stage.	A	number	of	atlas	selection	methods	[410-412],	global	or	local	similarity	weightings	[413-416]	and	markers	of	atlas	“performance	level”	[417]	have	shown	improved	performance	by	doing	this.	
For	all	approaches,	the	atlas	pool	is	then	aligned	to	the	target	image,	“registration”,	by	a	spatial	 transformation	 to	 remove	basic	differences	such	as	 image	orientation	and	size	before	 comparison	 with	 the	 target	 image.	 Several	 categories	 of	 transformation	 exist	(Table	2.6).		
 Translation,	rotation	 Scaling,	shearing	 Non-linear	transformations	
Rigid	 X	 	 	
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Affine	 X	 X	 	
Non-rigid	 X	 X	 X	
Table	2.6.	Classification	of	transformations	
Rigid and affine transformations are global transformations and therefore retain global topology well, but 
cannot adapt to local geometric differences between images. Non-rigid transformations fit well to local 
changes but do not preserve shape. Algorithm may combine both transformations to attempt to preserve both 
aspects. 	
Analogous	to	statistical	model	fitting,	more	complex	transformations	fit	the	target	more	closely,	but	risk	overfitting	and	deviating	from	biologically	plausible	shapes.		
Each	 voxel	 on	 the	 target	 image	 can	 now	 be	 considered	 sequentially,	 and	 a	 predicted	label	 assigned,	 based	 on	 the	 findings	 at	 the	 same	 voxel	 in	 the	 atlas	 images.	 Several	methods	of	reaching	a	consensus,	“label	fusion”,	have	been	proposed	[404].	Expanding	the	match	area	to	a	patch	of	voxels,	rather	than	a	single	voxel,	improves	accuracy	[418-422].	 Comparing	 patches,	 “PatchMatch”,	 has	 demonstrated	 good	 results	 in	 cardiac	imaging	 even	with	 small	 errors	 in	 registration	 [399,	 423,	 424].	 The	 relaxation	 of	 the	match	 area	 from	 voxel	 to	 patch	 allows	 good	 performance	 even	 if	 registration	 is	imperfect.	In	turn	this	has	led	to	an	increase	in	registration	using	affine	transformations,	which	retain	shape	better	than	non-rigid	transformations,	but	as	a	consequence	fit	less	accurately.	Affine	registration	preserves	biological	organ	shape	better	resulting	in	more	realistic	final	segmentations.	Several	methods	of	identifying	the	closest	matching	patch	have	been	suggested.	Methods	of	differential	weighting	of	suggested	patches,	 linked	to	patch	intensities	have	been	trialled	[425].	Proximity	methods	have	also	been	trialled	to	estimate	 the	 “best”	 fitting	patch	–	Tong	 [426]	and	Zhang	 [427]	by	using	 the	L1	norm,	Wang	by	minimising	the	expectation	of	the	labelling	error	[419].	Although	a	large	body	
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of	work	using	this	approach	exists,	most	studies	focus	on	optimising	the	weight	function	[419,	425-427]	or	adapting	a	patch	approach	to	specific	areas	[428-431].	
A	 more	 substantial	 development	 in	 patch-based	 approaches	 combines	 intensity	information	with	spectral	registration.	By	representing	images	as	a	web	of	connections	between	points,	a	“graph”,	the	degree	of	deformation	required	to	match	an	atlas	patch	with	the	target	can	be	quantified.	Matches	requiring	a	large	degree	of	deformation	can	be	penalised	 in	 the	 label	decision.	This	allows	an	easy	 form	of	 regularisation	which	 is	lacking	 in	 PatchMatch	 approaches,	 and	 further	 improves	 on	 the	 overfitting	 problem	described	above,	in	which	intensity	matches	are	tightly	adhered	to,	at	the	expense	of	a	physiological	 result.	 Simultaneously	 assessing	 the	 intensity	 and	 the	 degree	 of	deformation	has	led	to	the	spectral	PatchMatch	method	[399].	
To	 allow	 comparison	 between	 subjects,	 a	 target	 image	 may	 be	 co-registered	 to	 a	common	 template	 image	 with	 a	 consistent	 numbering	 scheme.	 Co-registration	 aligns	the	 target	 image	 with	 the	 template	 image	 by	 affine	 transformation,	 again	 retaining	shape,	and	identifies	points	on	the	target	image	nearest	to	each	vertex	on	the	template.	Both	 images	 are	 converted	 to	meshes	 by	 the	Marching	 Cubes	 algorithm	 to	 allow	 this	[432].	The	choice	of	standardised	mesh	here	is	arbitrary	-	typically	a	representative	or	mean	 image	–	but	 serves	 to	ensure	 the	points	on	each	 target	 correspond	 to	 the	 same	anatomical	 points	 across	 all	 subjects.	 Once	 correspondence	 has	 been	 established	between	points	 on	 the	 target	mesh	 and	 the	 template,	 the	 target	mesh	 is	 transformed	back	to	its	original	size	and	phenotypes	such	as	wall	position	measured	at	each	of	these	points.	
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Shi’s	 algorithm	 typifies	 this	 process	 and	 has	 demonstrated	 higher	 Dice	 coefficients,	indicating	improved	accuracy,	than	any	other	algorithm	for	RV	segmentation	[399].	The	workflow	for	this	algorithm	is	shown	in	Figure	2.27.	
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Figure	2.27.	Overview	of	the	spectral	PatchMatch	algorithm	
The following describe the steps in the spectral PatchMatch algorithm. Although some steps are common to 
many methods, the details may also vary. 1. From the localisation images a bounding box is set around the heart 
in the short axis and information outside this region is discarded. 2. Landmarks are placed manually at six 
locations marking the extremities of the ventricles. 3. The end-diastolic (ED) and end-systolic (ES) frames are 
automatically detected using ECG-gating and greyscale difference, respectively. 4. Atlas images (no box) are 
aligned (green box) by an affine transformation (translation, rotation, scaling and shearing) to the target image 
from which a maximum of 40 atlases were selected on the basis of best fit (image shows only four atlases). 5. 
Greyscale patches of side 1-5mm are matched to patches within the atlas pool, with fit judged by greyscale and 
point deformation data. Labels are voted on for each patch based on these patches weighted to best fits. 6. The 
segmentation produced is co-registered to a template image (red) and mesh generated by the Marching Cubes 
algorithm [432] to ensure point correspondence between subjects. 	
We	 suggest	 that	 this	 approach	 provides	 an	 effective,	 consistent	 approach	 to	 high-resolution	 phenotyping,	 which	 avoids	 the	 variability	 of	 manual	 approaches	 and	
99	
provides	a	highly	powered	tool	for	population-based	studies	of	the	determinants	of	RV	structure	and	function.		
2.5. Statistics	Although	 3D	 segmentation	 techniques	 allow	 high-resolution	whole-ventricle	 analysis,	large	datasets	bring	specific	statistical	challenges.		
2.5.1. Segmentation	Data	and	Statistical	Challenges	Segmentation	 produces	 datasets	 describing	 the	 2D	 manifold	 using	 scalar	 quantities	such	as	wall	thickness	or	curvature	measured	at	a	large	(104	-	105)	number	of	points	in	3D	 space.	 Each	 point	 is	 co-registered	 between	 subjects	 and	 so	 represents	 the	 same	anatomical	position	on	each	heart.		
2.5.2. The	Curse	of	Dimensionality	For	any	single	segmentation,	data	consist	of	a	 large	number	of	dimensions	which	may	greatly	 exceed	 the	 number	 of	 samples	 available	 which	 typically	 number	 102	 -	 103,	 a	problem	described	as	the	“curse	of	dimensionality”	[433]	or	“small-n-large-p”	paradigm	[434].	The	problems	caused	depend	on	the	analysis,	but	some	general	principles	apply.	
As	the	dimension	of	the	sample	space	grows,	the	density	of	points	uniformly	distributed	in	a	unit-hypercube	reduces	as	the	reciprocal	of	the	dimension	power.	For	example,	in	d	dimensions,	a	hypercube	of	side	 l,	sized	to	capture	a	fraction	f	of	the	observations	will	have	volume:	
𝑙! = 𝑓	
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Or:	𝑙 = 𝑓!/! .	So,	when	d=1	if	we	want	to	capture	1%	of	the	samples	(i.e.	f	=	0.01),	then	l	=	0.01.	However,	then	d	=	10,	to	capture	the	same	fraction	of	samples,	(i.e.	f	=	0.01),	then	l	=	0.63.	This	problem	is	shown	for	several	dimensions	in	Figure	2.28.	
(a) (b) 
	 	
Figure	2.28.	Point	density	decreases	as	dimensionality	increases 
(a) For a 3D cube, the contained cube of side l = 0.011/3 = 0.21 will contain 1% of the total number of points in 
the larger cube, if they are evenly distributed. (b) As dimensionality increases, the size of the smaller hypercube 
big enough to capture the same fraction of points rapidly tends to the size of the larger hypercube. 	
This	can	conversely	be	thought	of	as	a	reduction	in	the	density	of	samples	in	the	sample	space,	 so	 for	 techniques	which	aim	 to	 identify	patterns	across	 samples,	 such	as	ML,	 a	larger	number	of	points	 is	 required.	For	example,	 in	one	dimension,	100	samples	will	provide	a	sample	density	over	 the	unit	 interval	of	1/100	=	0.01.	To	provide	 the	same	density	of	points	in	a	10-dimensional	space,	(102)10	=	1020	points	are	needed.	Each	point	here	represents	an	 imaged	subject,	and	providing	this	number	of	samples	 is	 therefore	not	 practical.	 Conversely,	 if	 only	 a	 small	 fraction	 of	 these	 samples	 are	 provided,	inferences	are	likely	to	be	poor.		
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A	direct	consequence	of	reducing	sample	density	is	that	in	high-dimensional	datasets	it	becomes	 easier	 to	 separate	 out	 the	 test	 samples	 perfectly	 into	 separate	 groups	 using	additional	 dimensions	 to	 separate	 the	 data.	 In	 the	 extreme,	 when	 the	 number	 of	dimensions	 is	 equal	 to	 or	 greater	 than	 the	number	of	 samples,	 individual	 dimensions	can	be	used	to	categorise	individual	samples	so	the	classification	of	“training”	data	will	be	perfect.	However,	the	classification	method	may	be	unrealistic	and	perform	poorly	in	unseen,	“test”	datasets,	sampled	from	the	same	population.	The	aim	of	model	fitting	is	to	use	 the	 sampled	 data	 to	 understand	 the	 population	 model	 most	 accurately,	 not	 the	sampled	data.	
To	 illustrate	this,	consider	Figure	2.29	which	shows	two	groups	of	subjects,	shown	by	black	 and	 red	 dots,	 classified	 using	 two	 parameters	 indicated	 by	 the	 x-	 and	 y-	 axis	variables.	 The	 subjects	 form	 fairly	 distinct	 groups:	 black-dot	 subjects	 have	 higher	 y-values	 than	 red-dot	 subjects	 for	 any	 x,	 though	 noise	 in	 the	 signal	 prevents	 a	 linear	classifier	 with	 two	 parameters	 separating	 the	 groups	 with	 100%	 accuracy4	 (Figure	2.29a).	 Adding	 further	 parameters	 (dimensions)	 with	 more	 complex	 dependencies,	allows	 the	 model	 to	 classify	 the	 subjects	 more	 accurately	 but	 gets	 no	 nearer	 to	 the	underlying	 relationship.	 This	 is	 apparent	when	 the	more	 complex	model	 is	 projected	back	 to	 the	 2D	 space,	 Figure	 2.29b,	 where	 the	 accuracy	 of	 the	 classification	 is	numerically	improved,	but	the	more	complex	classification	method	fails	to	capture	the	underlying	 relationship	 any	 better.	 (Note	 that	 apart	 from	 the	 case	 in	 which	 the	additional	 dimensions	 are	 completely	 linearly	 independent,	 this	 leads	 to	 non-linear	boundaries	in	the	lower-dimensional	space	as	shown	in	Figure	2.29).	Numerically,	this	problem	becomes	apparent	when	the	more	complex	method	 is	used	 in	a	new,	unseen																																																									4	“Accuracy”	can	be	formally	defined	as	the	sum	of	the	true	positive	and	true	negative	classifications	as	a	fraction	of	the	total	number	of	subjects.	
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dataset	 sampled	 from	 the	 same	 population	 and	 therefore	 with	 the	 same	 underlying	relationship	between	x	and	y.	Classification	in	the	new	dataset	is	now	worse	than	using	the	original,	simpler	model,	and	becomes	progressively	worse	as	the	complexity,	or	the	dimensionality,	of	the	model	increases	(Figure	2.30).	
(a)	 (b)	 (c)	 (d)	
	 	 	 	
Figure	2.29.	Overfitting	
Two groups of patients (red and blue) are classified by a low-dimensional linear model (left column) and a high 
dimensional linear model (right column) with predicted classification given in light-blue and purple. The low-
dimensional model (a) fits the training data with moderate accuracy (78%) and comparable accuracy (82%) in the 
unseen, test group, (b). The high-dimensional model fits the training data more accurately (c, accuracy 86%) but 
performs poorly in the test group (d, accuracy 73%) suggesting the training model has been overfitted.  
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Figure	2.30.	The	importance	of	testing	out	of	sample 
Increasing model complexity improves classification performance in the training data (blue) but may impair 
performance in unseen data (red)  
	These	 data	 also	 show	 the	 importance	 of	 separate	 training	 (“in	 sample”)	 and	 testing	(“out	 of	 sample”)	 cohorts	 when	 selecting	 and	 tuning	 a	 model,	 especially	 in	 high-dimensional	 datasets.	 Several	 methods	 allow	 separate	 in-/out-of	 sample	 testing	including	hold-out	and	cross-validation	methods.	In	all	approaches,	classification	error	may	then	be	quantified	by	accuracy	(for	groups)	or	mean	squared	error	(for	continuous	outcomes).	
The	hold-out	method	splits	the	available	data	into	two	groups	–	a	training	dataset	which	is	used	to	train	the	classifier	and	a	test	dataset	which	is	used	to	estimate	the	error	rate	of	the	trained	classifier.	This	is	a	simple	method	though	it	has	two	disadvantages:	 in	a	
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sparse	sample-space	this	may	not	be	an	efficient	use	of	the	data,	and	the	model	is	prone	to	bias	if	the	train/test	split	is	non-representative	of	the	population.	
Cross-validation	methods	within	the	same	data	set	allow	a	more	efficient	use	of	the	data	and	 include	 random	 subsampling,	 K-fold	 and	 “leave-one-out”	 methods.	 Random	resampling	 rebuilds	 the	model	 from	scratch	using	a	 fixed	number	of	 random	samples	taken	 from	 the	 population	 and	 then	 tested	 in	 the	 remaining	 samples.	 K-fold	 cross-validation	randomly	partitions	the	data	into	k-equal	sized	samples,	using	k	–	1	samples	to	 train	 the	 model	 and	 one	 sample	 to	 test	 the	 model.	 Training	 and	 testing	 then	progresses	through	all	other	combinations	of	the	partitions,	 implying	that	all	data	will	be	 used	 in	 both	 training	 and	 testing	 at	 some	 point.	 If	 k	 is	 equal	 to	 the	 number	 of	samples,	then	this	process	is	known	as	“leave-one-out”	sampling.		
If	model	selection	including	regularisation	estimates	and	error	estimates	are	calculated	at	 the	 same	 time,	 then	 data	 should	 be	 split	 into	 training,	 validation	 and	 testing	 sets.	Training	data	are	then	used	to	develop	the	model,	cross-validation	data	are	then	used	to	fit	the	tuning	parameters	of	the	model	such	as	regularisation	terms	and	a	test	set	then	used	to	estimate	the	out-of-sample	errors	of	the	model.	
High-dimensional	 statistics	 lead	 to	 several	 other	 analytical	 difficulties	 which	 are	considered	in	more	detail	elsewhere	as	not	all	relate	to	the	analysis	methods	here	[435,	436].	The	curse	of	dimensionality	can	be	avoided	in	several	ways,	though	the	choice	of	method	may	 depend	 on	 other	 factors	 such	 as	 the	 availability	 of	 sample	 data	 and	 the	type	of	classifier	used.	
If	an	infinite	number	of	training	examples	is	available,	then	the	curse	of	dimensionality	does	not	apply.	Clearly	this	is	not	a	realistic	possibility,	and	though	additional	data	help,	
105	
as	shown	earlier	retaining	sample	density	requires	sample	number	(N)	to	scale	as	the	power	of	dimensionality	(Nd).	However,	if	training	examples	are	plentiful	and	d	can	be	minimised	then	this	may	be	a	valid	approach.	
Non-linear	 classifiers	 (such	 as	 neural	 networks,	 k-nearest	 neighbour	 algorithms	 and	tree-based	 methods)	 may	 not	 generalise	 as	 well	 as	 linear	 classifiers	 to	 a	 high-dimensional	 space	 as	 their	 decision	 boundaries	 will	 fit	 around	 exceptions	 and	 are	vulnerable	to	over-fitting.		
Other	approaches	tackle	this	problem	by	reducing	the	dimensionality	of	the	data.	This	may	 be	 done	 by	 selecting	 a	 subset,	M,	 of	 the	 original,	 N,	 features	 and	 training	 the	classifier	 based	 only	 on	 the	 subset.	 Exhaustive	 testing	 of	 all	 possible	 subsets	 of	 N	features	 is	simple	but	computationally	 intensive	(2N	possible	subsets)	and	 likely	 to	be	inefficient,	so	a	“feature	selection”	method	may	be	used	to	identify	the	most	promising	predictors.	 A	 further	 approach	would	 be	 to	 combine	 the	N	 features	 into	 sets	 of	 new	features,	M,	where	M<<N.	The	techniques	–	feature	extraction	methods	–	may	combine	features	linearly	or	non-linearly.	A	commonly	used	method	in	this	category	is	principal	component	analysis	(PCA)	which	generates	linearly	independent	combinations	of	the	N	features,	 aiming	 to	 retain	 the	 highest	 proportion	 of	 the	 original	 data	 variance	 in	 the	smallest	number	of	 features.	These	 techniques	are	discussed	 in	some	detail	 in	section	2.5.4.		
One	of	 the	 commonest	 treatments	of	high-dimensional	data	 is	 to	 treat	 the	original,	N,	features	as	N	 separate	one-dimensional,	 or	univariate,	problems.	This	approach	when	combined	with	 linear	 regression	–	mass	univariate	 regression	 -	 has	 successfully	been	applied	 in	several	neuroimaging	[437,	438]	and	cardiac	studies	 [39].	This	method	has	the	great	advantage	of	providing	effect	size	and	significance	at	 the	same	resolution	as	
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the	imaging	data,	giving	the	potential	to	retain	spatially	specific	effects,	and	making	the	results	 readily	 interpretable.	Univariate	 analysis	 can	be	done	 independently,	 allowing	analysis	 to	be	parallel	processed,	so	despite	 the	volume	of	analysis	 the	burden	can	be	easily	 spread.	 Disadvantages	 of	 this	 approach	 are	 that	 it	 cannot	 detect	 dependence	patterns	 between	 voxels,	 statistical	 power	 is	 lost	 due	 to	 the	 correction	 for	 multiple	comparisons	 which	 gives	 a	 high	 false-negative	 rate	 and	 poor	 reproducibility.	 It	 also	generates	 a	 non-trivial	 multiple	 testing	 problem	 (discussed	 below).	 Despite	 this	 the	method	 is	 widely	 used	 and	 has	 been	 successfully	 applied	 within	 population-based	cardiac	imaging	studies	[39].		
A	final	method	which	may	be	combined	with	the	techniques	mentioned	above	is	to	use	cross-validation	 to	avoid	 the	over-fitting	problems	of	high-dimensional	data.	Although	this	does	nothing	to	reduce	the	sparsity	of	the	sample	space,	it	minimises	overfitting	by	partitioning	 data	 from	 the	 same	 population	 into	 training	 and	 validation	 groups	 to	estimate	how	well	the	training	model	will	generalise	to	an	unseen	group.	If	limited	data	are	 available,	 a	 single	 group	 of	 samples	 can	 be	 multiply	 partitioned	 (“k-fold	 cross-validation”)	 or	 each	 sample	 may	 be	 successively	 omitted	 from	 training	 and	 then	predicted	(“leave-one-out”	analysis).		
2.5.3. The	Mass	Univariate	Approach	The	mass	univariate	approach	described	above	is	commonly	used	in	neuro-	and	cardiac-imaging	and	 typically	produces	a	 test	 statistic	 (usually	an	F-,	 t-	or	z-	 statistic)	at	each	voxel	position.	This	“statistic	image”	can	then	be	tested	against	the	null.	This	approach	allows	several	types	of	analysis	to	be	performed,	as	described	by	Nichols	[439].	We	will	consider	 these	 first	briefly,	before	discussing	 the	general	 linear	model,	which	 forms	a	key	analysis	method.	
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Test	 statistics	may	be	generated	at	 the	 individual	voxel	 level,	by	clusters,	peaks	or	by	the	 entire	 group	 (“set-wise”).	 The	 test	 statistic	 image	 T,	 will	 be	 considered	 with	 the	statistic	 value	 at	 voxel	 i,	 Ti	 ,	 the	 test	 statistic	 threshold	u	 (which	may	 differ	 between	voxel,	 cluster,	 peak	 or	 set	 approach)	 and	 the	 cluster	 size,	 k.	 The	 test	 statistics	 of	 the	image	 may	 then	 be	 tested	 “voxelwise”	 with	 the	 null	 hypothesis	 rejected	 at	 voxels	 i	where	 Ti	 >	 uv.	 Alternatively,	 analysis	 may	 be	 “clusterwise”,	 focusing	 on	 identifying	clusters	which	contain	at	least	one	voxel	exceeding	the	threshold	uc	,	which	are	also	part	of	a	contiguous	cluster	larger	than	threshold	k.	Thirdly,	“peakwise”	inference	identifies	the	 local	 maximum	 in	 regions	 which	 fall	 above	 a	 threshold,	 up.	 Lastly,	 “setwise”	inference	is	based	on	global	parameters	such	as	the	number	of	clusters.	
Setwise	analysis	provides	no	spatial	resolution,	since	the	parameters	are,	by	definition	global.	 Clusters,	 by	 including	more	 than	 one	 voxel,	 have	 spatial	 resolution	 below	 the	voxel	 level,	 as	 do	 peakwise	 inferences,	 though	 it	 has	 been	 argued	 that	 this	 applies	 to	voxelwise	analysis	 too	since	 statistic	 images	are	 routinely	 smoothed	 in	many	analysis	protocols	 [440-442],	 and	 only	 topological	 features,	 like	 peaks,	 are	 interpretable.	However,	although	initial	smoothing	may	reduce	voxelwise	spatial	specificity	below	the	single	 voxel	 level,	 this	 approach	 is	 useful	 [439],	 and	 widely	 applied	 [39].	 One	 of	 the	commonest	methods	to	apply	at	a	voxelwise	level	is	the	general	linear	model.		
The	 origins	 of	 the	 general	 linear	 model	 (GLM)	 trace	 back	 to	 mathematics	 of	 the	nineteenth	 century	 and	 specifically	 the	 theory	 of	 algebraic	 invariants	 [443].	 The	 first	published	example	of	the	least	squares	technique	comes	from	Legendre	[444],	though	it	was	 developed	 further	 by	Gauss,	 Laplace,	 Boole,	 Cayley	 and	 Sylvester	 throughout	 the	nineteenth	century	[445].	This	work	formed	the	basis	of	identifying	quantities	central	to	inferential	statistics,	namely	those	which	were	invariant	to	linear	transformations,	and	
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includes	 concepts	 such	 as	 correlations,	 regression,	 eigenvalues/eigenvectors	 and	determinants.	In	the	twentieth	century	Pearson	and	Fisher	emphasized	the	importance	of	the	normality	assumption	as	these	methods	began	to	be	used	for	inference	[446].	
Despite	advances	in	statistical	techniques,	the	general	linear	model	(GLM)	has	remained	central	 to	MRI	 analysis.	 The	 GLM	 has	mostly	 been	 used	 in	 the	 analysis	 of	 functional	neuroimaging	 and	 although	 non-linear,	 multivariate	 and	 Bayesian	 frameworks	 have	worthwhile	 advantages,	 there	 are	 several	 characteristics	 of	 the	GLM	which	 suggest	 it	will	persist	imaging	overall	and	is	at	least	an	appropriate	start-point	for	high-resolution	3D	cardiac	imaging.		
A	 GLM	 is	 defined	 by	 two	 elements:	 the	 pattern	 of	 association	 between	 response	 and	explanatory	variables	and	the	pattern	of	errors	seen	in	this	estimation	[447].	These	two	elements	will	be	described	in	more	detail	here.	Suppose	we	investigate	the	association	between	a	cardiac	phenotype	which	we	have	measured	at	a	point	on	the	heart,	such	as	wall	 thickness	or	 curvature,	 and	other,	 explanatory,	variables.	The	quantity	measured	on	the	heart	is	denoted	by	Yp,	where	p	is	the	index	of	the	point	and	ranges	from	1,	…	,	P,	the	 total	 number	 of	 points.	 Yp	 here	 is	 a	 random	 variable,	 since	 by	 classical	 statistics	under	 the	 null	 hypothesis,	 H0,	 the	 value	 of	 Yp	 is	 random	 until	 measured	 and	 is	 the	
dependent	or	response	variable.	There	are	L	explanatory	variables	which	are	denoted	by	
xpl,	where	l	=	1,	…	,	L.	Explanatory	variables	may	be	continuous	variables	or	categorical	variables,	 though	 in	 the	 latter	 case,	 C	 categories	 within	 the	 variable	 (e.g.	 C	 =	 2	 for	gender)	will	 be	 spread	 over	C-1	 variables.	 In	 this	way,	 each	 of	 the	C-1	 variables	 is	 a	binary	marker,	indicating	whether	a	subject	does,	or	does	not	have	membership	of	this	category.	A	GLM	is	therefore	described	in	the	following	way:	
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	 𝑌! =  𝑥!!𝛽! + 𝑥!!𝛽! +⋯+  𝑥!"𝛽! +  𝜖!	 (2.11)	
βL	 are	 coefficients	 specific	 to	 each	 explanatory	 variable.	 εp	 are	 error	 terms	which	 are	normally	distributed,	with	mean	zero	and	variance	σ2.	The	 linear	 regression	model	 is	usually	written	as:	
	 𝑌! =  𝜇 +  𝑥!𝛽 +  𝜖!	 (2.12)	
where	μ	is	a	constant	term,	which	can	be	reformulated	into	the	format	of	Eqn	(2.11)	by	making	xp1	=	1	for	all	I,	and	replacing β1	with	μ.	Therefore:	
	 𝑌! =  𝑥!!𝜇 +  𝑥!!𝛽! +  𝜖!	 (2.13)	
which	 is	 the	 general	 form	 of	 the	 univariate	 linear	 model.	 When	 a	 large	 number	 of	dependent	 variables	 are	 measured	 and	 univariate	 hypothesis	 tests	 applied	 to	 these	measurements,	 this	 is	 known	 as	 “mass	 univariate	 analysis”,	 of	which	mass	 univariate	regression	is	one	subtype.	
In	the	GLM,	the	parameter	𝛽	 is	estimated	so	that	 the	values	of	x	provide	the	expected	value	 of	 Y,	 by	minimising	 the	 sum	 of	 the	 squared	 differences	 between	 the	 predicted	values	and	the	observed	data	(i.e.	the	residuals,	𝜖)	over	all	P	points.	The	sum	of	squared	errors	is	given	by:	
𝑆 =  𝑌! −  𝑋!!𝛽! −⋯−  𝑋!"𝛽! !!! 	 (2.14)	
This	function	can	be	minimised	by	finding	the	partial	differential	with	respect	to	𝛽	and	setting	 this	 equal	 to	 zero.	 It	 can	be	deduced	 that	 the	 values	of	𝛽	 -	 i.e.	 the	 coefficients	which	give	the	“ordinary	least	squares”	fit	–	when	S	is	minimised	are:	
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	 𝛽 = (𝑋!𝑋)!!.𝑋! .𝑦	 (2.15)	
To	 test	 significance	 the	 t-statistic	 can	 be	 calculated.	 This	 is	 done	 by	 calculating	 the	difference	between	the	estimated	values	of	𝛽	and	the	value	of	𝛽	 in	the	null	hypothesis	(𝛽!)	in	terms	of	the	standard	error	of	𝛽.	The	t-statistic	is	then	given	by:	
	 𝑡! =  𝛽 −  𝛽!𝑠. 𝑒. (𝛽)	 (2.16)	
In	the	null	hypothesis,	𝛽! = 0	simplifying	Eqn	(2.16).	When	the	variance	of	the	errors	is	similar	across	all	the	observations	(homoscedasticity)	the	variance	of	𝛽	is	calculated	as:	
Variance	of	𝛽	=	𝑣𝑎𝑟𝑖𝑎𝑛𝑐𝑒 𝑜𝑓 𝜖 . (𝑋! .𝑋)!!	 (2.17)	
from	which	the	standard	error	of	𝛽	can	be	calculated	as:	
𝑆𝑡𝑎𝑛𝑑𝑎𝑟𝑑 𝑒𝑟𝑟𝑜𝑟 =  𝑉𝑎𝑟𝑖𝑎𝑛𝑐𝑒 𝑜𝑓 𝛽𝑁 	 (2.18)	
	Using	 the	estimate	of	 standard	error	 from	Eqn	 (2.18),	 the	 t-statistic	 can	be	calculated	from	Eqn	(2.16)	and	significance	values	deduced	from	the	t-distribution.		
A	mass	univariate	approach	to	segmentation	data	has	challenges	though,	some	of	which	are	 described	 below.	 Having	 decided	 a	 method	 of	 inference	 a	 test	 statistic	 can	 be	defined	from	this	method.	For	voxelwise	or	peakwise	approaches,	these	are	simply	the	value	of	 the	 test	 statistic	 t	 at	 the	point	p.	 For	 clusterwise	 analysis,	 the	 test	 statistic	 is	likely	to	include	some	measure	of	the	cluster	size	as	well	as	the	test	statistic.	However,	for	 all	 methods	 apart	 from	 setwise	 analysis,	 several	 test	 statistics	 per	 image	 will	 be	
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produced,	with	a	proportion,	under	the	null,	exceeding	the	threshold	for	“significance”.	For	 example,	 naïve	 thresholding	 of	 104	 voxels	 at	α	 =	 0.05	 threshold	will	 lead	 to	 500	voxelwise	 false	 positives	 in	 the	 null.	 This	 presents	 a	 significant	 statistical	 problem	 in	avoiding	type	1	errors	without	reducing	study	power.	
Although	 voxelwise	 approaches	 retain	 spatial	 specificity,	 few	 methods	 use	neighbourhood	information	to	alter	belief	in	signal.	Areas	of	signal	might	be	expected	to	be	 coherent	 and	 monotonic	 compared	 to	 areas	 of	 noise,	 though	 a	 purely	 univariate	approach	 will	 not	 be	 able	 to	 reward	 such	 effects	 by	 attributing	 greater	 statistical	significance.	
Mass	 univariate	 approaches	 may	 seek	 to	 analyse	 103-106	 individual	 data	 points.	 If	analysis	includes	resampling	techniques,	such	as	bootstrapping	or	permutation	testing,	or	 methods	 which	 involve	 post-processing	 such	 as	 cluster	 enhancement	 [448],	computation	time	may	be	considerable.		
Although	the	mass	univariate	approach	is	widely	used	in	high-dimensional	data,	 there	are	several	assumptions	of	GLM	which	underpin	its	use	[449]	.	These	are:	
1. The	observations	must	be	independent.	i.e.	the	subjects	(total	number	N	above)	should	be	independent	observations	2. The	model	errors	should	be	normally	distributed	3. The	variance	in	errors	should	be	uniform	over	the	range	of	the	data	4. The	data	should	be	adequately	modelled	by	a	linear,	“straight-line”,	relationship		
Independence	 of	 data	 can	 be	 checked	 by	 consideration	 of	 the	 data	 source	 and	more	formally	 by	 the	Durbin-Watson	 test	 [450,	 451]	which	 detects	 autocorrelations	within	
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the	data.	Normality	of	the	model	errors,	the	“residuals”,	can	be	assessed	formally	by	the	Shapiro-Wilk,	or	Kolmogorov-Smirnoff	tests,	but	may	be	better	assessed	qualitatively	by	visual	inspection	of	a	QQ-plot,	box-and-whisker	plot	or	histogram.	
Homogeneity	of	error	variance	(“homoscedasticity”)	 in	 imaging	data	means	 that	error	variance	 is	 similar	 across	 voxels.	 This	 can	 be	 assessed	 by	 visual	 inspection	 of	 the	residuals	over	the	range	of	the	covariates,	though	Levene’s	and	the	Brown-Forsyth	test	formalise	this	process.	 	Corrections	are	necessary	to	avoid	incorrect	inference.	Several	heteroscedasticity-consistent	 estimators	 have	 been	 described,	 which	 are	 detailed	 in	Appendix	6.	
The	 linearity	 of	 the	 relationship	 can	 be	 considered	 by	 understanding	 the	 data	 fields	involved,	and	by	inspection	of	plots	of	the	dependent	variable	against	each	covariate.	
A	robust	model	should	also	not	depend	on	a	small	number	of	influential	observations	as	such	 a	 model	 will	 be	 unstable	 to	 the	 presence	 or	 otherwise	 of	 these	 examples.	 A	jackknife	 procedure	 –	 sequential	 omission	 of	 data	 points,	 re-fitting	 of	 the	model	 and	measurement	of	the	change	in	coefficients	–	provides	an	empiric	method	of	measuring	this,	which	can	be	 formalised	 in	 the	dfbeta	statistic,	by	 leverage	or	by	Cook’s	distance	[452].	
Hypothesis	 testing	 and	 significance	 levels	 depend	 on	 model	 assumptions	 and	 the	validity	of	inferences	should	not	be	trusted	unless	the	assumptions	are	checked	[453].	It	has	been	suggested	that	these	inferences	are	not	checked	often	enough	currently	[446].	The	 standard	method	of	 checking	assumptions	 involves	visualisation	of	 residual	plots	which	 can	 identify	 outliers,	 non-constant	 variance	 and	 non-linear	 fits.	 However,	 this	approach	 is	 not	 practical	 when	 data	 points	 are	 numerous	 (e.g.	 104-105),	 results	may	
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vary	from	one	dataset	to	another,	and	different	assumptions	may	be	invalid	at	different	points,	 requiring	 different	 statistical	 treatment	 [453].	 We	 therefore	 suggest	 that	analysis	methods	should	be	chosen	which	satisfy	these	assumptions.	
2.5.4. Dimensionality	Reduction	Although	voxelwise	analysis	techniques	of	high-resolution	datasets	continue	to	provide	novel	insights	in	many	forms	of	whole-organ	imaging	[39]	a	fundamental	problem	is	the	inability	 to	 recognise	 spatially	 or	 temporally	 correlated	 patterns	 of	 effect.	 High-resolution	imaging	is	therefore	limited,	since	the	only	effects	which	are	then	detected	by	a	univariate	analysis	are	those	which	express	at	the	single-voxel,	and	that	relies	on	the	signal	 to	 noise	 ratio	 obtained	 from	 that	 unit.	 This	 may	 become	 worse	 at	 higher	resolution,	not	better.	
Machine	learning	(ML)	techniques	aim	to	identify	multivariate	patterns	within	imaging	datasets,	 but	 to	 do	 so	 must	 avoid	 the	 “curse	 of	 dimensionality”	 (section	 2.5.2)	 if	overfitting	and	sparsity	within	the	image	space	is	to	be	avoided.	Reducing	the	number	of	features	 mitigates	 against	 this,	 but	 also	 may	 improve	 the	 interpretation	 of	 the	 final	model	and	reduce	processing	time.	The	number	of	features	can	be	reduced	in	two	ways:	feature	selection,	where	information	is	selectively	retained	or	discarded	on	the	basis	of	a	 characteristic	 deemed	 to	 suggest	 the	 information	 at	 those	 features	 carries	 good	predictive	 value,	 and	 feature	 extraction,	 where	 features	 in	 the	 current	 model	 are	combined	 into	 a	 composite	 feature.	 Feature	 reduction	 techniques	 can	 be	 broadly	divided	into	supervised	and	unsupervised	approaches	[454].	
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2.5.5. Supervised	Feature	Reduction	Techniques	Supervised	feature	reduction	techniques	reduce	the	number	of	features	based	on	their	association	with	a	specified	outcome.	Methods	are	commonly	subdivided	by	the	way	in	which	 this	 association	 is	 used,	 into	 filters,	wrappers	 and	 embedded	 techniques	 [454-456].	Filter	methods	pre-process	the	features	based	on	a	proxy	measure	chosen	for	its	relevance	 to	 the	 outcome	 of	 interest,	 ease	 of	 computation	 and	 speed.	 It	 has	 been	suggested	 that	 filters’	 main	 role	 is	 to	 avoid	 overfitting,	 and	 therefore	 it	 should	 be	 a	linear	measure	[456],	allowing	a	more	complex	non-linear	measure	to	be	trained	in	the	main	ML	algorithm.	Many	filters	are	both	linear,	easily	computed	and	not	specific	to	the	predictive	model.	It	has	been	argued	that	this	provides	a	more	“generic”	set	of	features	suitable	 for	 testing	 in	 a	 variety	 of	 ML	 models	 thereafter	 [456].	 T-tests	 [457-460],	ANOVA	 [461-464]	 and	 non-parametric	 measures	 such	 as	 Wilcoxon	 test	 [465]	 and	signal-to-noise	ratio	[466]	have	all	been	used,	and	features	will	typically	be	ranked	with	a	threshold	optimised	by	cross-validation.	The	Pearson	correlation	coefficient	has	been	used	in	several	studies	[467-472],	both	for	regression	and	classification.	Its	insensitivity	to	 non-linear	 and	multivariate	 relationships	 has	 been	 criticised	 [456,	 473],	 though	 in	datasets	 with	 particularly	 small	 numbers	 of	 subjects	 compared	 to	 the	 number	 of	features,	this	has	also	been	cited	as	a	useful	guard	against	overfitting	[456].		
Wrappers	 use	 the	 ML	 algorithm	 itself	 to	 select	 features,	 by	 sequential	 training	 on	subsets	of	the	data,	before	assessment	on	a	different	subset	of	the	data.	The	method	is	viewed	as	simple	since	it	uses	a	single	algorithm	to	select	and	predict,	and	need	not	be	computationally	 intense	 despite	 the	 large	 number	 of	 possible	 subsets	 for	 all	 but	 the	smallest	datasets.	
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Embedded	models	incorporate	feature	selection	as	part	of	the	ML	process,	by	enforcing	penalties	 on	 the	 addition	 of	 variables.	 This	 group	 of	methods	 has	 efficiency	 gains	 on	wrapper-methods	 as	 they	 avoid	 splitting	 the	 data	 into	 non-overlapping	 training	 and	testing	 subsets	 and	 iteratively	build	 a	model,	 rather	 than	 restart	 the	 learning	process	with	a	new	set	of	features[456].		
2.5.6. Unsupervised	Feature	Reduction	Techniques	These	techniques	construct	new	features	based	on	linear,	or	non-linear	combinations	of	the	 original	 features.	 Many	 techniques	 exist	 and	 several	 reviews	 [474-476]	 provide	further	detail	 including	a	taxonomy	on	which	Figure	2.31	is	based	[474].	Discussion	is	limited	 to	 one	 of	 the	 most	 common	 linear	 techniques,	 principal	 component	 analysis	(PCA).	
	
Linear	
Principal	
component	
analysis	
Independent	
component	
analysis	
Non-Linear	
Preserving	global	properCes	
• Distance	preservaCon	
• Mul$-Dimensionality	Scaling,	Isomap	
• Neural	network	
• Autoencoder	
Preserving	local	properCes	
• ReconstrucCon	weights	
• Local	Linear	Embedding	
• Neighbourhood	graph	Laplacian	
• Laplacian	Eigenmaps	
• Local	tangent	space	
• Hessian	local	linear	embedding,	Local	
Tangent	Space	Analysis	
Global	alignment	of	linear	models	
• Locally	Linear	Coordina$on	
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Figure	2.31.	Taxonomy	of	dimensionality	reduction	techniques	
After van der Maaten [474] 	
PCA	 is	 commonly	 used	 in	 data	 exploration	 as	 it	 summarises	 the	 variation	 seen	 in	 a	dataset	 by	 reformulating	 data	 points	 into	 new,	 linearly-independent	 vectors	 which	allow	 a	 large	 proportion	 of	 the	 data	 to	 be	 represented	 by	 a	 smaller	 number	 of	independent	variables.	This	 avoids	 the	problems	of	high-dimensional	data	 and	allows	methods	 which	 rely	 on	 linearly-independent	 variables,	 such	 as	 regression,	 to	 be	performed	without	violation	of	their	assumptions.	Figure	2.32	shows	an	example	of	PCA	used	 in	 CT	 brain	 data	 compression,	 where	 re-expressing	 the	 imaging	 data	 into	 new	principal	component	variables	allows	compression	of	the	data	with	only	a	small	loss	of	signal,	manifest	as	mild	degradation	in	image	quality.		
	 (a)	 (b)	 (c)	 (d)	
Image	
	 	 	 	
Memory	 262144	 57344	 16384	 6144	
Compression	factor	 1	 0.219	 0.0625	 0.0234	
Principal	components	 (Original)	 112	 32	 12	
Figure	2.32.	Computed	tomograph	of	the	brain	after	image	compression	
“Memory” indicates the memory necessary to illustrate the final image; 0 ≤ Compression Factor ≤ 1. Sequence 
shows the original image, (a), at 512 x 512 resolution and three reconstructions using 112, 32 and 12 principal 
components, (b-d), respectively. PCA allows information to be efficiently stored in fewer independent data pieces 
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with a small loss of image quality but large reductions in the memory required for image storage. Images taken 
from de Espirito Santo [477]. 
 PCA	is	performed	by	centring	and	scaling	the	data,	followed	by	eigen-decomposition	of	the	covariance	matrix.	The	eigenvalues	produced	indicate	the	variance	contained	in	the	corresponding	eigenvectors	(“components”),	with	the	largest	eigenvalues	indicating	the	most	informative	components.	Eigenvalues,	with	their	corresponding	eigenvectors,	are	typically	arranged	in	descending	order	and	a	proportion	used	to	represent	the	original	data.	 The	 exact	 number	 of	 components	 used	 to	 represent	 the	 image	 varies	 and	 is	controversial	 [478],	but	would	 typically	be	chosen	such	 that	a	pre-defined	cumulative	variance	 is	 represented	 (e.g.	 90%)	 [479],	 an	 elbow-point	 on	 the	 graph	 of	 cumulative	variance	against	number	of	principal	component,	or	after	cross-validation.	
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Figure	2.33.	Cumulative	variance	in	principal	component	analysis	
The number of principal components can be chosen by a priori chosen values of the cumulative variance (blue 
line is >900% of the variance, suggesting five principal components), or by “elbow points” in the cumulative 
variance graph (red line, suggesting six principal components). The choice of number of principal components 
remains controversial [478]. 	PCA’s	ease	of	computation	and	familiarity	has	led	to	widespread	use	in	a	wide	variety	of	brain	and	cardiac	imaging	studies	[473,	479-481].	Components	may	also	be	represented	in	the	original	vector-space,	“back-scoring”,	which	helps	interpretation.	One	example	of	how	PCA	may	lend	additional	insights	above	those	given	by	mass	univariate	approaches	to	 high-resolution	 cardiac	 imaging	 is	 Lewandowski‘s	 study	 of	 the	 differences	 in	 LV	shape	between	adults	born	preterm	and	term.	The	prospective	study	identified	greater	mass	 and	 reduced	 longitudinal	 systolic	 and	 diastolic	 function	 but	 also	 more	 subtle	patterns	of	 shape	change	by	using	PCA	 to	 identify	 the	predominant	patterns	of	 shape	within	 the	 left	 ventricle.	 Figure	 2.34	 shows	 the	 six	 largest	 principle	 components	 and	how	they	correspond	to	changes	in	3D	ventricular	shape.	
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Figure	2.34.	PCA	of	LV	Shape	
From Lewandowski et al [479]. (A) Shows significance testing between the first 20 principal components. Left, 
between preterm-born young adults (PTYAs) and young adults born at term (YATs) showing the significant 
differences between five principal components (PCs). Middle, between PTYAs and old adults born at term (ATs) 
showing significant differences between three PCs. Right, between YATs and ATs, showing no significant 
differences. (B) Cumulative explained variance by PCs. (C) Shape changes associated with the first 6 PCs. Mean 
value for each group is in the middle. Crosses indicate the average position for each PC for PTYAs (blue), YATs 
(green) and ATs (red). Modes of variation (number on the left side) correspond to shape changes as described 
on the right side of the diagram. 	
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PCA,	 however,	 has	 a	 number	 of	 disadvantages	 [454].	 Firstly,	 the	 optimal	 number	 of	principal	components	is	not	clear,	though	methods	of	optimising	this	choice	have	been	made	 [478,	 482].	 Secondly,	 since	 components	 consist	 of	 aggregated	 features,	 spatial	resolution	 is	 lost	 from	 the	 interpretation	 and	 spatially-disparate	 features	 may	 be	combined	by	the	technique	making	physiological	interpretation	difficult	[483].	Thirdly,	components	are	selected	based	on	the	modes	of	largest	variation	in	the	data,	which	may	mask	 the	 association	of	 interest	 if	 other	 factors	have	 larger	 effects	 on	 the	data	 [483].	Fourthly,	non-linear	effects	will	be	approximated	to	 linear	effects	which	may	result	 in	loss	of	signal	 [436].	 In	 large	datasets,	 computing	eigenvectors	 from	a	 large	number	of	features	may	be	computationally	intensive,	though	work-arounds	[484]	and	alternative	methods	such	as	Simple	PCA	[485]	or	probabilistic	PCA	[90][484]	have	been	suggested.	
Supervised	principal	components	(SPC)	is	a	derivative	technique	which	selects	a	subset	of	features	based	on	association	strength	with	an	outcome	of	interest.	Standard	PCA	is	then	 applied	 to	 the	 reduced	 feature	 set.	 The	 threshold	 for	 retaining	 features	 is	determined	 by	 cross-validation.	 The	model	 can	 be	 applied	 to	 either	 linear,	 logistic	 or	survival	 regression	 models.	 The	 initial	 feature	 selection	 process	 makes	 PCA	computationally	simpler,	limited	to	the	data	which	are	most	relevant	to	the	outcome	of	interest	 and	 allows	 covariates	 to	 be	 adjusted	 for.	 Linear	 features	 also	 guard	 against	overfitting.	Other	authors	have	also	employed	feature	selection	 followed	by	PCA	[486,	487]	though	SPC	has	shown	success	in	large	medical	datasets	[488,	489].	
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3. The	Digital	Heart	Project:	Right	Ventricular	2D	Phenotyping	
3.1. Introduction	LV	morphology	is	strongly	affected	by	age,	sex,	race,	weight,	height,	blood	pressure	and	physical	 activity	 [490-493].	 Large	 population-based	 studies	 have	 allowed	 the	determinants	 of	 these	 quantities	 to	 be	 discovered	 and	 an	 appreciation	 of	 their	prognostic	 significance	 [494,	 495].	 However,	 the	 right	 ventricle	 has	 a	 different	macroscopic	 and	 myofibrillar	 architecture	 and	 is	 exposed	 to	 different	 afterload	pressures,	so	extrapolating	these	findings	is	not	straightforward	[34,	35].		
The	complex	3D	structure	of	the	right	ventricle	makes	assessment	difficult,	studies	less	common	 and	 results	 non-uniform	 [50,	 336,	 338,	 496].	 Despite	 these	 difficulties,	 RV	morphology	has	demonstrated	prognostic	relevance	in	health	[17,	18]	and	disease	[1-7,	9,	10].		
Cardiac	magnetic	resonance	has	rapidly	become	the	gold	standard	for	assessment	of	the	right	ventricle	[37,	98-103]	because	of	 its	superior	accuracy	[106]	and	reproducibility	[104].	However,	volumetric	data	are	insensitive	to	regional	and	asymmetric	effects	and	have	 significant	 inter-observer	 variability.	 Normal	 ranges	 are	 based	 on	 spoiled	 echo	gradient	sequences	[21,	50],	though	steady-state	free	precession	(b-SSFP)	is	now	widely	used	 for	 its	 faster	acquisition	and	superior	blood-tissue	contrast.	The	 improvement	 in	blood-tissue	 contrast	 affects	 estimations	 of	 blood	 and	 tissue	 volume	 [497,	 498]	 and	reference	values	for	RV	volume	and	function,	adjusted	for	age,	sex	and	level	of	activity	remains	an	important	unmet	goal	[37].		
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The	 Digital	 Heart	 Project	 aims	 to	 provide	 robust,	 contemporary	 cardiovascular	phenotyping	for	a	UK-based	population.	It	phenotypes	a	younger	population	than	either	the	 Multi-Ethnic	 Study	 of	 Atherosclerosis	 [21]	 (mean/SD	 age:	 61.5±10.1)	 or	 the	Framingham	 Heart	 Study	 Offspring	 Cohort	 [499]	 (mean/SD	 age:	 60±9)	 and	 all	participants	 are	 self-declared	 healthy	 and	 drug	 naïve.	 The	 study	 phenotypes	 both	ventricles	 with	 parallel	 volumetric	 and	 3D	 methods	 to	 investigate	 the	 additional	insights	gained	(see	Chapter	4).	
Ventricular	 volumes	 are	 significantly	 affected	 by	 body	 habitus	 [490,	 496,	 500]	 and	although	 indexing	 by	weight,	 height,	 body	 surface	 area	 and	body	mass	 index	have	 all	been	 suggested,	 no	 consensus	 exists.	 Ratiometric	 indexing,	 in	 which	 measures	 are	divided	by	 the	 index	of	choice,	has	been	used	 in	right	 [496]	and	 left	 [501]	ventricular	assessment	 and	 international	 guidelines	 [502],	 though	 allometric	 indexing,	 in	 which	measures	 are	 divided	 by	 the	 index	 of	 choice	 raised	 to	 a	 power	 fitted	 to	 remove	 all	effects	 of	 size	 from	 the	 cohort,	 may	 provide	 better	 standardisation	 [503]	 and	 is	preferred	 in	 some	 large	 population-based	 studies	 [21].	 Both	methods	 are	 considered	here.	
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3.2. Methods	
3.2.1. Study	Population	The	 study	 was	 approved	 by	 a	 local	 ethics	 committee	 to	 prospectively	 recruit	participants	by	newspaper	advertisement	to	the	Digital	Heart	Study	at	Imperial	College	London	 (single	 site	 study).	 Subjects	were	 screened	 by	 two	 dedicated	 senior	 research	nurses	 and	 excluded	 if	 they	 had	 a	 history	 of	 cardiovascular	 disease,	 were	 taking	treatment	for	diabetes,	hypertension	or	dyslipidaemia,	were	breastfeeding	or	pregnant,	were	taking	prescription	medicines	or	had	contraindications	to	MRI	including	a	weight	limit	of	120kg	[504].	Simple	analgesics,	antihistamines	and	the	oral	contraceptive	were	not	 exclusion	 criteria.	 1530	 volunteers	 (age	 range:	 18-81	 years,	mean/SD	 41.3	 ±13.0	years,	74.8%	Caucasian,	55%	females)	were	recruited.	
3.2.2. Participant	phenotyping	All	measurements	were	recorded	by	the	research	nurses	at	the	Robert	Steiner	MR	Unit,	Hammersmith	 Hospital,	 UK.	 Participants	 were	 asked	 to	 starve	 for	 four	 hours	 before	scanning.	 History	 was	 taken	 including	 ethnic	 background	 which	 was	 categorised	 as	African,	 Asian,	 Caucasian,	 Chinese,	 Japanese,	 Mixed,	 Other	 or	 Unknown.	 Participants	were	asked	about	their	usual	levels	of	activity	and	subjectively	rated	on	an	ordinal	scale	(Table	3.1).	
Activity	score	 Activity	description	1	 Sedentary	/	no	exercise	2	 Occasional,	or	less	than	3	hours	per	week	3	 3-5	hours	per	week	4	 Greater	than	5	hours	per	week	
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Table	3.1.	Activity	scoring		
Subjects	wore	scrubs	without	shoes	for	height	and	weight	measurements.	Body	surface	area	(BSA)	was	calculated	by	the	Mosteller	formula	[505]:	
𝐵𝑆𝐴 (𝑚!) =  𝐻𝑒𝑖𝑔ℎ𝑡 𝑐𝑚 𝑥 𝑊𝑒𝑖𝑔ℎ𝑡 (𝑘𝑔)3600 	 (3.1)	
CMR	was	performed	immediately	by	specialist	cardiac	radiographers	on	the	same	1.5T	Philips	Achieva	system	(Best,	Netherlands)	with	a	32-element	cardiac	phased-array	coil	for	signal	reception.	Maximum	gradient	strength	was	33	mT.m-1	and	the	maximum	slew	rate	 was	 160mT.m-1.ms-1.	 Sensitivity	 encoding	 was	 used	 in	 the	 anterior-posterior	(factor	 2)	 and	 right-left	 (factor	 2)	 directions	 with	 partial-Fourier	 acceleration.	 Scout	images	were	 used	 to	 plan	 2D	 cine	 steady-state	 free	 precession	 (b-SSFP)	 images.	 The	long-axis	of	the	heart	was	planned	from	LV	apex	to	the	middle	of	the	mitral	valve	plane,	with	the	short-axis	(LVSA)	perpendicular	to	this,	to	include	the	right	ventricle.	Vertical	long-axis	 planes	were	 obtained	 for	 the	 left-	 and	 right-	 ventricles.	 Typical	 parameters	were:	
	 2D	 3D	 PC*	 Path	length	
Field	of	view	(mm)	 370	x	370	 370	x	370	 370	x	370	 320	x	320	
TR/TE	(ms)	 3.0/1.5	 3.0/1.5	 2.8/1.4	 3.4	/	1.7	
Flip	angle	(0)	 60	 50	 15	 60	
Bandwidth	(Hz/pixel)	 1250	 1250	 1250	 1250	
Acquired	pixel	size	(mm)	 2.0	x	2.2	 2.0	x	2.0	 1.65	x	1.92	x	10	 1.65	x	1.92	x	10	
Section	thickness	&	gap	 8/2	 2†	 	 	
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Reconstructed	voxel	size	 1.2	x	1.2	x	8	 1.2	x	1.2	x	2	 	 	
Number	of	sections		 10-12	 50-60	 	 	
Phases	 30	 20	 	 	
Other	 	 SENSE	factor	2.0	AP	&	RL	directions	 Temporal	resolution	23ms	 	
Breath-hold	duration‡	(s)	 5-6	 25-30	 	 	*PC	=	phase-contrast;	†overlapping;	‡Protocols	require	6-8	(2D)	and	single	(3D)	acquisitions	so	total	acquisition	time	is	longer	for	2D	protocol.	
Table	3.2.	Typical	scanning	parameters	for	2D	and	3D	b-SSFP	sequences		
Pulmonary	phase-contrast	 sequences	were	 acquired	perpendicular	 to	 the	direction	of	flow	in	the	main	PA	1cm	above	the	valve	annulus	and	in	the	right	PA.	For	the	calculation	of	path	length	ECG-gated	b-SSFP	images	were	acquired	along	the	course	of	the	main	and	right	PA.	Parameters	for	both	are	given	in	Table	3.2.		
2D	images	were	manually	analysed	using	commercially	available	semi-automated	valve-tracking	 volumetric	 software	 (CMRtools,	 Cardiovascular	 Imaging	 Solutions,	 London,	UK),	which	has	been	widely	used	for	volumetric	analysis	of	the	right	[104,	336]	and	left	[104,	 506]	 ventricles	 and	 atria	 [507,	 508].	 In-keeping	 with	 published	 work,	reproducibility	 for	right	ventricular	mass	was	poorer	than	for	volumes	with	CMRtools	software	 [104].	 For	 subgroups	 requiring	 estimates	 of	 RV	 mass,	 volumetry	 and	 mass	estimations	 were	 performed	 using	 ViewForum	 (Best,	 Netherlands),	 in	 which	reproducibility	was	higher,	in	keeping	with	techniques	offering	fully	manual	delineation	of	 the	RV	border	 [21].	With	CMRtools,	 ventricular	volumes	were	 calculated	 from	cine	images	 from	 the	 LVSA	 and	 from	 long-axis	 images	 of	 each	 ventricle.	 RV	 function	was	
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assessed	using	feature-tracking	software	(TomTec	Imaging	Systems,	Munich,	Germany)	which	has	been	validated	in	both	the	right	and	left	ventricles	[509-511]to	derive	peak	systolic	strain	and	strain	rate,	as	well	as	peak	early-diastolic	strain	rate	 .	Analysis	was	done	 by	 two	 physicians	 with	 Level	 1	 CMR	 accreditation	 after	 training	 and	reproducibility	 testing.	 End-systole	 and	 end-diastole	were	defined	 as	 the	 frames	with	the	 smallest	 and	 largest	 cross-sectional	 areas,	 at	 the	 LV	 mid-papillary	 level.	 The	epicardium	and	atrioventricular	valves	were	manually	delineated,	and	the	endocardium	delineated	 using	 manually	 controlled	 thresholding.	 Right	 ventricular	 volume	 was	calculated	by	Simpson’s	rule	by	summing	the	area	of	each	slice	multiplied	by	the	sum	of	slice-thickness	and	image	gap.	Papillary	muscles	were	excluded	from	the	blood	volume	in	both	ventricles.	
Volumes	were	indexed	ratiometrically	and	allometrically.	Ratiometric	correction	was	by	body	surface	area	[505]	since	this	is	the	most	common	method	used	in	clinical	practice.	However,	to	understand	whether	indexing	by	BSA	achieves	independence	of	body	size,	indexed	volumes	were	regressed	against	BSA.	
Allometric	 scaling	was	 derived	 from	 the	 data	 to	minimise	 each	 volumetric	measure’s	association	 with	 height	 and	 weight.	 The	 association	 between	 indexed	 volumes,	 and	markers	of	body	size	such	as	height	and	weight	can	be	formulated	as	follows	(example	of	RVEDV	used	here):	
𝑅𝑉𝐸𝐷𝑉 .𝐻𝑒𝑖𝑔ℎ𝑡!  .𝑊𝑒𝑖𝑔ℎ𝑡! = 𝑚 .𝐻𝑒𝑖𝑔ℎ𝑡 + 𝑛 .𝑊𝑒𝑖𝑔ℎ𝑡 + 𝑘	 (3.2)	
where:	RVEDV	indicates	right	ventricular	end-diastolic	volume;	c/d,	allometric	scaling	factors	for	height/weight	respectively;	m/n/k	regression	constants.	
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When	 c	 and	d	 are	 correctly	 chosen,	m	 and	n	 are	 not	 significantly	 different	 from	 zero	indicating	 no	 association	 between	 the	 indexed	 volumetric	 measure	 and	 height	 and	weight.	To	find	c	and	d	we	transform	Eqn.	(3.2)	by	logarithm	to:		
log 𝑅𝑉𝐸𝐷𝑉 + 𝑐. log 𝐻𝑒𝑖𝑔ℎ𝑡 + 𝑑. log 𝑊𝑒𝑖𝑔ℎ𝑡 = log (𝑘)	 (3.3)	
log 𝑅𝑉𝐸𝐷𝑉 =  −𝑐 . 𝑙𝑜𝑔𝐻 − 𝑑. 𝑙𝑜𝑔𝑊 + log𝐾	 (3.4)	
c	 and	 d	 can	 be	 obtained	 by	 a	 least-squares	 fit	 of	 Eqn	 (3.4).	 By	 estimating	 these	parameters	 in	a	 randomly	chosen,	 training	group	of	 subjects	parameters	may	 then	be	applied	 to	 the	 remaining	 subjects.	 This	 approach	 has	 been	 used	 in	 other	 large	population	 studies	of	 cardiac	data	 including	 the	Multi-Ethnic	 Study	of	Atherosclerosis	(MESA)	 cohort	 [21].	 Here,	 training	 was	 performed	 on	 500	 patients,	 with	 coefficients	estimated	 from	 10,000	 bootstrapped	 samples	 before	 application	 to	 the	 remaining,	reported	group.	
Stroke	volume	was	calculated	as	the	difference	between	end-diastolic	and	end-systolic	volume.	 Ejection	 fraction	 was	 calculated	 as	 stroke	 volume	 divided	 by	 end-diastolic	volume.	Cardiac	output	was	calculated	as	stroke	volume	multiplied	by	heart	rate	during	scanning.	 Pulmonary	 pulse	 wave	 velocity	 was	 calculated	 by	 dividing	 the	 path-length	between	phase-contrast	images	in	the	main-	and	right-	pulmonary	arteries	by	the	phase	differences	between	the	pulse	 flow	waveforms	 in	 these	vessels	 in	a	manner	similar	 to	that	used	in	the	aorta	[512,	513].	
Inter-study	and	inter-observer	reproducibility	was	observed	on	twenty	subjects,	using	2D	 and	 3D	 imaging.	 For	 inter-study	 reproducibility,	 each	 subject	 briefly	 got	 off	 the	scanning	 table	 and	 the	 scanning	protocol	was	 repeated	 in	 full,	 including	 the	planning	images.	For	each	 image,	 the	mean	value	 from	the	 two-observers	above	was	compared	
128	
between	 the	 two	 studies.	 For	 inter-observer	 reproducibility,	 the	mean	value	 from	 the	two	 studies	 for	 each	 subject	 was	 compared	 between	 the	 two	 observers.	 In	 both	analyses,	observers	were	blinded	to	the	results.		
3.2.3. Statistical	analysis	Data	 were	 analysed	 in	 R	 using	 RStudio	 Server	 version	 0.98	 (Boston,	 MA)	 [514].	Categorical	 variables	 were	 expressed	 as	 percentages.	 Continuous	 variables	 were	expressed	as	mean	±	standard	deviation	(SD)	or	median	±	inter-quartile	range	(IQR)	for	non-normal	 variables.	 The	 association	 between	 anthropometric	 and	 environmental	variables	 with	 cardiac	 phenotypes	 was	 investigated	 using	 linear	 regression	 after	variables	 were	 centred	 and	 scaled.	 The	 assumptions	 of	 linear	 regression	 were	confirmed	 and	 variables	 log-transformed	 where	 necessary.	 Groups	 of	 continuous	variables	were	 compared	 non-parametrically	 to	make	 conservative	 predictions,	 using	the	Mann-Whitney	U	test	for	two	groups,	or	the	Kruskal-Wallis	test	for	more	than	two	groups.	 Test/re-test	 reproducibility	was	 assessed	 by	 intraclass	 correlation	 coefficient	(ICC)	 with	 a	 two-way	 random	 model	 for	 absolute	 agreement.	 Variability	 in	 repeat	measures	 was	 measured	 using	 the	 coefficient	 of	 variability	 which	 expresses	 the	standard	 deviation	 as	 a	 percentage	 of	 the	 mean.	 For	 duplicate	 measurements	 on	 a	number	(n)	of	different	subjects	this	is	calculated	as	[515]:	
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𝑆𝐷 =  (𝑥! −  𝑥!)!2𝑛 	
𝑀𝑒𝑎𝑛 =  (𝑥! −  𝑥!2𝑛 	
𝐶𝑜𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑡 𝑜𝑓 𝑣𝑎𝑟𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑦 % = 100 ×  𝑆𝐷𝑀𝑒𝑎𝑛	
(3.5)	
For	all	analysis,	a	p-value	of	≤	0.05	was	considered	significant.	
3.3. Results	1543	volunteers	completed	health	screening	and	underwent	CMR.	Of	these,	one	subject	was	 unable	 to	 complete	 the	 scanning	 protocol	 and	 one	 subject	 could	 not	 be	 scanned	because	of	technical	problems	with	the	scanner.	In	14	further	subjects,	images	were	of	insufficient	quality	to	complete	volumetric	analysis.	11	of	these	were	due	to	inadequate	LVSA	 coverage,	 3	 were	 due	 to	 inadequate	 long-axis	 views	 of	 the	 right	 ventricle.	 The	remaining	1527	subjects	underwent	2D	and	3D	CMR	analysis	(see	Chapters	3	and	4).	
Volunteers	 were	 categorised	 into	 8	 ethnic	 groups:	 Afro-Caribbean	 (n	 =	 53,	 3.5%),	African	 (51,	3.3%),	Asian	 (194,	12.7%),	Caucasian	 (1141,	74.7%),	Chinese	 (23,	1.5%),	Japanese	 (3,	 0.2%),	Mixed	 (42,	 2.8%)	 and	Other/Unidentified	 (20,	 1.3%).	 To	 improve	statistical	 power	 and	 reduce	 the	 problems	 of	 multiple	 testing,	 Afro-Caribbean	 and	African	 subjects	 were	 pooled.	 The	 four	 smallest	 groups	 collectively	 represented	 only	5.8%	of	the	population	and	were	therefore	pooled	into	a	single	group	(“Other”).		
Volumetric	data	are	given	 in	total	and	by	gender	 in	Table	3.3,	by	age	 in	Table	3.4	and	Table	 3.5	 to	 allow	 direct	 comparison	 with	 published	 normal	 ranges	 (Table	 2.3).	Volumetric	data	are	also	divided	by	activity	score	(Table	3.7,	Figure	3.2),	by	race	(Table	
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3.6)	and	by	body	surface	area	quartile	in	Table	3.8.	The	effects	of	gender,	age	and	race	are	investigated	by	linear	regression	with	summaries	given	in	Table	3.9.	
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	 Full	Cohort	(n	=	1527)	 Males	(n	=690)	 Females	(n	=837)	 p-value	
Age	(years)	 41.3	±	13.0	(18	–	81)	 40.9	±	12.5	(19	–	81)	 41.5	±	13.4	(18	–	75)	 0.56	
Race	/	Ethnicity	 	 	 	 0.89	Caucasian	 1141	(74.7%)	 517	(75.0%)	 624	(74.6%)	 	South	Asian	 194	(12.7%)	 97	(14.0%)	 97	(11.6%)	 	African	 104	(6.8%)	 39	(5.6%)	 65	(7.7%)	 	Other	 88	(5.8%)	 37	(5.4%)	 51	(6.1%)	 	
Height	(cm)	 170	±	9	 177	±	7	 164	±	7	 <0.001	
Weight	(kg)	 71	±	13	 79	±	12	 65.3	±	11.2	 <0.001	
BSA	(m2)	 1.8	±	0.2	 2.0	±	0.2	 1.7	±	0.2	 <0.001	
BMI	(kg/m2)	 24.7	±	3.8	 25.1	±	3.3	 24.3	±	4.2	 <0.001	
RVEDV	(ml)	 164	±	38	(77	–	312)	 190	±	36	(97	–	312)		 143	±	25	(77	–	239)	 <0.001	
RVESV	(ml)	 70	±	23	(16	–	169)	 84	±	22	(28	–	169)	 58	±	15	(16	–	119)	 <0.001	
RVSV	(ml)	 94	±	20	(44	–	192)	 106	±	20	(48	–	192)	 85	±	14	(44	–	141)	 <0.001	
RVEF	(%)	 58	±	6	(40	–	80)	 56	±	6	(40	–	77)	 60	±	6	(40	–	80)	 <0.001	
RVEDVI	(ml/m2)	 89	±	16	(50	–	145)	 97	±	16	(50	–	145)	 83	±	13	(51	–	134)	 <0.001	
RVESVI	(ml/m2)	 38	±	11	(10	–	78)	 43	±	11	(17	–	78)	 34	±	9	(10	–	75)	 <0.001	
RVSVI	(ml/m2)	 51	±	8	(25	–	101)	 54	±	9	(25	–	101)	 49	±	7	(29	–	75)	 <0.001	
CI	(L/min)	 3.3	±	0.7	 3.4	±	0.7	 3.3	±	0.6	 <0.001	
Cardiac	Output	(L)	 6.1	±	1.4	 6.6	±	1.5	 5.6	±	1.2	 <0.001	
Heart	Rate	(BPM)	 64	±	10	 63	±	11	 66	±	9.5	 <0.001	
Activity	score	 122/620/527/253	 50/223/251/165	 73/397/276/88	 <0.001	
Table	3.3.	Digital	Heart	Project	volumetric	data	for	the	full	cohort	and	by	gender	
Values are mean ± standard deviation (SD) or total number (percentage). CMR values include total range in brackets. BPM 
indicates beats per minute; BSA, body surface area; PWV, pulse wave velocity; RVEDV, right ventricular end-diastolic 
volume; RVESV, right ventricular end-systolic volume; RVSV, right ventricular stroke volume; RVEF, right ventricular ejection 
fraction; Significance values apply to the comparison between genders. Indexing is to body surface area. 
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	 Males	(n=690)	 Females	(n=837)	
	 <60	years	(n=622)	 ≥60	years	(n=68)	 p-value	 <60	years	(n=736)	 ≥60	years	(n=101)	 p-value	
RVEDV	(ml)	 192	±	36	(97-312)	 167	±	29	(127	–	243)	 0.002	 145	±	25	(77-239)	 128	±	23	(84-187)	 <0.001	
RVESV	(ml)	 85	±	22	(50-169)	 73	±	21	(28-135)	 <0.001	 60	±	15	(16-119)	 49	±	15	(25-106)	 <0.001	
RVSV	(ml)	 107	±	20	(48-192)	 97	±	19	(57-150)	 <0.001	 86	±	14	(44-141)	 79	±	13	(52-107)	 <0.001	
RVEF	(%)	 56	±	6	(40-74)	 58	±	6	(46-77)	 0.04	 59	±	6	(41-80)	 62	±	6	(40-76)	 <0.001	
RVEDVI	(ml/m2)	 98	±	16	(50-145)	 88	±	16	(60	–	126)	 <0.001	 84	±	13	(51-134)	 75	±	12	(51-109)	 <0.001	
RVESVI	(ml/m2)	 43	±	11	(21-78)	 38	±	10	(17-59)	 <0.001	 35	±	9	(10-75)	 29	±	8	(15-66)	 <0.001	
RVSVI(ml/m2)	 54	±	9	(25-101)	 51	±	9	(32-70)	 0.003	 50	±	7	(29-75)	 46	±	6	(33-61)	 <0.001	
Table	3.4.	Digital	Heart	Project	volumetric	data	by	gender	and	age.	
Data are mean ± standard deviation with range in brackets. Significance relates to comparisons between age groups by gender. RVEF indicates right ventricular ejection 
fraction; RVEDV, right ventricular end-diastolic volume; RVESV, right ventricular end-systolic volume; RVSV, right ventricular stroke volume; I, indexed to body surface area. 
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Males	(n=690)	
	 18-29	(n=128)	 30-39	(n=234)	 40-49	(n=154)	 50-59	(n=106)	 60-69	(n=54)	 70-81	(n=14)	 p-value	
RVEDV	(ml)	 199±36	(117-297)	 194±37	(107-309)	 187±34	(97-269)	 185±35	(124-312)	 172±35	(106-278)	 162±33	(124-243)	 <0.001	
RVESV	(ml)	 89±22	(43-152)	 88±23	(40-169)	 82±19	(41-135)	 80±23	(44-150)	 75±21	(28-135)	 66±21	(37-126)	 <0.001	
RVSV	(ml)	 109±19	(73-159)	 106±20	(63-174)	 105±22	(11-192)	 105±20	(68-175)	 97±19	(57-151)	 96±17	(70-131)	 <0.001	
RVEF	(%)	 55±5	(42-68)	 55±6	(40-71)	 56±5	(40-71)	 57±6	(41-74)	 57±7	(46-77)	 60±6	(48-72)	 <0.001	
RVEDVI	(ml/m2)	 102±15	(61-145)	 100±16	(63-144)	 94±16	(50-134)	 92±15	(55-140)	 90±16	(60-126)	 82±14	(68-114)	 <0.001	
RVESVI	(ml/m2)	 46±10	(23-76)	 45±11	(21-78)	 41±10	(21-73)	 40±10	(21-74)	 39±10	(17-59)	 33±9	(21-59)	 <0.001	
RVSVI(ml/m2)	 56±8	(36-74)	 55±9	(37-89)	 53±10	(6-92)	 52±9	(33-101)	 51±9	(32-70)	 49±9	(35-66)	 <0.001	
Females	(n=837)	
	 n=196	 n=212	 n=172	 n=156	 n=88	 n=13	 	
RVEDV	(ml)	 146±25	(77-239)	 149±25	(82-220)	 146±22	(97-213)	 139±25	(78-209)	 130±23	(87-187)	 114±20	(84-146)	 <0.001	
RVESV	(ml)	 62±15	(30-107)	 62±16	(23-119)	 59±13	(30-106)	 54±14	(16-98)	 50±15	(26-106)	 41±10(25-65)	 <0.001	
RVSV	(ml)	 83±14	(45-132)	 87±14	(53-133)	 88±14	(55-128)	 84±15	(44-140)	 80±13	(52-107)	 73±12	(58-97)	 0.03	
RVEF	(%)	 57±5	(41-73)	 59±6	(44-76)	 60±5	(45-72)	 61±6	(48-80)	 62±6	(40-76)	 64±4	(54-70)	 <0.001	
RVEDVI	(ml/m2)	 88±12	(60-132)	 87±13	(59-134)	 83±11	(61-116)	 79±12	(51-110)	 76±12	(51-109)	 67±8	(52-81)	 <0.001	
RVESVI	(ml/m2)	 37±8	(19-59)	 36±9	(17-75)	 33±7	(20-63)	 31±7	(10-55)	 30±8	(16-66)	 24±5	(15-37)	 <0.001	
RVSVI(ml/m2)	 50±7	(30-73)	 51±7	(33-76)	 50±7	(33-74)	 48±7	(29-69)	 47±7	(33-61)	 43±4	(36-48)	 <0.001	
Table	3.5.	Digital	Heart	project	volumetric	data	by	age	and	gender	
Data	are	mean	± 	standard	deviation	with	range	in	brackets.	Significance	relates	to	comparisons	between	age	groups	by	gender	(by	ANOVA).	RVEF	indicates	right	
ventricular	ejection	fraction;	RVEDV,	right	ventricular	end-diastolic	volume;	RVESV,	right	ventricular	end-systolic	volume;	RVSV,	right	ventricular	stroke	volume;	I,	indexed	
to	body	surface	area.	
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Males	 Females	
	 	
	
Figure	3.1.	Digital	Heart	Project	volumetry	compared	to	historical	data	
Graphs show volumetric and functional data by decade from the Digital Heart project (DHP) and from historical data [336] by gender. Dotted lines indicate historical data, 
continuous lines indicate data from the DHP. RVEF indicates right ventricular ejection fraction; RVEDVI, indexed right ventricular end-diastolic volume; RVESVI, indexed right 
ventricular end-systolic volume; RVSVI, indexed right ventricular stroke volume. 
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	 	 	 	 	 C	vs	SA	 C	vs	AF	 C	vs	O	 SA	vs	AF	 SA	vs	O	 AF	vs	O	
RVEDV	(ml)	 168±39	(83-312)	 144±33	(77-246)		161±32	(78-254)	 157±33	(94-284)	 <0.001	 <0.001	 0.57	 0.06	 <0.001	 0.04	 0.76	
RVESV	(ml)	 71±23	(16-169)	 62±20	(23-125)	 71±21	(34-147)	 67±21	(30-141)	 <0.001	 <0.001	 0.98	 0.51	 0.002	 0.23	 0.53	
RVSV	(ml)	 97±20	(48-192)	 82±16	(44-138)	 90±16	(44-126)	 89±16	(57-144)	 <0.001	 <0.001	 0.007	 0.006	 0.002	 0.01	 1.0	
RVEF	(%)	 58±6	(40-80)	 58±6	(41-77)	 56±5	(42-69)	 58±6	(44-72)	 0.006	 0.43	 0.006	 0.86	 0.27	 >0.99	 0.31	
RVEDVI	(ml/m2)	 91±16	(50-145)	 81±13	(52	–	125)	 86±13	(51-128)	 89±16	(55-139)	 <0.001	 <0.001	 0.02	 0.80	 0.05	 <0.001	 0.51	
RVESVI	(ml/m2)	 38±11	(10-76)	 35±9	(16-64)	 38±9	(22-66)	 38±11	(20-78)	 <0.001	 <0.001	 >0.99	 >0.99	 0.05	 0.09	 >0.99	
RVSVI		(ml/m2)	 53±8	(25-101)	 46±6	(31-70)	 48±7	(29-63)	 51±7	(31-66)	 <0.001	 <0.001	 <0.001	 0.41	 0.28	 <0.001	 0.03	
CO	(L)	 6.2±1.4	(3.2-16.1)	5.4±1.2	(3.3-10.2)	5.8±1.4	(2.6-11.6)	5.7±1.2	(3.2±8.5)	 <0.001	 <0.001	 0.01	 0.01	 0.06	 0.12	 >0.99	
CI	(L/m2)	 3.4±0.7	(1.7-8.1)	 3.1±0.5	(2.2-5.2)	 3.1±0.7	(1.7-6.6)	 3.3±0.6	(2.1-4.5)	 <0.001	 <0.001	 <0.001	 0.58	 0.97	 0.02	 0.11	
HR	(bpm)	 64±10	(40-110)	 66±10	(45-105)	 63±9	(38-85)	 64±9	(45-89)	 0.37	 -	 -	 -	 -	 -	 -	
Table	3.6.	Digital	Heart	Project	volumetric	data	by	race	
Data are mean ± standard deviation with range in brackets. Significance is compared by group (Kruskal-Wallis test) with post-hoc testing by Nemenyi tests when p<0.05 (all 
parameters). AF indicates African / Afro-Caribbean; C, Caucasian; SA, South-Asian; BPM indicates beats per minute; CI, cardiac index; CO, cardiac output; HR, heart rate; RVEF, 
right ventricular ejection fraction; RVEDV, right ventricular end-diastolic volume; RVESV, right ventricular end-systolic volume; RVSV, right ventricular stroke volume; I, indexed 
to body surface area 	 	
	 Caucasians	
(n=1141)	
South	Asians	
(n=194)	
Africans	
(n=104)	
Other	
(n=88)	
Kruskal	
Wallis	p-value	
Post-hoc	Nemenyi		p-value	
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	 Level	1	
(n=122)	
Level	2	
(n=625)	
Level	3	
(n=527)	
Level	4	
(n=253)	
KW	
p-value	
Post-hoc	Nemenyi	p-Value	
1	vs	2	 1	vs	3	 1	vs	4	 2	vs	3	 2	vs	4	 3	vs	4	
RVEDV	(ml)	 153±32	(84-238)	 153±33	(77-309)	 168±37	(87-312)	 188±43	(87-303)	 <0.001	 >0.99	 <0.001	 <0.001	 <0.001	 <0.001	 <0.001	
RVESV	(ml)	 63±20	(25-128)	 65±20	(16-169)	 71±22	(28-142)	 83±26	(28-152)	 <0.001	 0.97	 0.001	 <0.001	 <0.001	 <0.001	 <0.001	
RVSV	(ml)	 89±16	(51-132)	 89±17	(44-148)	 97±20	(52-192)	 104±23	(11-174)	 <0.001	 0.89	 0.006	 <0.001	 <0.001	 <0.001	 <0.001	
RVEF	(%)	 59±6	(44-72)	 58±6	(40-80)	 58±6	(40-76)	 56±6	(41-77)	 <0.001	 0.57	 0.17	 <0.001	 0.55	 <0.001	 0.002	
RVEDVI	(ml/m2)	 82±13	(52-124)	 85±14	(50-137)	 91±15	(57-145)	 101±17	(61-144)	 <0.001	 0.58	 <0.001	 <0.001	 <0.001	 <0.001	 <0.001	
RVESVI	(ml/m2)	 34±9	(15-66)	 36±10	(10-75)	 39±10	(17-75)	 45±12	(17-78)	 <0.001	 0.49	 <0.001	 <0.001	 <0.001	 <0.001	 <0.001	
RVSVI	(ml/m2)	 48±9	(33-62)	 49±7	(25-73)	 53±8	(33-101)	 56±9	(6-89)	 <0.001	 0.83	 <0.001	 <0.001	 <0.001	 <0.001	 <0.001	
CO	(L)	 6.3±1.5	(3.4-10.2)	 5.9±1.3	(2.5-11.3)	 6.2±1.5	(3.2-16.1)	 6.2±1.5	(3.2-11.6)	 0.009	 0.10	 0.87	 0.99	 0.05	 0.05	 0.95	
CI	(L/m2)	 3.4±0.7	(2.1-5.4)	 3.3±0.6	(1.7-5.6)	 3.3±0.7	(1.7-8.1)	 3.3±0.6	(2.1-6.6)	 0.37	 -	 -	 -	 -	 -	 -	
HR	 70±12	(50-110)	 66±10	(38-100)	 64±10	(40-110)	 59±9	(40-85)	 <0.001	 0.05	 <0.001	 <0.001	 <0.001	 <0.001	 <0.001	
Table	3.7.	Digital	Heart	Project	volumetric	data	by	activity	score.	
Data are mean ± standard deviation with range in brackets. Significance is compared by group (Kruskal-Wallis test) with post-hoc testing by Nemenyi tests when p < 0.05 (all 
parameters); BPM indicates beats per minute; CI, cardiac index; CO, cardiac output; HR, heart rate; KW, Kruskal-Wallis; RVEF, right ventricular ejection fraction; RVEDV, right 
ventricular end-diastolic volume; RVESV, right ventricular end-systolic volume; RVSV, right ventricular stroke volume; I, indexed to body surface area. 	  
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	 1st	quartile:	
1.21-1.68	
2nd	quartile:	
1.68-1.81	
3rd	quartile:	
1.81-1.97	
4th	quartile:	
1.97-2.57	
ANOVA	
p-value	
Post-hoc	Tukey’s	test	(p-value)	
1	vs	2	 1	vs	3	 1	vs	4	 2	vs	3	 2	vs	4	 3	vs	4	
RVEDV	(ml)	 133±23	(77-214)	 154±26	(98-251)	 172±32	(97-272)	 199±36	(120-312)	 <0.001	 <0.001	 <0.001	 <0.001	 <0.001	 <0.001	 <0.001	
RVESV	(ml)	 55±15	(16-119)	 64±17	(29-141)	 74±21	(31-141)	 87±24	(41-169)	 <0.001	 <0.001	 <0.001	 <0.001	 <0.001	 <0.001	 <0.001	
RVSV	(ml)	 78±12	(44-117)	 90±14	(57-175)	 97±16	(48-174)	 112±20	(11-192)	 <0.001	 <0.001	 <0.001	 <0.001	 <0.001	 <0.001	 <0.001	
RVEF	(%)	 59±6	(40-80)	 59±6	(40-74)	 57±6	(40-76)	 57±6	(41-74)	 <0.001	 0.99	 0.002	 <0.001	 0.005	 <0.001	 0.56	
RVEDVI	(ml/m2)	 84±14	(51-134)	 88±15	(57-140)	 91±17	(50-145)	 95±17	(55-144)	 <0.001	 0.002	 <0.001	 <0.001	 0.04	 <0.001	 0.001	
RVESVI	(ml/m2)	 35±9	(10-75)	 37±10	(17-78)	 39±11	(17-75)	 41±11	(20-76)	 <0.001	 0.07	 <0.001	 <0.001	 0.002	 <0.001	 0.02	
RVSVI	(ml/m2)	 49±7	(29-72)	 51±8	(32-101)	 52±8	(25-89)	 53±9	(6-92)	 <0.001	 0.001	 <0.001	 <0.001	 0.95	 0.002	 0.01	
CO	(L)	 5.1±1.0	(2.5-8.6)	 5.8±1.1	(3.6-11.6)	 6.3±1.3	(3.9-12.2)	 7.0±1.5	(3.5-16.1)	 <0.001	 <0.001	 <0.001	 <0.001	 <0.001	 <0.001	 <0.001	
CI	(L/m2)	 3.2±0.6	(1.7-5.3)	 3.3±0.6	(2.1-6.6)	 3.3±0.7	(2.1-6.6)	 3.3±0.7	(1.7-8.1)	 0.03	 0.12	 0.09	 0.12	 >0.99	 >0.99	 >0.99	
HR	(bpm)	 65±10	(38-100)	 65±10	(40-110)	 65±10	(40-110)	 63±11	(40-100)	 0.004	 0.99	 >0.99	 0.01	 >0.99	 0.03	 0.02	
Table	3.8.	Digital	Heart	Project	volumetric	data	by	BSA	quartiles.	
All quartiles have n=382 apart from 2nd quartile (n=381). Data are mean ± standard deviation with range in brackets. Significance is compared by group (ANOVA) with post-
hoc Tukey’s testing when p < 0.05 (all parameters); BPM indicates beats per minute; CI, cardiac index; CO, cardiac output; HR, heart rate; KW, Kruskal-Wallis; RVEF, right 
ventricular ejection fraction; RVEDV, right ventricular end-diastolic volume; RVESV, right ventricular end-systolic volume; RVSV, right ventricular stroke volume; I, indexed to 
body surface area. 
 
  
138	
 
Females	 Males	
  
Figure	3.2.	Digital	Heart	Project	volumetric	data	by	activity	and	gender 
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	 	 Indexed	to	body	surface	area	 Allometrically	indexed		 	 Standardised	β	 p	 Standardised	β 	 p	
RVEDVI	 	 	 	 		 Gender*	 0.37	 <0.001	 0.66	 <0.001		 Age	 -0.28	 <0.001	 -0.13	 <0.001		 Activity	score	 0.29	 <0.001	 0.10	 <0.001		 Race:	Caucasian	 0.03	 0.51	 0.17	 <0.001		 Race:	Asian	 -0.11	 0.003	 -0.08	 0.008		 Race:	African	 0.03	 0.38	 0.08	 0.002		 Gender	:	Age	 -0.03	 0.14	 -0.05	 0.002		 Model	adjusted	R2	 0.37	 	 0.54	 	
RVESVI	 	 	 	 	 		 Gender*	 0.38	 <0.001	 0.64	 <0.001		 Age	 -0.29	 <0.001	 -0.17	 <0.001		 Activity	score	 0.20	 <0.001	 0.10	 <0.001		 Race:	Caucasian	 0.03	 0.51	 0.13	 <0.001		 Race:	Asian	 -0.11	 0.003	 -0.06	 0.04		 Race:	African	 0.03	 0.38	 0.09	 <0.001		 Gender	:	Age	 -0.01	 0.64	 -0.05	 0.004		 Model	adjusted	R2	 0.29	 	 0.49	 	
RVSVI	 	 	 	 	 		 Gender*	 0.21	 <0.001	 0.61	 <0.001		 Age	 -0.16	 <0.001	 -0.08	 <0.001		 Activity	score	 0.26	 <0.001	 0.09	 <0.001		 Race:	Caucasian	 0.10	 0.02	 0.18	 <0.001		 Race:	Asian	 -0.17	 <0.001	 -0.09	 0.005		 Race:	African	 -0.06	 0.05	 0.06	 0.03		 Gender	:	Age	 -0.05	 0.03	 -0.05	 0.005		 Model	adjusted	R2	 0.19	 	 0.46	 	
RVEF	 	 	 	 	 		 Gender*	 -0.27	 <0.001	 -	 -		 Age	 0.21	 <0.001	 -	 -		 Activity	score	 -0.07	 0.006	 -	 -		 Race:	Caucasian	 0.04	 0.41	 -	 -		 Race:	Asian	 <0.01	 0.85	 -	 -		 Race:	African	 -0.08	 0.02	 -	 -		 Gender	:	Age	 -0.05	 0.04	 -	 -		 Model	adjusted	R2	 0.14	 	 	 	
Cardiac	Index	 	 	 		 Gender*	 0.09	 <0.001	 0.57	 <0.001		 Age	 -0.19	 <0.001	 -0.11	 <0.001		 Activity	score	 -0.04	 0.13	 -0.04	 0.05		 Race:	Caucasian	 0.10	 0.04	 0.18	 <0.001		 Race:	Asian	 -0.12	 0.005	 -0.08	 0.02		 Race:	African	 -0.05	 0.13	 0.05	 0.06		 Gender	:	Age	 -0.06	 0.02	 -0.07	 0.002		 Model	adjusted	R2	 0.03	 	 0.37	 	
Table	3.9.	Digital	Heart	Study	summaries	of	regression	models	
*Genders are coded such that positive regression coefficients correspond to greater values in males. Data were scaled and centred 
before analysis. Blue columns show data indexed ratiometrically to body surface area; red columns show data indexed allometrically 
with constants calculated for each parameter separately.
 : indicates an interaction term; BSA, body surface area; RVEDV, right 
ventricular end-diastolic volume; RVEF, right ventricular ejection fraction; RVESV, right ventricular end-systolic volume. 
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3.3.1. Summary	of	linear	regression	models	by	gender	
	 	 Indexed	by	body	surface	area	 Allometric	indexing		 	 Males	 Females	 Males	 Females		 	 β	 p	 β	 p	 β	 p	 β	 p	
RVEDVI	 	 	 	 	 	 	 	 		 Age	 -0.31	 <0.001	 -0.33	 <0.001	 -0.21	 <0.001	 -0.18	 <0.001		 Activity	score	 0.29	 <0.001	 0.25	 <0.001	 0.16	 <0.001	 0.11	 <0.001		 Race:	Caucasian	 0.10	 0.11	 0.05	 0.39	 0.27	 <0.001	 0.18	 0.003		 Race:	Asian	 -0.19	 0.001	 -0.17	 <0.001	 -0.08	 0.18	 -0.16	 0.002		 Race:	African	 -0.04	 0.39	 <-0.01	 0.88	 0.05	 0.27	 0.16	 <0.001		 Model	adjusted	R2	 0.25	 	 0.23	 	 0.16	 	 0.13	 	
RVESVI	 	 	 	 	 	 	 	 		 Age	 -0.29	 <0.001	 -0.34	 <0.001	 -0.29	 <0.001	 -0.26	 <0.001		 Activity	score	 0.22	 <0.001	 0.21	 <0.001	 0.22	 <0.001	 0.14	 <0.001		 Race:	Caucasian	 0.10	 0.15	 -0.04	 0.53	 0.10	 0.16	 0.01	 0.08		 Race:	Asian	 -0.09	 0.13	 0.13	 0.008	 -0.09	 0.13	 -0.15	 0.004		 Race:	African	 0.03	 0.54	 0.02	 0.65	 0.03	 0.54	 0.15	 0.001		 Model	adjusted	R2	 0.16	 	 0.18	 	 0.16	 	 0.15	 	
RVSVI	 	 	 	 	 		 Age	 -0.21	 <0.001	 -0.18	 <0.001	 -0.15	 <0.001	 -0.07	 0.03		 Activity	score	 0.25	 <0.001	 0.20	 <0.001	 0.15	 <0.001	 0.07	 0.03		 Race:	Caucasian	 0.06	 0.37	 0.13	 0.02	 0.24	 <0.001	 0.21	 <0.001		 Race:	Asian	 -0.22	 <0.001	 -0.15	 0.004	 -0.11	 0.09	 -0.14	 0.007		 Race:	African	 -0.11	 0.03	 -0.04	 0.42	 <0.01	 0.85	 0.14	 0.004		 Model	adjusted	R2	 0.11	 	 0.08	 	 0.15	 	 0.10	 	
RVEF	 	 	 	 	 	 	 	 		 Age	 0.16	 <0.001	 0.27	 <0.001	 -	 	 -	 		 Activity	score	 -0.04	 0.33	 -0.10	 0.004	 -	 	 -	 		 Race:	Caucasian	 -0.07	 0.37	 0.11	 0.08	 -	 	 -	 		 Race:	Asian	 -0.06	 0.34	 0.04	 0.41	 -	 	 -	 		 Race:	African	 -0.11	 0.03	 -0.07	 0.17	 -	 	 -	 		 Model	adjusted	R2	 0.03	 	 0.10	 	 -	 	 -	 	
Cardiac	Index	 	 	 	 	 	 	 		 Age	 -0.22	 <0.001	 -0.16	 <0.001	 -0.17	 <0.001	 -0.06	 0.05		 Activity	score	 <-0.01	 0.87	 -0.06	 0.04	 -0.02	 0.56	 -0.10	 0.005		 Race:	Caucasian	 0.02	 0.78	 0.15	 0.01	 0.20	 0.005	 0.22	 <0.001		 Race:	Asian	 -0.19	 0.003	 -0.07	 0.23	 -0.11	 0.09	 -0.10	 0.06		 Race:	African	 -0.09	 0.07	 -0.28	 0.57	 <-0.01	 0.99	 0.12	 0.01		 Model	adjusted	R2	 0.08	 	 0.06	 	 0.02	 	 0.07	 	
Table	3.10.	Digital	Heart	Study	volumetric	data	regression	statistics.	
Data were scaled and centred before analysis. Blue columns show data indexed ratiometrically to body surface 
area; red columns show data indexed allometrically. β-values are standardised to unit standard deviation. 
RVEDV, right ventricular end-diastolic volume; RVEF, right ventricular ejection fraction; RVESV, right ventricular 
end-systolic volume. 
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3.3.2. Comparison	of	non-,	ratiometric-	and	allometric-	indexing	approaches	A	 B	 C	
Unscaled	 Ratiometric	indexing	 Allometric	indexing	
	 Height	 Weight	 Height	 Weight	 	 Height	 Weight		 β	 p	 β	 p	 β	 p	 β	 p	 k*	 β	 p	 order*	 β	 p	 order*	RVEDV	 0.54	 <0.001	 0.27	 <0.001	 0.52	 <0.001	 -0.14	 <0.001	 0.97	 0.02	 0.81	 -2.20	 -0.01	 0.66	 -0.36	RVESV	 0.49	 <0.001	 0.18	 <0.001	 0.45	 <0.001	 -0.11	 <0.001	 0.92	 -0.02	 0.89	 -2.89	 -0.01	 0.90	 -0.23	RVSV	 0.47	 <0.001	 0.39	 <0.001	 0.42	 <0.001	 -0.14	 <0.001	 0.97	 0.01	 0.96	 -1.73	 0.01	 0.76	 -0.37	CO	/	CI	 0.32	 <0.001	 0.28	 <0.001	 0.22	 <0.001	 0.12	 <0.001	 0.97	 -0.08	 0.54	 -0.82	 -0.04	 0.31	 -0.09	
(A)	The	association	of	height	and	weight	with	unscaled	volumetric	and	functional	measures.	All	measures	are	significantly	associated	with	height	and	weight,	p	<	0.001.	(B)	The	association	of	height	and	weight	with	volumetric	and	functional	measures	indexed	ratiometrically.	Height	and	weight	were	still	significantly	associated	with	all	ratiometrically	 indexed	measures	 (all	 p	 <	 0.001)	 suggesting	 that	 ratiometric	 indexing	 does	 not	 generate	measures	which	 are	 independent	 of	 body	 size.	 In	 allometric	indexing,	height	and	weight	have	no	significant	association	with	body	size	(all	p>0.05).	*k	=	constant	of	proportionality;	order	=	power	to	which	height	and	weight	are	raised	 for	 effective	 indexing.	 These	 values	were	 discovered	 from	 a	 training	 group	 (500	 subjects)	 from	which	 10,000	 bootstrap	 samples	 are	 randomly	 generated	 and	optimised	coefficients	fitted.	The	mean	value	over	10,000	values	is	taken	as	the	best	estimator	of	optimal	coefficients	before	being	applied	to	the	remaining	subjects.	β	and	p	values	show	the	performance	of	these	indexing	factors	in	the	test	group.	
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8.7. Tables	
	 	 	 	
Marker	 Log	Rank*	 AUC*	 Difference	in	MST	(years)	 Optimised	threshold		 	 	 Median	 IQR	 IQR	(%)†	CI	(l/min/m2)	 15.6	(12.0-18.8)	 0.52	(0.50-0.56)	 2.3	(1.1-3.9)	 2.3	 2.3-2.4	 8.6	mPAP	(mmHg)	 17.1	(13.6-20.7)	 0.60	(0.57-0.63)	 1.9	(1.1-2.6)	 43	 42-45	 15.0	PVR	(U)	 18.0	(14.4-22.0)	 0.58	(0.54-0.61)	 2.1	(1.1-2.9)	 7.2	 6.9-7.8	 14.6	mRAP	(mmHg)	 16.8	(13.2-19.8)	 0.62	(0.58-0.66)	 2.4	(1.5-3.7)	 11.0	 11.0-12.0	 5.8	RVEDP	(mmHg)	 21.0	(17.7-24.6)	 0.62	(0.59-0.65)	 3.1	(2.4-3.7)	 13	 11-14	 8.3	RVEDVI	(ml/m2)	 17.8	(14.1-21.5)	 0.58	(0.54-0.62)	 2.4	(1.6-3.2)	 103	 98-107	 9.7	RVESVI	(ml/m2)	 18.2	(14.7-22.0)	 0.60	(0.57-0.64)	 2.7	(2.0-3.3)	 63	 59-67	 12.9	RVEF	(%)	 17.2	(13.5-21.0)	 0.60	(0.57-0.64)	 2.0	(1.4-2.4)	 36	 35-38	 6.6	SV/RVESV	(%)	 17.3	(13.9-21.3)	 0.61	(0.57-0.65)	 1.8	(1.1-2.4)	 2.20	 2.17-2.24	 12.7	3D	Motion	(PC)	 19.5	(16.1-22.9)	 0.72	(0.69-0.76)	 4.1	(3.6-4.6)	 0.06	 0.04-0.09	 5.2	6MWD	(m)	 19.6	(16.5-22.9)	 0.67	(0.62-0.71)	 3.0	(2.5-3.6)	 354	 318-396	 16.3	
Table	8.2.	Survival	prediction:	strength	of	association	and	threshold	variability	
Median, inter-quartile range (IQR). Receiver operating characteristics’ area under the curve (AUC) indicates the performance of the marker in one-year survival prediction. 
*Kruskal-Wallis test, †Permutation testing. CI indicates cardiac index; mPAP, mean pulmonary artery pressure; MST, median survival time; PC, principal component units; 
PVR, pulmonary vascular resistance; mRAP, mean right atrial pressure; RVEDP, RV end-diastolic pressure; RVEDVI, indexed RV end-diastolic volume; RVESVI, indexed RV end-
systolic volume; RVEF, RV ejection fraction; SV/RVESV, stroke volume/RV end-systolic volume; U, Woods Units; 3D, three-dimensional; 6MWD, six-minute walk distance. 
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Figure	8.1.	Study	Overview	
Flow diagram for recruitment and analysis of PH patients. CMR indicates cardiac magnetic resonance; PH, 
pulmonary hypertension; and RHC, right heart catheterisation. 
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Figure	8.2.	Hazards	ratios	for	survival	
Hazards ratios and 95% confidence intervals for 3D motion and conventional prognostic markers at median 
iteration. Values greater than five were truncated. CI indicates cardiac index; CIs, 95% confidence intervals; HR, 
hazard ratio; mPAP, mean pulmonary artery pressure; PVR, pulmonary vascular resistance; mRAP, mean right 
atrial pressure; RVEDP, RV end-diastolic pressure; RVEDVI, indexed RV end-diastolic volume; RVESVI, indexed RV 
end-systolic volume; RVEF, RV ejection fraction; SV/RVESV, stroke volume / RV end-systolic volume; 6MWD, six-
minute walk distance; 3D, three-dimensional. 	 	
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Figure	8.3.	Kaplan	Meier	curves	for	3D	motion	and	RVEF	
Kaplan Meier curves and numbers-at-risk for the survival of pulmonary hypertension patients stratified by 3D 
modelling (a) and RV ejection fraction (b). Colours indicate patients identified as low-risk (red) and high-risk (green) 
using optimised thresholds given in Table 2. 
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Figure	8.4.	RV	model	showing	survival	prediction	in	PH	patients	
3D model of the right ventricle showing the regional contributions to survival prediction in pulmonary hypertension 
patients, overall (a), and by components of function, (b-d). The right ventricle is shown in anterior and septal views 
with the left ventricle as a mesh. Colour denotes whether reduced (red) or increased (blue) regional function is 
associated with poor survival.  
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Figure	8.5.	3D	contributions	to	function	in	PH	patients	
3D model of the right ventricle showing the regional contributions to global function prediction in pulmonary 
hypertension patients, overall (a), and by components of function, (b-d). The right ventricle is shown in anterior and 
septal views with the left ventricle as a mesh. Colour denotes whether reduced (red) or increased (blue) regional 
function is associated with reduced global function. 	
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Figure	8.6.	3D	contributions	to	global	function	in	healthy	volunteers	
3D model of the right ventricle showing the regional contributions to global function prediction in healthy controls, 
overall (a), and by components of function, (b-d). The right ventricle is shown in anterior and septal views with the 
left ventricle as a mesh. Colour denotes whether reduced (red) or increased (blue) regional function is associated 
with reduced global function.  	
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Figure	8.7.	Contributions	of	directional	components	to	global	function	and	prediction	
A. Contribution of the directional components of RV function to the prediction of global function in healthy 
controls, and to the prediction of global function and survival in pulmonary hypertension (PH) patients. Values 
represent the median 3D motion of myocardial points associated with survival or RV ejection fraction (RVEF). B. 
Relative contribution of function to survival in idiopathic pulmonary arterial hypertension (IPAH), PH due to left 
heart disease (LHD) and chronic thromboembolic pulmonary hypertension (CTEPH). IPAH indicates idiopathic 
pulmonary arterial hypertension; CTEPH, chronic thromboembolic pulmonary hypertension; LHD, pulmonary 
hypertension due to left heart disease; PH, pulmonary hypertension; RVEF, RV ejection fraction. 	
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Figure	8.8.	Regional	contributions	to	survival	prediction	in	subtypes	of	PH	
3D models of the right ventricle (colour) in anterior and septal views with the left ventricle as a mesh showing the 
regional contributions to survival prediction in three subtypes of pulmonary hypertension. These models show the 
relative shape and volume differences in each subgroup of our cohort. Colour denotes whether reduced (red) or 
increased (blue) regional function is associated with death. CTEPH; chronic thromboembolic pulmonary 
hypertension; LHD, pulmonary hypertension due to left heart disease; IPAH indicates idiopathic pulmonary arterial 
hypertension. 	
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	 	 	 			 Patients	 Controls	 P	Value	Patients	 Controls	 Controls	vs	patients		 Females	(n=143)	 Male	(n=113)	 Female	(n=143)	 Male	(n=113)	 Male	vs	Female	 Male	vs	Female	 Both	sexes	Age	(years)	 67	(52-75)	 67	(52-73)	 58	(51-63)	 58	(50-63)	 0.65	 0.24	 <0.001	BSA	(m2)	 1.78±0.21	 1.96±0.22	 1.73±0.16	 1.94±0.18	 <0.001	 <0.001	 0.32	Race	 African	Asian	Caribbean	Caucasian	European	Sub-continent	Middle	East	
	7	3	5	116	1	10	1	
	2	2	7	95	1	5	0	
	2	0	9	121	4	16	0	
	2	0	1	93	5	12	0	
0.62	 0.27	 0.35	
RVEDVI	(ml.m-2)	 95	(74-123)	 107	(80-127)	 78	(69-86)	 88	(78-103)	 0.07	 <0.001	 <0.001	RVESVI	(ml.m-2)	 55	(38-80)	 67	(43-85)	 30	(24-36)	 38	(32-45)	 0.05	 <0.001	 <0.001	RVEF	(%)	 42	(31-52)	 38	(28-48)	 61	(58-66)	 57	(53-61)	 0.07	 <0.001	 <0.001	SV	/	RVESV	(%)	 74	(46-107)	 60	(39-93)	 91	(78-113)	 67	(59-81)	 0.07	 <0.001	 <0.001	
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Diagnosis			WHO	Group	1					IPAH					HPAH					DPAH					APAH					PVOD			WHO	Group	2*			WHO	Group	3			WHO	Group	4			WHO	Group	5	
	56	35	1	1	17	2	28	(5/21/2)	6	50	3	
	32	22	2	0	8	0	15	(0/14/1)	9	56	1	
	 	 	 	 	
NYHA	functional	class	I	II	III	IV	
	2	21	92	28	
	1	21	72	19	
	 	 0.48	 	 	
6MWD	(m)	 258	(96-360)	 302	(150-398)	 	 	 0.05	 	 	
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Haemodynamics		mPAP	(mmHg)	mSBP	(mmHg)	CI	PVR	(U)	mRAP	mRVEDP	PCWP	
	46	(32-55)	95	(83-106)	2.3	(1.8-2.9)	7.8	(3.8-12.2)	10	(6-15)	10	(6-14)	12	(9-16)	
	43	(33-52)	89	(76-103)	2.3	(2.0-2.9)	6.3	(4.2-10.1)	11	(7-14)	12	(8-15)	12	(8-14)	
	 	0.49	0.10	0.31	0.82	0.58	0.06	0.39	
	 	
Table	8.3.	Baseline	characteristics	of	patients	and	controls	
*Numbers in brackets represent LV dysfunction due to systolic/diastolic/valvular dysfunction. APAH indicates pulmonary arterial hypertension associated with another condition; BSA, Body 
Surface Area; CI, cardiac index; CMR, cardiac magnetic resonance; DPAH, drug- and toxin- induced pulmonary arterial hypertension; HPAH, hereditary pulmonary arterial hypertension; IPAH, 
idiopathic pulmonary arterial hypertension; NYHA, New York Heart Association; mPAP, mean pulmonary artery pressure; PCWP, pulmonary capillary wedge pressure; PH, pulmonary 
hypertension; PVOD, pulmonary veno-occlusive disease; PVR, pulmonary vascular resistance; mRAP, mean right atrial pressure; RVEDVI, indexed right ventricular end-diastolic volume; RVEF, 
right ventricular ejection fraction; RVESVI, indexed right ventricular end-systolic volume; mSBP, mean systemic blood pressure; SD, standard deviation; SV / RVESV, stroke volume divided by 
right ventricular end-systolic volume; WHO, World Health Organisation; 6MWD, six-minute walk distance.  
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	Group	1	 	 	 	 	 	 Group	2	 Group	3	 Group	4	 Group	5		 IPAH	 HPAH	 DPAH	 APAH	 PVOD	 	 	 	 	Age	 64	(44-73)	 68	(46-74)	 69	(61-77)	 49	 52	(42-70)	 56	(48-64)	 72	(60-77)	 70	(69-80)	 65	(51-72)	 67	(63-72)	Sex	(M/F)	 32/54	 22/35	 2/1	 0/1	 8/17	 0/2	 15/28	 7/4	 56/50	 1/3	6WMD	(m)	 243	(96-365)	 215	(95-360)	 120	(90-276)	 309	 308	(106-371)	 146	(115-177)	 180	(80-316)	 276	(168-330)	 297	(144-368)	 45	(26-157)	WHO	FC§	 	 	 	 	 	 	 	 	 	 			I	 3	 1	 0	 0	 2	 0	 0	 0	 0	 0			II	 14	 8	 0	 0	 6	 0	 7	 1	 21	 0			III	 51	 33	 2	 1	 15	 1	 23	 6	 67	 4			IV	 16	 13	 1	 0	 2	 1	 5	 4	 18	 0	Haemodynamics	 	 	 	 	 	 	 	 	 	 			mPAP	(mmHg)	 49	(39-58)‡	 50	(42-59)†	 34	(34-38)	 66	 42	(31-50)	 54	(54-55)	 32	(27-43)	 38	(33-44)	 46	(35-54)‡	 49	(47-50)			mRAP	(mmHg)	 9	(5-15)	 10	(5-15)	 7	(5-15)	 28‡	 8	(6-15)	 7	(5-8)	 15	(12-17)†	 6	(5-9)†	 10	(6-13)†	 16	(14-19)			PCWP	(mmHg)	 10	(7-14)‡	 10	(7-14)	 8	(8-12)	 15	 10	(8-13)	 9	(8-9)	 17	(16-22)*	 14	(11-17)	 10	(8-13)‡	 19	(15-23)			PVR	(U)	 8.2	(5.3-12.2)†	 9.0	(5.6-13.9)*	 9.1	(5.1-10.0)	 20.4*	 7.0	(2.8-10.7)	 13.1	(11.0-15.2)	 3.3	(2.0-5.9)	 5.7	(3.2-6.6)	 8.3	(4.5-12.1)‡	 7.8	(5.0-10.5)			RVEDP	(mmHg)	 10	(6-16)	 10	(6-16)	 8	(7-10)	 20	 10	(6-14)	 7	(6-8)	 12	(8-16)	 10	(8-12)	 11	(7-14)	 19	(14-23)†	CI	(l/min/m2)	 2.4	(2.0-3.0)*	 2.4	(2.0-2.9)*	 2.0	(1.9-5.4)*	 1.5	 2.8	(2.2-3.3)	 2.4	(2.1-2.6)	 2.4	(2.1-2.9)	 2.5	(2.4-3.0)	 2.2	(1.9-2.8)*	 2.2	(1.7-2.6)	HR	(/min)	 74	(66-85)	 75	(68-86)	 70	(58-72)	 72	 73	(63-84)†	 107	(98-115)	 68	(60-80)	 76	(66-79)	 76	(67-87)*	 75	(69-85)	CMR	Measurements			RVEDVI	(ml)	 104	(77-124)	 107	(75-129)	 94	(78-175)	 103	 104	(88-120)	 74	(71-76)	 81	(74-109)	 83	(73-110)	 104	(80-131)†	 87	(67-117)			RVESVI	(ml)	 63	(45-82)	 67	(46-94)	 45	(40-85)	 51	 61	(38-75)	 47	(47-47)	 44	(31-56)	 49	(39-64)	 70	(43-95)‡	 41	(34-65)			RVEF	(%)	 38	(31-49)	 34	(27-42)‡	 51	(46-52)	 50	 48	(37-57)	 36	(33-39)	 50	(44-57)	 44	(38-49)	 34	(27-46)‡	 49	(42-51)			SV/RVESV	(%)	 62	(44-94)	 52	(37-72)‡	 103	(88-107)	 101	 93	(58-132)	 57	(49-64)	 99	(80-132)	 80	(60-96)	 50	(37-86)‡	 95	(78-104)			3D	motion	 9	(6-15)	 9	(6-14)	 11	(6-16)	 15	(9-20)	 9	(5-15)	 9	(5-12)	 11	(6-16)	 10	(6-16)	 10	(6-16)	 11	(7-17)	Mortality			(%)	 39	 37	 67	 0	 36	 100	 37‡	 92	 26‡	 50							n/total	 34/88	 21/57	 2/3	 0/1	 9/25	 2/2	 12/43	 11/12	 28/106	 2/4	
Table	8.4.	PH	patients'	baseline	clinical	data	by	diagnostic	subgroup		
Values are median and inter-quartile range. Survival models were adjusted for right ventricular ejection fraction. *Significant p < 0.05, †significant, p < 0.01, ‡significant, p < 0.001. §World Health 
Organization Functional Class I to IV. Higher numbers indicate lower functional capacity. APAH indicates pulmonary hypertension associated with another condition; CI, cardiac index; DPAH, drug- and 
toxin-induced pulmonary arterial hypertension; HPAH, hereditary pulmonary arterial hypertension; HR, heart rate; IPAH, idiopathic pulmonary hypertension; PVOD, pulmonary veno-occlusive disease; 
PVR, pulmonary vascular resistance; U, Woods Units; mRAP, mean right atrial pressure; RVEDP, right ventricular end-diastolic pressure; RVEDV, end-diastolic volume; RVESV, end-systolic volume; RVEF, 
ejection fraction; SV / RVESV, stroke volume divided by right ventricular end-systolic volume; TPG, trans-pulmonary gradient; 6MWD, six-minute walk distance. Clinical subgroups based on Simonneau 
et al. [84] 
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Variable	 PEA	 No	PEA	 P	Value	Age	 64.6	(50.7-69.2)	 64.9	(51.2-73.2)	 0.31	Sex	(M/F)	 22/24	 34/25	 0.36	WHO	FC	 	 	 0.09			I	 0	 0	 			II	 6	 15	 			III	 30	 36	 			IV	 10	 8	 	Haemodynamics	 	 	 			mPAP	(mmHg)	 48.5	(42.3-55.8)	 43.0	(29.5-52.0)	 0.01			mRAP	(mmHg)	 10.0	(7.0-13.8)	 10	(6.0-12.0)	 0.55			PCWP	(mmHg)	 11.0	(9.3-14.8)	 10.0	(7.5-12.0)	 0.22			PVR	(U)	 9.5	(5.4-12.3)	 7.0	(3.9-11.7)	 0.09			RVEDP	(mmHg)	 10.0	(8.0-15.0)	 11.0	(7.0-13.5)	 0.46			CI	(l/min/m2)	 2.1	(1.9-2.8)	 2.2	(1.9-2.8)	 0.50			HR	(.min-1)	 79	(68-87)	 74	(65-87)	 0.36	CMR	measurements			RVEDVI	(ml/m2)			RVESVI	(ml/m2)			RVEF	(%)	
	102.9	(77.4-120.7)	68.5	(42.9-88.6)	35.0	(27.3-44.2)	
	108.8	(84.5-135.0)	74.4	(44.1-97.5)	33.4	(26.5-47.9)	
	0.24	0.47	1.0			SV	/	RVESV	(%)	 53.7	(37.6-79.4)	 50.1	(36.0-92.0)	 1.0	Mortality				%,	n/total				Hazards	ratio		
	17,	8/46	0.511	(0.230-1.134)	
	32,	19/59	1	
		0.10	
Table	8.5.	Clinical	characteristics	of	CTEPH	patients	categorised	by	subsequent	PEA	
CI indicates cardiac index; HR, heart rate; mPAP, mean pulmonary artery pressure; PCWP, pulmonary capillary wedge 
pressure; PEA, pulmonary endarterectomy; PVR, pulmonary vascular resistance; mRAP, mean right atrial pressure; RV –
EDP / -EDV(I) / -EF / -ESV(I), right ventricular -end-diastolic pressure, (indexed) end-diastolic volume, -ejection fraction, 
(indexed) -end-systolic volume; SV / RVESV, stroke volume / right ventricular end-systolic volume; WHO FC, World Health 
Organization Functional Class I to IV. 
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		Variable	 Performed	 Unable	to	perform	 p-value	Age	 67	(51-74)	 69	(55-72)	 0.59	Sex	(M/F)	 109/131	 4/12	 0.13	WHO	FC	 	 	 0.01			I	 3	 0	 			II	 41	 2	 			III	 157	 6	 			IV	 39	 8	 	Haemodynamics	 	 	 			mPAP	(mmHg)	 46	(33-54)	 36	(27-42)	 0.02			mRAP	(mmHg)	 10	(7-14)	 11	(6-15)	 0.97			PCWP	(mmHg)	 12	(8-15)	 14	(10-17)	 0.29			PVR	(U)	 7.0	(4.0-11.4)	 5.2	(2.7-9.9)	 0.13			RVEDP	(mmHg)	 10	(7-15)	 12	(8-14)	 0.72			CI	(l/min/m2)	 2.3	(1.9-2.9)	 2.3	(1.8-2.9)	 0.77			HR	(.min-1)	 75	(65-85)	 72	(68-81)	 0.76	CMR	measurements			RVEDVI	(ml/m2)			RVESVI	(ml/m2)			RVEF	(%)	
	102	(77-124)	62	(41-84)	39	(30-49)	
	84	(68-111)	44	(30-68)	50	(38-60)	
	
0.20	
0.08	
0.04			SV/RVESV	(%)	 0.64	(0.42-0.97)	 0.99	(0.61-1.50)	 0.04	Mortality,	(%)										n	 35	85/240	 50	8/16	 0.05	
Table	8.6.	Baseline	characteristics	of	PH	patients	who	could,	and	who	could	not,	perform	the	6MWT		
CI indicates cardiac index; HR, heart rate; mPAP, mean pulmonary artery pressure; PCWP, pulmonary capillary 
wedge pressure; PEA, pulmonary endarterectomy; PVR, pulmonary vascular resistance; mRAP, mean right atrial 
pressure; RV –EDP / -EDV(I) / -EF / -ESV(I), right ventricular -end-diastolic pressure / (indexed) end-diastolic 
volume / -EF, ejection fraction; -ESVI, (indexed) end-systolic volume; SV/RVESV, stroke volume / RV end-systolic 
volume; WHO FC, World Health Organization Functional Class I to IV. 
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9. Pulmonary	artery	stiffness	is	an	independent	predictor	of	right	
ventricular	mass	and	function	
9.1. Introduction	RV	systolic	function	is	strongly	associated	with	outcome	in	several	diseases	[1-16]	and	in	 Section	 8	 we	 demonstrate	 how	 3D	 assessment	 of	 RV	 systolic	 function	 improves	prognostication	in	incident	PH	patients.	However,	deterioration	in	RV	systolic	function	is	 a	 late	 sign	 of	 dysfunction,	 typically	 preceded	 by	 compensatory	 increases	 in	 RV	contractility,	 an	 increase	 in	 RV	mass	 and	 diastolic	 disease	 [42,	 90].	 Identifying	 early	markers	of	disease	is	a	desirable	goal	since	RV	dysfunction	is	reversible	but	otherwise	carries	a	high	mortality	[640,	651-653].	
Vascular	stiffness	in	the	systemic	circulation	is	an	early	manifestation	of	vascular	aging	[31,	 32,	 654]	 and	 a	 strong	 predictor	 of	 future	 cardiovascular	 events	 and	 all-cause	mortality	[350-353,	655].	The	 importance	of	vascular-ventricular	coupling	 in	the	right	heart	 [382,	637]	suggests	 that	alterations	 in	pulmonary	vascular	stiffness	may	 impact	structure	and	function	of	the	right	heart,	though	this	has	not	been	demonstrated	to	date.		This	 is	 clinically	 important	 since	 even	 mild	 RV	 hypertrophy	 in	 populations	 free	 of	clinical	 cardiovascular	 disease	 is	 an	 independent	 predictor	 of	 heart	 failure	 and	 death	[18].	 There	 is	 some	 evidence	 to	 suggest	 that	 arterial	 stiffness	 is	 amenable	 to	 drug	treatment,	 suggesting	 early	 identification	 may	 allow	 therapeutic	 intervention	 [656-658].		
Assessment	 of	 pulse	wave	 velocity	 (PWV)	 in	 the	 aorta	 using	phase-contrast	 CMR	 is	 a	well-established	 technique	 that	 has	 also	 shown	 promise	 as	 a	 reproducible	method	 in	
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the	pulmonary	circulation	[354,	659].	In	this	study	we	set	out	to	discover	if	age-related	changes	 in	PA	 stiffness	were	 associated	with	 structural	 and	 functional	 changes	 in	 the	right	ventricle.	
9.2. Methods	
9.2.1. Subjects	A	total	of	156	healthy	adult	volunteers	(62%	female;	age	19-61;	mean	36.1	years)	were	prospectively	 recruited	by	advertisement.	We	excluded	participants	at	 screening	with	known	 cardiovascular	 disease	 or	 taking	 treatment	 for	 hypertension,	 diabetes	 or	hypercholesterolaemia.	 All	 subjects	 provided	 written	 informed	 consent	 for	participation	in	the	study,	which	was	approved	by	a	research	ethics	committee.	
9.2.2. MR	imaging	protocol		All	 images	 were	 acquired	 on	 a	 Philips	 1.5T	 MR	 Achieva	 system	 (Best,	 Netherlands).	Pulmonary	phase-contrast	 sequences	were	 acquired	perpendicular	 to	 the	direction	of	flow	 in	 the	main	 PA	 1cm	 above	 the	 valve	 annulus	 and	 in	 the	 right	 PA.	 The	 sequence	parameters	were	as	 follows:	 field-of-view	=	370	mm	×	370	mm,	 repetition	 time	=	2.8	ms,	echo	time	=	1.4	ms,	flip	angle	=	15°,	voxel	size	=	1.65	mm	×	1.92	mm	x	10	mm,	with	a	temporal	resolution	of	23	ms.	
For	 the	 calculation	 of	 path	 length	 ECG-gated	 b-SSFP	 images	were	 acquired	 along	 the	course	of	the	main	and	right	PA	using	the	following	parameters:	field-of-view	=	320	mm	×	320	mm,	repetition	time	=	3.4	ms,	echo	time	=	1.7	ms,	flip	angle	=	60°,	voxel	size	=	1.65	mm	×	1.92	mm	x	10	mm.	
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Ventricular	function	was	assessed	using	standard	cine	images	acquired	in	conventional	cardiac	planes	with	50	phases	[309].	
9.2.3. Pulmonary	pulse	wave	velocity	analysis	Pulmonary	 PWV	 was	 calculated	 from	 the	 3D	 vessel	 length	 (D)	 and	 transit	 time	 (Δt)	between	the	flow	waveforms	in	each	phase-encoded	sequence	using	validated	software	(ART-FUN,	 Inserm,	 Paris,	 Figure	 1	 [290,	 291].	 The	 path	 length	 was	 defined	 on	 the	anatomical	 images	 to	 create	 a	 3D	 Bezier	 curve	 through	 the	 centre	 of	 the	 vessel,	intersecting	the	plane	at	which	flow	measurements	had	been	obtained.	The	transit	time	was	 calculated	using	 the	 time-shift	between	 the	upslope	 (log	phase)	of	 the	 respective	flow	curves.	
	
9.2.4. Reliability	Repeatability	 and	 inter-observer	 reproducibility	 was	 assessed	 in	 twenty	 consecutive	subjects	who	were	each	scanned	twice.		
9.2.5. Right	ventricular	function	analysis	Analysis	 of	 the	 cine	 images	was	 performed	 on	 ViewForum	 (Philips	Medical	 Systems)	and	data	indexed	to	body	surface	area	(BSA).	Endocardial	and	epicardial	borders	of	the	RV	were	 traced	manually	 on	 the	 short	 axis	 cine	 images	 at	 the	 end-systolic	 and	 end-diastolic	phase.	Reference	to	the	position	of	the	pulmonary	and	tricuspid	valves	on	long-axis	 images	was	made	 to	ensure	correct	placement	of	 the	contours.	Papillary	muscles	and	trabeculae	were	 included	 in	 the	RV	volumes	but	excluded	 from	the	mass.	Systolic	and	 diastolic	 function	were	 quantified	 using	 feature	 tracking	 (FT)	 software	 (TomTec	
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Imaging	Systems,	Munich,	Germany)	which	has	been	validated	in	both	the	right	and	left	ventricles	[509-511].	Longitudinal,	circumferential	and	radial	strain	and	strain	rate,	as	well	as	peak	early-diastolic	strain	rate	(PEDSR)	were	measured.		
9.2.6. Statistical	Analysis	Data	 were	 analysed	 in	 R	 (version	 3.1.1).	 Associations	 were	 assessed	 by	 univariate	regression	 and	 adjusted	 for	 the	 effects	 of	 age,	 gender	 and	 BSA.	 Data	 were	 log	transformed	 where	 necessary	 to	 satisfy	 the	 assumptions	 of	 linear	 regression.	Significance	was	assessed	using	two-tailed	testing	with	significant	results	taken	as	a	p	<	0.05.	Continuous	variables	were	compared	between	groups	by	the	Mann-Whitney	U	test	(two	groups)	or	Kruskal-Wallis	rank	sum	test	(more	than	two	groups).	
	
9.3. Results	All	 156	 subjects	 completed	 the	 imaging	 protocol.	 All	 datasets	 were	 analysed	 and	included	in	the	final	analysis.	Subjects’	anthropometric	data	are	described	in	Table	9.1.	Test-retest	reliability	of	pulmonary	PWV	and	strain	analysis	is	shown	in	Table	9.2.	
9.3.1. Pulmonary	pulse	wave	velocity	Pulmonary	PWV	showed	no	 significant	difference	between	genders	 (Mann-Whitney	U	test,	p	=	0.81)	or	races	(Kruskal-Wallis	rank	sum	test,	p	=	0.82).	Pulmonary	pulse	wave	velocity	was	strongly	associated	with	age	(R	=	+0.31,	p	<	0.001).	
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9.3.2. Right	ventricular	function	RVEF	 was	 significantly	 higher	 in	 females	 than	males	 (Mann	Whitney	 U	 test,	 60%	 vs	54%,	p	<	0.001)	with	no	effect	of	 race	 (Kruskal-Wallis	 rank	sum	test,	p	=	0.35).	RVEF	increased	with	age	(R	=	+0.15,	p	=	0.03,	figure	3),	and	was	related	to	alterations	of	both	RVESV	(R	=	-0.68,	p	<	0.001)	and	RVEDV	(R	=	-0.90,	p	=	0.005).		
9.3.3. Pulmonary	pulse	wave	velocity	and	right	ventricular	function	Pulmonary	PWV	was	independently	associated	with	an	increase	in	RVEF	(R	=	+0.17,	p	=	0.03)	and	RVM	(R	=	+0.26,	p	<	0.001),	after	adjustment	for	age,	BSA	and	gender.	Pulse	wave	velocity	was	associated	with	radial	strain	(R	=	+0.36,	p	=	0.007)	and	strain	rate	(R	=	 +0.38,	 p	 =	 0.001),	 but	 had	 no	 association	with	 longitudinal	 strain	 (R	 =	 -0.004,	 p	 =	0.95),	longitudinal	strain	rate	(R	=	-0.04,	p	=	0.72)	or	circumferential	strain	(R	=	0.17,	p	=	0.27,	figure	2).	Circumferential	strain	rate	showed	a	weak	association	with	PPWV	(R	=	0.28,	p	=	0.04,	table	3).	Pulmonary	pulse	wave	velocity	was	associated	with	significant,	and	similarly	sized,	reductions	in	radial,	longitudinal	and	circumferential	PEDSR	(table	3).	All	significant	associations	persisted	after	adjustment	for	age,	BSA	and	gender	(table	4).	
9.4. Discussion	To	our	knowledge	this	is	the	largest	reported	population-based	study	characterising	the	relationship	between	PA	stiffness	and	RV	function	in	healthy	adults.	We	found	that	PA	stiffness	 increases	 with	 age	 and	 is	 independently	 associated	 with	 an	 increase	 in	 RV	mass	and	diastolic	stiffness.	These	findings	indicate	that,	in	common	with	the	systemic	circulation,	 prognostically	 adverse	 changes	 in	 the	 right	 ventricle	 are	 associated	 with	vascular	aging.	
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Systemic	arterial	stiffness	and	wave	reflection	phenomena	are	recognised	as	important	pathophysiological	mediators	of	the	powerful	contribution	that	arterial	blood	pressure	has	on	cardiovascular	risk	[660].	However,	much	less	is	understood	about	the	effect	of	vascular	 aging	on	RV	 function	and	 its	 impact	on	health	outcomes	 -	 in	part	due	 to	 the	technical	challenges	that	are	posed	in	measuring	these	parameters.	Our	data	show	that	PA	stiffness	increases	with	age,	consistent	with	experimental	evidence	that	pulmonary	vascular	elastic	properties	decline	over	time	with	an	 increase	 in	medial	 thickness	[92,	661-664].	Haemodynamic	studies	also	suggest	that	PA	stiffness	influences	RV	function	[357-360],	 and	 that	 an	 age-related	 increase	 in	 PA	 pressure	 occurs	 in	 the	 general	population	associated	with	all-cause	mortality	[551].		
An	 association	 between	 LV	 hypertrophy	 and	 arterial	 stiffness	 is	 well-documented	 in	both	 adults	 and	 adolescents	 independent	 of	 blood	 pressure	 and	 is	 a	well-established	risk	 factor	 for	cardiovascular	events	[665-667].	PA	stiffness	 is	also	widely	accepted	to	have	deleterious	effects	on	RV	performance	 in	patients	with	raised	afterload	[64].	We	observed	that	rising	PA	stiffness	was	associated	with	both	an	increase	in	RV	mass	and	a	decline	 in	 diastolic	 function	 amongst	 apparently	 healthy	 adults.	 It	 has	 recently	 been	recognised	 that	 RV	 hypertrophy	 (measured	 by	 CMR)	 in	 adults	 without	 clinical	cardiovascular	disease	at	baseline	is	associated	with	an	increased	risk	of	heart	failure	or	cardiovascular	death	even	accounting	for	variation	in	LV	mass	[18].	The	authors	of	this	study	 proposed	 several	 mechanisms	 to	 account	 for	 the	 excess	 risk	 including	interventricular	 dependence.	 Another	 potential	 contributory	 factor	 is	 increasing	 RV	afterload	and,	although	we	did	not	have	invasive	haemodynamic	data,	our	findings	are	supportive	of	a	vascular	mechanism	contributing	to	an	increase	in	RV	mass.	
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A	 tandem	 rise	 in	 vascular	 and	 ventricular	 stiffness	 occurs	with	 aging	 in	 the	 systemic	circulation	 [668]	and	our	data	 show	 that	an	equivalent	process	may	also	occur	 in	 the	pulmonary	 circulation.	Abnormal	 relaxation	of	 the	 left	 ventricle	 in	 response	 to	 raised	systemic	afterload	typically	causes	LV	hypertrophy	[669],	and	our	data	suggest	a	similar	stimulus-response	 relationship	 may	 exist	 in	 the	 right	 ventricle.	 An	 “aging	cardiomyopathy”	 affecting	 the	 right	 ventricle	 has	 been	 previously	 proposed	 due	 to	fibrotic	replacement	and	subsequent	myocardial	stiffening,	and	our	observations	using	strain	imaging	suggest	that	diastolic	dysfunction	may	be	a	consequence	of	this	process	[21,	670].		
9.4.1. Limitations	Our	 cross-sectional	 study	 cannot	 determine	 if	 increased	 PA	 stiffness	 preceded	 the	development	 of	 higher	 RV	mass	 or	 if	 these	 abnormalities	 in	 cardiovascular	 structure	and	function	developed	simultaneously.	There	may	also	have	been	other	non-measured	confounders	 (e.g.	 activity	 and	 cardiovascular	 fitness)	 which	 affected	 the	 cardio-pulmonary	unit.	Collecting	 invasive	pulmonary	haemodynamic	was	not	 feasible	 in	our	cohort	 and	 although	 pulmonary	 pressures	 can	 be	 estimated	 by	 Doppler,	 in	 low-risk	populations	 these	 are	 not	 measurable	 in	 over	 30%	 of	 subjects	 [551].	 The	 temporal	resolution	 of	 CMR	 is	 inferior	 to	 echocardiography	 and	 is	 likely	 to	 underestimate	 true	peak	velocities.	We	also	did	not	examine	the	effect	of	reflection	waves	in	the	PA	which	are	known	to	influence	ventriculo-arterial	coupling	and	RV	function	[671,	672].	It	is	also	unclear	 whether	 these	 findings	 represent	 a	 spectrum	 shared	 by	 conditions	 of	 high	afterload	 such	 as	 PH,	 or	 whether	 healthy	 subjects	 represent	 a	 separate	 phenotype.	However,	this	demonstrates	the	value	of	extending	high-resolution	phenotyping	beyond	the	 right	 ventricle.	 This	 may	 have	 benefits	 in	 understanding	 the	 determinants	 of	
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deterioration	 when	 RV	 dysfunction	 is	 present,	 and	 in	 risk	 stratification	 of	 diseased	patients.	
9.5. Conclusions	In	subjects	with	no	known	cardiovascular	disease,	PA	stiffness	increases	with	age	and	is	independently	associated	with	both	RV	mass	and	diastolic	dysfunction.	These	findings	suggest	 that	 prognostically	 adverse	 changes	 in	 RV	 function	 and	 morphology	 are	associated	 with	 an	 age-related	 increase	 in	 PA	 stiffness	 and	 that	 pulmonary	haemodynamics	 are	 a	 significant	 determinant	 of	 RV	 dysfunction	 in	 this	 group.	 These	findings	 support	 the	 view	 that	 interactions	 between	 the	 pulmonary	 vasculature	 and	right	ventricle	have	significant	structural	and	functional	consequences.	We	suggest	that	modelling	the	cardiopulmonary	unit	as	a	whole	may	be	beneficial	in	understanding	the	mechanisms	of	RV	dysfunction.	
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9.6. Figures	
	
Figure	9.1.	Pulse	wave	velocity	assessment	
Pulse wave velocity calculation method. Main diagram shows the normalised flow in the main (MPA) and right 
(RPA) pulmonary arteries in blue and red respectively. (a) shows the phase-contrast superimposed on the 
greyscale images from which flow was measured. (b) shows the orientation of the scanning planes. 	
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Strain	 Strain	rate	
	 	
Figure	9.2.	Pulmonary	pulse	wave	velocity	and	components	of	systolic	function	
Pulmonary pulse wave velocity and components of systolic strain and strain-rate were logarithm-transformed 
for a least-squares fit and back-transformed for display. Fitted values for radial (blue), longitudinal (green) and 
circumferential (red) function are shown. An increase in pulmonary pulse wave velocity is associated with 
significant increases in radial strain and strain rate but not longitudinal or circumferential strain or strain rate 
(tables 3,4).  
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Figure	9.3.	Pulmonary	pulse	wave	velocity	and	components	of	diastolic	function	
Pulmonary pulse wave velocity and components of peak early-diastolic strain rate were logarithm-transformed 
for a least-squares fit and back-transformed for display. Fitted values for radial (blue), longitudinal (green) and 
circumferential (red) function are shown. An increase in pulmonary pulse wave velocity is associated with 
significant reductions in all components of diastolic function (tables 3,4). 	
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9.7. Tables		 Females	(n=98)	 Male	(n=58)	
	 Median	 IQR	 Median	 IQR	
Age	(years)	 33	 28	–	48	 33	 28	–	39	
Body	Surface	Area	(m2)	 1.72	 1.64	–	1.81	 1.98	 1.88	–	2.08	
RVEDVi	 85	 73	–	95	 97	 88	–	107	
RVESVi	 40	 32	–	49	 50	 45	–	58	
RVMi	 13	 10	–	16	 13	 11	–	18	
RVEF	(%)	 60	 55	–	64	 49	 41	–	53	
Table	9.1.	Subject	characteristics	and	right	ventricular	volumetry	
CMR indicates Cardiovascular Magnetic Resonance; IQR, Inter-quartile range; RVEDVi / RVESVi, Indexed Right 
Ventricular End-Diastolic / End-Systolic Volume; RVEF, Right Ventricular Ejection Fraction. 
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	 Mean	difference	±	SD	 Coefficient	of	variation	 ICC	(95%	CI)	
	 	 	 	
RVEDVi	 4.2	±	5.0	 3.0%	 0.99	(0.98	–	1.00)	
RVESVi	 5.6	±	7.0		 9.7%	 0.96	(0.89	–	0.98)	
RVEF	 2.9	±	3.4	 6.1%	 0.75	(0.47	–	0.89)	
RVMi	 3.6	±	2.0	 3.9%	 0.94	(0.85	–	0.98)	
PWV	 0.20	±	0.16	 3.6%	 0.96	(0.85	–	0.98)	
GLS	 3.0	±	2.0	 17.2%	 0.85	(0.65	–	0.94)	
GLSR	 0.24	±	0.3		 22.1%	 0.83	(0.62	–	0.93)	
GCS	 2.0	±	2.7	 30.2%	 0.77	(0.51	–	0.90)	
GCSR	 0.1	±	0.2	 30.2%	 0.69	(0.36	–	0.86)	
GRS	 3.0	±	3.7	 16.9%	 0.91	(0.79	–	0.96)	
GRSR	 0.2	±	0.2	 22.7%	 0.79	(0.53	–	0.91)	
EDLSR	 0.2	±	0.2	 17.6%	 0.89	(0.75	–	0.96)	
EDCSR	 0.1	±	0.2	 28.3%	 0.85	(0.66	–	0.94)	
EDRSR	 0.2	±	0.2	 26.5%	 0.77	(0.51	–	0.90)	
Table	9.2.	Test-retest	characteristics	
RVEDVi/ESVi indicates Indexed Right Ventricular End-Diastolic Volume / End-Systolic Volume; RVEF, Right 
Ventricular Ejection Fraction; PWV, Pulmonary Pulse Wave Velocity; GLS/R, Global Longitudinal Strain/Strain 
Rate; GCS, Global Circumferential Strain/Strain Rate; GRS/R, Global Radial Strain/Strain Rate; EDLSR, Early 
Diastolic Longitudinal Strain Rate; EDCSR, Early Diastolic Circumferential Strain Rate; EDRSR, Early Diastolic 
Radial Strain Rate; SD, Standard deviation; ICC, Intraclass correlation coefficient; CI, Confidence Interval. 
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Measure	 Strain	 Strain	rate	
Systolic	Function	 	 	
Radial	 R	=	+0.36,	p	=	0.007	 R	=	+0.38,	p	<	0.001	
Circumferential	 R	=	+0.17,	p	=	0.27	 R	=	+0.28,	p	=	0.04	
Longitudinal	 R	=	-0.004,	p	=	0.95	 R	=	-0.04,	p	=	0.72	
Diastolic	Function	 	 	
Radial	 	 R	=	-0.45,	p	=	0.002	
Circumferential	 	 R	=	-0.45,	p	=	0.003	
Longitudinal	 	 R	=	-0.42,	p	=	0.01	
Table	9.3.	Change	in	RV	function	with	PPWV	
Univariate regression of PPWV against components of function. RV function indicates right ventricular function; 
PPWV, pulmonary pulse wave velocity. 	
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Measure	 Strain	 Strain	rate	
Systolic	Function	 	 	
Radial	 R	=	+0.36,	p	=	0.005	 R	=	+0.38,	p	<	0.001	
Circumferential	 R	=	-0.17,	p	=	0.27	 R	=	+0.28,	p	=	0.07	
Longitudinal	 R	=	-0.004,	p	=	0.95	 R	=	-0.04,	p	=	0.71	
Diastolic	Function	 	 	
Radial	 	 R	=	-0.45,	p	=	0.002	
Circumferential	 	 R	=	-0.45,	p	=	0.003	
Longitudinal	 	 R	=	-0.42,	p	=	0.008	
Table	9.4.	Change	in	RV	function	with	PPWV	after	correction	for	age,	gender	and	body	surface	area	
Univariate regression of PPWV against the components of RV function after correction for age, gender and body 
surface area. RV function, right ventricular function; PPWV = pulmonary pulse wave velocity. 	
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10. The	Effects	of	Titin	Truncating	Variants	on	the	Right	Ventricle	in	
Healthy	Subjects		
Given	 the	 right	 ventricle’s	 prognostic	 significance	 in	 disease	 and	 in	 health	 [1-19],	genetic	influences	of	structure	and	function	are	likely	to	be	clinically	important	for	both	patients	 and	 healthy	 subjects.	 Their	 identification	 may	 also	 allow	 molecular	mechanisms	of	RV	dysfunction	to	be	understood	with	the	potential	to	improve	outcome,	since	RV	dysfunction	appears	to	be	a	reversible	insult	[374,	653].	Despite	its	prognostic	importance,	 few	genetic	variants	affecting	 the	right	ventricle	have	been	 identified	and	no	RV-specific	therapies	exist	[1,	568].	In	PH	where	excess	afterload	ultimately	causes	RV	dysfunction	 treatment	has	variable	effects	on	RV	contractility	 [673,	674]	and	 little	prognostic	benefit	[675].		
It	is	suggested	that	RV	dysfunction,	in	common	with	other	cardiomyopathies,	may	have	a	genetic	basis.	20-50%	of	patients	with	dilated	cardiomyopathy	(DCM)	have	pathogenic	variants	[676],	with	more	than	twenty	genes	identified	as	causative	[4,10-17][676-683].	Truncating	 variants	 in	 TTN	 (TTNtv),	 which	 codes	 for	 the	 sarcomeric	 protein	 titin,	account	 for	approximately	a	quarter	of	 familial	and	severe	DCM	[248].	Approximately	80%	 of	 patients	 with	 hypertrophic	 cardiomyopathy	 (HCM)	 have	 variants	 in	 either	MYH7	 or	 MYBPC3	 [684,	 685],	 10-15%	 have	 variants	 in	 three	 other	 genes,	 TNNT2,	TNNI3	 and	 TPM1	 [684-686],	 and	 a	minority	 have	mitochondrial	 variants	 [686,	 687].	Familial	 patterns	 have	 been	 described	 in	 arrhythmogenic	 RV	 cardiomyopathy	(autosomal	dominant	and	recessive)	and	 in	 restrictive	cardiomyopathy,	 in	association	with	amyloidosis	and	sarcoidosis	[688],	though	despite	phenotypic	variability	there	is	a	notable	absence	of	rare	variants	associated	with	RV	dysfunction.	
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More	comprehensive	cardiac	phenotyping	has	already	proven	its	benefits	in	identifying	new	 pathogenic	 variants,	 improving	 the	 proportion	 of	 DCM	 known	 to	 have	 a	 genetic	basis	 from	 1-2%	 in	 the	 early	 1980s,	 to	 20-50%	 by	 the	 1990s	 [676].	 3D	 CMR	 has	continued	this	trend	in	phenotyping,	showing	new	insights	in	the	localisation	of	effects	and	 increasing	 statistical	 power	 [39].	 These	 are	 particularly	 relevant	 in	 cardiac	dysfunction	 where	 effects	 are	 variable	 and	 often	 asymmetric	 [689,	 690].	 This	 may	contribute	 to	 the	“genotype-positive,	phenotype-negative”	problem	[691,	692],	 though	incomplete	penetrance,	and	late-onset	disease	may	also	be	responsible.	
The	sarcomeric	protein	titin	is	a	single	giant	polypeptide	running	from	the	Z-disk	to	the	M-band	 of	 the	 sarcomere	 [693]	 and	 contributing	 to	 passive	 cardiomyocytic	 tension	[238,	 694-697].	 The	TTN	 gene	 is	 the	 sole	 gene	 encoding	 for	 titin	 and	 consists	 of	 368	exons.	Variants	 in	TTN	are	associated	with	a	higher	proportion	of	 familial	 and	severe	DCM	 than	 all	 other	 known	 DCM	 variants	 (25%	 vs	 20%)	 and	 are	 associated	 with	 a	reduction	in	RV	global	function	in	disease	cohorts	[176].	TTNtv’s	effect	in	other	groups	is	 unclear.	 Large	 cohort	 studies	 suggest	 that	 TTNtv	 occur	 in	 approximately	 2%	 of	healthy	subjects	and	the	titin	isoform	N2B	triggers	adaptive	ventricular	hypertrophy	in	response	to	pressure	overload	[239,	698].	Understanding	the	effect	of	TTNtv	in	the	right	ventricle	has	 implications	therefore	for	healthy	subjects	and	for	PH	patients.	Although	NGS’	 principal	 advantage	 is	 to	 provide	 high-throughput	 sequencing	 at	 comparatively	low-cost,	 it	also	provides	over	99.5%	sensitivity	to	variant	detection	with	read	depths	or	 20	 or	 more	 (378).	 Combining	 this	 approach	 with	 Sanger	 validation	 therefore	provides	a	reliable	genotyping	platform	for	understanding	the	effects	of	TTNtv.	
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We	hypothesize	that	the	use	of	high-resolution	phenotyping	coupled	with	NGS	and	WES	approaches	may	provide	more	sensitive	analysis	of	the	effects	of	TTN	on	RV	structure	and	 function.	This	approach	 is	contrasted	with	2D	volumetric	parameters	as	a	clinical	standard.	 These	 data	 are	 contrasted	 with	 phenotypic	 and	 genotypic	 data	 from	 DCM	patients.	
10.1. Methods	
10.1.1. Study	Population	As	part	of	a	 long-term	plan	to	sequence	the	full	cohort	 in	the	Digital	Heart	Project	the	first	928	healthy	volunteers	were	the	study	were	sequenced	and	included	in	this	study.	Inclusion	 and	 exclusion	 criteria	 and	 the	 recruitment	 process	 are	 described	 in	 Section	3.2.	 Images	 from	 one	 participant	 were	 not	 retrievable	 from	 the	 storage	 database	(MRIdb,	 Imperial	 College	 London,	 UK)	 [615]	 and	 this	 participant	 has	 therefore	 been	excluded	from	the	analysis.	
Genetic	data	are	also	included	which	describe	the	prevalence	and	distribution	of	TTNtv	variants	 in	 other	 cohorts,	 derived	 from	work	 undertaken	 by	 our	 group	 [176].	 These	cohorts	are	described	 in	more	detail	elsewhere	 [176],	but	briefly	originate	 from	3603	participants	 in	 the	Framingham	Heart	Study	(FHS)	 [699]	and	 the	 Jackson	Heart	Study	(JHS)	 [700],	 374	 prospectively-enrolled	 unselected	 ambulatory	 DCM	 patient,	 163	patients	 with	 familial	 DCM,	 155	 end-stage	 DCM	 patients	 with	 a	 LV	 assist	 device	 or	considered	for	transplantation	and	667	ethnicity-matched	population	controls	from	the	Women’s	Health	Initiative	(WHI)	[701].	
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10.1.2. Imaging	Protocol	Healthy	volunteers	underwent	CMR	on	a	1.5T	Philips	scanner	with	the	2D	b-SSFP	and	3D	b-SSFP	protocols	described	in	Section	3.2.2.		
10.1.3. Statistical	Analysis	Data	 were	 analysed	 in	 R	 using	 RStudio	 Server	 version	 0.98	 (Boston,	 MA)	 [638].	Categorical	 variables	 were	 expressed	 as	 percentages.	 Continuous	 variables	 were	expressed	as	mean	±	standard	deviation	(SD)	or	median	±	inter-quartile	range	(IQR)	for	non-normal	variables.	Baseline	anthropometric	data	were	compared	by	unpaired	t-tests	and	Mann-Whitney	U	tests	pending	normality	(continuous	variables)	and	Fisher’s	Exact	(nominal	variables).	TTNtv	was	coded	as	a	binary	variable	(0	or	1).	
The	exonal	distribution	of	TTNtv	was	considered	by	functional	groups:	Z-disk,	I-,	A-	and	M-bands.	 The	 frequency	 in	 each	 group	 was	 compared	 by	 odds	 ratios	 calculated	 by	Fisher’s	Exact	test.	The	number	of	variants	in	each	group	under	the	null	hypothesis	of	a	uniform	 distribution	 was	 predicted	 from	 domain	 annotations	 of	 the	 start	 and	 end	codons	 of	 each	 group.	 The	 effect	 of	 TTNtv	 status	 on	 RV	 volumetric	 measures	 was	estimated	by	linear	regression	after	centring	and	scaling	of	the	data,	controlling	for	age,	gender,	 race,	BSA	and	activity	 score.	Linear	 regression	with	HC	covariance	estimators	was	used	to	estimate	the	effect	size	and	significance	was	calculated	using	TFCE	and	low-rank	matrix	completion	with	FWER	correction	for	multiple	testing	by	using	the	maximal	permuted	 test	 statistic	 from	 each	 iteration,	 as	 described	 in	 Section	 5.6.	 p	 <	 0.05	was	considered	significant.	Principal	components	were	scaled	to	unity	and	centred	at	zero,	and	differences	expressed	as	percentages	for	comparison.	
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10.1.4. Manual	volumetry	2D	 b-SSFP	 cines	 were	 analysed	 using	 semi-automated	 valve-tracking	 volumetric	software	 (CMRtools,	 Cardiovascular	 Imaging	 Solutions,	 London,	 UK)	 with	 a	standardised	technique	described	in	Section	3.2.2.	Volumes	were	indexed	to	BSA.	
10.1.5. 3D	phenotyping	Semi-automated	 3D	 phenotyping	 of	 the	 right	 ventricle	 was	 undertaken	 using	 the	method	 described	 in	 Section	 0	 using	 Matlab	 (Mathworks,	 Natick,	 MA)	 on	 a	 high-performance	server	(Dell,	Round	Rock,	TX).	
3D	 phenotypes	 were	 analysed	 in	 two	 ways.	 Structural	 and	 functional	 changes	 may	manifest	as	localised	regional	changes	so	pointwise	analysis	using	linear	regression	was	undertaken	using	the	method	described	in	Section	2.5.3.	Global	variation	in	phenotype,	at	 low	 “spatial	 frequencies”,	 may	 also	 occur.	 Principal	 component	 analysis	 (PCA)	generates	 orthogonal	 modes	 of	 variation	 from	 data,	 allowing	 the	 variation	 within	 a	dataset	 to	 be	 described	most	 efficiently.	 Being	 orthogonal,	 principal	 components	 are	linearly	 uncorrelated	 with	 each	 other,	 and	 are	 therefore	 suitable	 as	 independent	variables	for	comparison	between	groups.	To	capture	the	more	global	changes,	PCA	was	used	 to	 summarise	 the	 position	 of	 the	 RV	 wall	 at	 end-diastole	 (“structural	 PCA”)	compared	 to	 a	mean	 shape	 RV,	 and	 the	 displacement	 of	 the	 RV	wall	 through	 systole	(“functional	PCA”).	Only	the	first	principal	component	was	retained	in	order	to	ensure	conservative	estimations.	Comparing	TTNtv	negative	and	positive	groups,	the	effects	of	gender,	 age,	 body	 surface	 area	 and	 activity	 score	 were	 controlled	 for	 in	 regression	analysis	after	centring	and	scaling	of	the	data.	
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10.1.6. Next-Generation	and	Whole	Exome	Sequencing	Genetic	data	were	analysed	by	two	platforms	due	to	an	expansion	of	the	project	during	recruiting.	
409	healthy	subjects	underwent	a	candidate	gene	approach,	with	a	panel	of	201	genes	associated	 with	 inherited	 cardiac	 conditions	 sequenced	 using	 custom	 hybridization	capture	 probes.	 TTN	was	 included	 in	 this	 panel.	With	 respect	 to	 TTN,	 using	Agilent’s	eArray	platform,	RNA	baits	were	designed	including	all	TTN	exons,	untranslated	regions	and	 a	 100	 base-pair	 overlap	 into	 neighbouring	 introns,	 as	 described	 in	 Ensembl	 v54	[702].	Sequencing	was	performed	on	 the	SOLiD	5500xl	 (Life	Technologies)	and,	using	the	 Lifescope	 v2.5.1	 “targeted.reseq.pe”	 pipeline	 reads	 were	 aligned	 to	 the	 human	reference	 genome	 (hg19)	 and	 the	 SOLiD	Accuracy	 Enhancement	 Tool	 (SAET)	 used	 to	improve	colour	call	accuracy	before	mapping.	Duplicate	reads	or	those	with	a	mapping	quality	 score	 of	 less	 than	 eight	 were	 removed.	 Variant	 calling	 was	 performed	 with	diBayes	 (SNPs)	 and	 small	 indels	modules,	 as	well	 as	 by	 GATK	 v1.5-2.7	 and	 SAMtools	v0.1.18	[703,	704].	All	positive	calls	were	Sanger	validated.	Measures	of	alignment	and	coverage	were	calculated	using	Picard	v1.40	(http://picard.sourceforge.net),	BEDTools	v2.12	 [705]	 and	 in-house	 scripts.	 Positive	 results	 as	 identified	 by	 GATK	 CallableLoci	Walker	had	a	minimum	depth	of	4,	base	quality	of	20	and	mapping	quality	of	10.	
519	 healthy	 subjects	 underwent	 WES	 on	 the	 Nextera	 Rapid	 Capture	 37MB	 Whole	Exome	kit,	and	sequenced	on	an	Illumina	HiSeq	2500.	Illumina	paired-end	reads	were	demultiplexed	with	HiSeq	Control	 software	with	quality	 check	using	FastQC	v.0.10.19.	The	 low-quality	 reads	 were	 trimmed	 using	 PrinSeq	 v0.20.4	 [706].	 The	 high-quality	reads	were	 aligned	 to	 the	 hg19	 reference	 using	BWA	v0.7.9	 [707].	Marking	 duplicate																																																									9	http//www.bioinformatics.babraham.ac.uk/projects/fastqc/	
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reads,	 local	 realignment	 around	 known	 indels	 and	 base	 quality	 score	 recalibration	processes	 were	 undertaken	 in	 Picard	 v1.11510	 and	 GATK	 v3.1-1.	 Picard,	 Samtools	v0.1.18,	Bedtools	v2.11.2	and	the	Royal	Brompton	genetic	and	genomics	 laboratory	 in	house	Perl	scripts	were	used	to	calculate	alignment	summary	measures,	callability	and	a	 coverage	 report.	 A	 subset	 file	was	 created,	 based	 on	 the	 reads	which	mapped	with	quality	 of	 eight	 or	 more,	 and	 used	 to	 make	 consistent	 variant	 calls	 in	 GATK	HaplotypeCaller.	 Callable	 bases	were	 those	with	mapping	 quality	 of	 ten	 or	more	 and	base	quality	of	twenty	or	more.	Variants	were	functionally	annotated	using	the	Ensembl	VEP	v75_37	and	HGMB	Professional	version	2014.1	[708]	which	predicts	the	functional	effects	of	a	protein	variant.	TTNtv	were	confirmed	by	Sanger	validation.	Results	were	reported	 using	 the	 standardised	 approach	 of	 the	 Locus	 Reference	 Genomic	 (LRG)	sequence	 for	 TTN	 which	 was	 developed	 in	 collaboration	 with	 the	 European	Bioinformatics	Institute	[709].		
10.2. Results	Twenty-nine	subjects	had	TTNtv	identified	of	which	eighteen	were	validated	on	Sanger	sequencing	(Figure	10.2).	
TTNtv	were	not	uniformly	distributed	by	protein	domains	 (Table	10.1).	 In	our	group,	1/18	was	localised	to	the	Z-disk,	13/18	to	the	I-band	and	4/18	to	the	A-band.	Compared	to	 a	 uniform	 distribution	 across	 the	meta-transcript,	 there	was	 a	 significantly	 higher	proportion	in	the	I-band	(OR	=	4.3,	95%	CIs:	1.45	–	15.55,	p	=	0.005)	and	sparing	of	the	A-band	(OR	=	0.29,	95%	CIs:	0.07	–	0.92,	p	=	0.03).	Figure	10.2	and	Table	 10.2	 show	the	
																																																								10	http://picard.sourceforge.net	 	 	 	
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positions	of	 the	 truncating	variants	 in	our	 group	more	precisely,	 and	 in	 the	DCM	and	longitudinal	populations	in	relation	to	the	sarcomeric	regions	(Figure	10.2,	colours).		
Domain	 Z-disk	 I-band	 A-band	 M-band	
Meta-transcript	 protein	 start	position	 1	 2170	 15656	 33589	
Meta-transcript	 protein	 end	position	 2170	 15656	 33589	 35991	
Number	of	𝛼𝛼	 2169	 13486	 17933	 2402	
Expected	number	of	TTNtv	 1.1	 6.7	 9.0	 1.2	
Observed	number	of	TTNtv	 1	 13	 4	 0	
Odds	Ratio	 0.92	 4.34	 0.29	 0	
95%	CI	(lower)	 0.02	 1.45	 0.07	 0	
95%	CI	(upper)	 5.86	 15.55	 0.92	 3.18	
p-value	 0.97	 0.005	 0.03	 0.63	
Table	10.1.	TTNtv	in	healthy	subjects	categorised	by	domain	
TTNtv positions in the meta-transcript by domain, and compared to a uniform distribution across the protein. 
Healthy subjects showed significant I-band localisation and A-band sparing compared to a uniform distribution. 
Band borders taken from Roberts et al. [176].  	
	298		
Compared	to	historical	data	 from	symptomatic	DCM	patients	 [176],	A-band	sparing	 in	healthy	 subjects	 was	 even	 more	 pronounced	 (4/18	 healthy	 subjects	 vs	 61/87	 case	variants,	OR	=	0.13	(0.03-0.40,	p	=	2x10-4).	
To	 assess	 whether	 TTNtv	 occurred	 at	 different	 positions	 in	 the	 titin	 gene	 in	 healthy	subjects	 compared	 to	 controls,	we	 compared	 exon	 numbers	 by	 clinical	 group	 (Figure	10.1).	 A	 significant	 association	 existed	 by	 clinical	 group,	 (two-way	 ANOVA,	 both	 p	 <	0.001).	
(a)	 (b)	
	 	
Figure	10.1.	The	role	of	exon	use	and	location	in	pathogenicity	
(a) Boxplot of the use of TTN exons containing TTNtv by clinical group. Exon use is expressed as the proportion 
of transcripts that contain each exon, the “proportion spliced-in” (PSI). TTNtv in healthy subjects had 
significantly lower PSI than in either the population or the disease cohorts (p < 0.001). (b) Boxplot of the TTNtv 
exon numbers by clinical group, which differed significantly by group, controlling for PSI (p = 0.03). Collectively, 
these findings suggest that disease status has independent and significant associations with PSI and exon 
position. Significance calculated by permutation testing. 	
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The	 anthropometrics	 and	 volumetrics	 for	 the	 groups	with,	 and	without,	 a	 TTNtv	 are	summarised	in	Table	10.3.	
	 300	
	
	
	
Figure	10.2.	Schematic	diagram	of	the	TTN	meta-transcript	
Diagram showing a schematic representation of TTN with Z-disk, I-, A- and M- band regions as marked. The two major cardiac isoforms (N2BA and N2B) and one 
minor short cardiac isoform (Novex-3) are marked with exon use below the meta-transcript. Exon use in DCM patients is marked as the proportion spliced in (PSI) 
(range: 0-1) and describes the proportion of transcripts which are included in a given exon. For distribution, TTNtv are more proximal (A-band depletion) in the 
population cohort and healthy volunteers (Digital Heart Project) and more distal (A-band enrichment) in DCM patients. 
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	 hg19	 LRG	 	 	 	 	 N2BA	 N2B	 Novex-3	 	
14AG01422	 179647533	 52997	 c.3100G>A	 p.Val1034Met	 18	 1.00	 Y	 Y	 Y	 Splice	variant	prediction	
14AH01539	 179549632	 150898	 c.32554+1G>C	 	 131	 0.17	 Y	 	 	 Splice	donor	variant	
14AJ02284	 179523083	 177447	 c.37628-1G>A	 	 186	 0.11	 	 	 	 Splice	acceptor	variant	
14AO01372	 179620947	 79583	 c.11254+2T>C	 	 46	 0.07	 	 	 	 Splice	donor	variant	
14CB02200	 179506963	 193567	 c.40558+1G>A	 	 220	 1.00	 Y	 Y	 	 Splice	donor	variant	
14EC01433	 179560998	 139532	 c.30803-2A>G	 	 115	 0.84	 Y	 	 	 Splice	acceptor	variant	
14HB02599	 179495671	 204859	 c.44015-1G>T	 	 239	 1.00	 Y	 Y	 	 Splice	donor	variant	
14JC01930	 179404286	 296244	 c.98506C>T	 p.Arg32836X	 353	 1.00	 Y	 Y	 	 Nonsense	
14JD01896	 179588844	 111686	 c.21142C>T	 p.Arg7048X	 74	 0.36	 Y	 	 	 Nonsense	
14JM01448	 179444855	 255675	 c.67159delA	 p.Ile22387X	 319	 1.00	 Y	 Y	 	 Nonsense	
14KN01429	 179553775	 146755	 c.32095+5G>A	 	 126	 0.22	 Y	 	 	 Splice	variant	prediction	
14MO01427	 179486054	 214476	 c.45391delA	 p.Ile15131TyrfsX46	 247	 1.00	 Y	 Y	 	 Frameshift	
14RH01353	 179620947	 79583	 c.11254+2T>C	 	 46	 0.07	 	 	 	 Splice	donor	variant	
14RM02225	 179529171	 171359	 c.36267_36280+16del	TGTACCTGTCAAAGGTACATTCTTAACTGT	 	 169	 0.02	 	 	 	 Splice	donor	variant	/	Frameshift	
14RS02105	 179444855	 255675	 c.48703C>T	 p.Gln16235X	 261	 1.00	 Y	 Y	 	 Nonsense	
14SM01546	 179444666	 255864	 c.67348C>T	 p.Gln22450X	 319	 1.00	 Y	 Y	 	 Nonsense	
14SS01830	 179621351	 79179	 c.10852C>T	 p.Gln3618X	 46	 0.07	 	 	 	 Nonsense	
14ZN01340	 179595884	 104646	 c.17508dupA	 p.Gly5837ArgfsX9	 61	 0.41	 Y	 	 	 Frameshift	
Table	10.2.	TTNtv	within	a	cohort	of	928	healthy	volunteers.	
HG19	indicates	human	genome;	LRG,	Locus	Reference	Genomic	sequence	for	TTN;	PSI,	proportion	spliced	in.	14JD01896	subsequently	excluded	due	to	loss	of	images.		
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	 TTNtv	Negative	(n=910)	 TTNtv	Positive	(n=17)	 p-value	
Age	(years)	 42.3	±	13.2	(20	–	81)	 43.0	±	13.7	(24	–	72)	 0.86	
Gender	
			Males	(%)	
			Females	(%)	
	
417	
491	
	
6	
11	
	
0.53*	
Race	
			Caucasian	
			South	Asian	
			African	
			Other	
	
698	
109	
55	
48	
	
13	
1	
2	
1	
	
0.70*	
Height	(cm)	 170	±	9	(142	–	194)	 166	±	7	(157	–	180)	 0.07	
Weight	(kg)	 72	±	13	(41	–	130)	 69	±	17	(47-116)	 0.28	
Body	surface	area	(m2)	 1.83	±	0.20	(1.34	–	2.57)	 1.77	±	0.22	(1.44	–	2.32)	 0.21	
RVEDV	(ml)	 165	±	39	(78	–	312)	 156	±	26	(103	–	229)	 0.46	
RVESV	(ml)	 71	±	24	(16-169)	 67	±	18	(38	–	121)	 0.58	
RVSV	(ml)	 95	±	20	(44	–	175)	 90	±	13	(65	–	108)	 0.41	
RVEF	(%)	 58	±	6	(40-80)	 58	±	6	(46	–	68)	 0.83	
RVEDVI	(ml/m2)	 90	±	16	(51	–	145)	 89	±	15	(61	–	122)	 0.83	
RVESVI	(ml/m2)	 39	±	11	(10	–	78)	 38	±	11	(23	–	64)	 0.81	
RVSVI	(ml/m2)	 51	±	8	(29	–	101)	 51	±	6	(39	–	60)	 0.84	
CO	(L/min)	 6.1	±	1.44	(3.3	–	16.1)	 6.2	±	1.5	(3.2	–	8.7)	 0.46	
CI	(L/min/m2)	 3.3	±	0.7	(1.7	–	8.1)	 3.5	±	0.6	(2.3	–	4.7)	 0.18	
HR	(bpm)	 65	±	11	(40	–	110)	 68	±	11	(45	–	85)	 0.10	
Table	10.3.	Anthropometric	and	RV	volumetric	data	by	TTNtv	status	
TTNtv positive and negative groups showed no significant differences in anthropometric or RV volumetric data. All significance testing used the Mann-Whitney U 
test apart from * which were compared by proportions testing. BPM indicates beats per minute; CI, cardiac index; CO cardiac output; HR, heart rate; RVEDV 
indicates right ventricular end-diastolic volume; RVESV, right ventricular end-systolic volume; RVSV, right ventricular stroke volume; RVEF, right ventricular 
ejection fraction; I, indexed by body surface area  
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	 	 Ratiometrically	indexed	to	BSA	 Allometrically	indexed		 	 Standardised	β	 p	 Standardised	β 	 p	
RVEDVI	 	 	 	 		 Gender*	 0.21	 <0.001	 -0.60	 <0.001		 Age	 -0.17	 <0.001	 -0.21	 <0.001		 Activity	score	 0.16	 <0.001	 0.18	 <0.001		 Race:	Caucasian	 0.02	 0.26	 0.17	 <0.001		 Race:	Asian	 -0.03	 0.003	 -0.07	 0.06		 Race:	African	 <-0.01	 0.83	 0.08	 0.01		 TTNtv	 <-0.01	 0.99	 -0.02	 0.30		 Model	adjusted	R2	 0.37	 	 0.52	 	
RVESVI	 	 	 	 	 		 Gender*	 0.33	 <0.001	 0.56	 <0.001		 Age	 -0.26	 <0.001	 -0.23	 <0.001		 Activity	score	 0.20	 <0.001	 0.17	 <0.001		 Race:	Caucasian	 0.02	 0.51	 0.13	 0.005		 Race:	Asian	 -0.02	 0.17	 -0.03	 0.43		 Race:	African	 0.01	 0.30	 0.10	 0.003		 TTNtv	 <0.01	 0.78	 -0.01	 0.55		 Model	adjusted	R2	 0.32	 	 0.45	 	
RVSVI	 	 	 	 	 		 Gender*	 0.11	 <0.001	 0.52	 <0.001		 Age	 -0.10	 <0.001	 -0.14	 <0.001		 Activity	score	 0.13	 <0.001	 0.16	 <0.001		 Race:	Caucasian	 0.02	 0.25	 0.19	 <0.001		 Race:	Asian	 -0.03	 <0.001	 -0.11	 0.01		 Race:	African	 -0.01	 0.09	 0.04	 0.25		 TTNtv	 <-0.01	 0.78	 -0.03	 0.27		 Model	adjusted	R2	 0.23	 	 0.41	 	
RVEF	 	 	 	 	 		 Gender*	 -0.10	 <0.001	 	 		 Age	 0.07	 <0.001	 	 		 Activity	score	 -0.03	 0.003	 	 		 Race:	Caucasian	 <0.01	 0.87	 	 		 Race:	Asian	 <-0.01	 0.43	 	 		 Race:	African	 -0.01	 0.03	 	 		 TTNtv	 <-0.01	 0.74	 	 		 Model	adjusted	R2	 0.15	 	 	 	
Cardiac	Index	 	 	 		 Gender*	 0.06	 0.001	 0.42	 <0.001		 Age	 -0.14	 <0.001	 -0.18	 <0.001		 Activity	score	 -0.05	 0.01	 -0.09	 0.004		 Race:	Caucasian	 0.03	 0.30	 0.17	 0.002		 Race:	Asian	 -0.03	 0.007	 -0.11	 0.002		 Race:	African	 -0.01	 0.12	 0.02	 0.63		 TTNtv	 0.01	 0.26	 0.01	 0.64		 Model	adjusted	R2	 0.08	 	 0.24	 	
	 Table	10.4.	Linear	regression	models	showing	the	effect	of	TTNtv	on	RV	volumetrics.	*Genders are coded such that positive regression coefficients correspond to greater values in males. Data were scaled 
and centred before analysis. Blue columns show data scaled ratiometrically to body surface area; red columns show data 
scaled allometrically with scaling calculated for each parameter separately.
 BSA, body surface area; RVEDV/EF/ESV, right 
ventricular end-diastolic volume / ejection fraction / end-systolic volume. 
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10.2.1. 3D	phenotyping	Voxelwise	 analysis	 showed	 a	 diffuse	 reduction	 in	 ventricular	 volume	 though	 these	differences	 only	 reached	 significance	 using	 FDR	 multiple-testing	 correction,	 and	 this	was	borderline	(p	=	0.05).	Difference	in	structure	was	most	pronounced	at	the	apex	and	the	 base.	 Structural	 PCA	 suggested	 that	 TTNtv	 positive	 status	 was	 associated	 with	 a	significant	reduction	in	ventricular	size	(R	=	-0.05,	p	=	0.03).	
Ventricular	function	was	diffusely	reduced,	though	this	did	not	reach	significance	after	correction	 for	 multiple	 testing.	 Functional	 PCA	 suggested	 there	 was	 no	 difference	 in	global	ventricular	function	between	TTNtv	positive	and	negative	subjects	(R	=	-0.06,	p	=	0.80).		
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Figure	10.3.	The	Effect	of	a	Titin	Truncating	Variant	on	3D	Shape	
3D model of right (colour) and left (mesh) ventricles as analysed by linear regression. The upper panel shows the 
standardised regression coefficients across the right ventricle for the association of TTNtv with pointwise shape, 
while controlling for gender, age, body surface area and activity score. Blue indicates a localised reduction in 
ventricular size with a TTNtv. The lower panel shows the significance values across the right ventricle. Lateral 
and septal views are shown in the upper and lower rows, respectively. Each column uses a different method of 
multiple-testing correction. (a) Shows the results with no correction for multiple-testing. In (b) and (c) multiple 
testing is corrected by the Bonferroni and false-discovery rate (FDR) methods respectively. In (d) significance is 
calculated by permutation testing, after threshold-free cluster enhancement (TFCE). (a) Demonstrates large 
areas of significant change, though these are not confirmed in (b) and (d). (c) shows a similar pattern to (a) but 
did not reach significance.  
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Figure	10.4.	The	Effect	of	a	Titin	Truncating	Variant	on	3D	Function	
3D model of right (colour) and left (mesh) ventricles. The upper panel shows the standardised regression 
coefficients across the right ventricle for the association of TTNtv with pointwise function, while controlling for 
gender, age, body surface area and activity score. Blue indicates a localised reduction in ventricular function 
associated with TTNtv. The lower panel shows the significance values across the right ventricle. Lateral and 
septal views are shown in the upper and lower rows, respectively. Each column uses a different method of 
multiple-testing correction. (a) Shows the results with no correction for multiple-testing. In (b) and (c) multiple 
testing is corrected by the Bonferroni and false-discovery rate (FDR) methods respectively. In (d) significance is 
calculated by permutation testing, after threshold-free cluster enhancement (TFCE). (a) Demonstrates a 
reduction in function in the basal freewall and basal septum, though these are not confirmed in (b-d). 	
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10.3. Discussion	This	work	demonstrates	the	prevalence	of	TTNtv	in	a	self-declared	healthy	population	at	1.9%	(18/927)	which	is	similar	to	that	found	in	other	healthy	cohorts	[176,	248,	710,	711].	Our	data	show	an	increased	frequency	of	TTNtv	in	the	I-band	which	has	a	low	PSI,	and	a	significant	sparing	of	 the	A-band,	 in	agreement	with	published	findings	 in	other	healthy	groups	[176].	The	sparing	of	the	A-band	was	further	exaggerated	in	comparison	to	a	symptomatic	DCM	clinical	group.	The	low	PSI	may	provide	a	mechanism	by	which	these	patients	do	not	develop	the	DCM	phenotype,	though	the	PSI	data	are	derived	from	a	DCM	cohort,	in	which	exon	use	may	differ	from	healthy	subjects.	
There	were	no	significant	differences	in	anthropometric,	haemodynamic	and	volumetric	data	 between	 those	with,	 and	without,	 a	 TTNtv	 either	 as	 a	 group	 (Table	 10.3),	 or	when	gender,	age,	race	and	activity	score	were	adjusted	for	(Table	10.4).	
3D	 imaging	 showed	 differences	 between	 the	 groups	 which	 bordered	 statistical	significance.	 Voxelwise	 dilatation	 analysis	 and	 PCA	 suggested	 that	 TTNtv	 positive	patients	 had	 diffusely	 smaller	 RV	 size	 in	 end-diastole	 with	 similar	 function.	 This	difference	was	similar	from	apex	to	base,	though	it	is	unclear	whether	all	components	of	function	 were	 affected	 evenly	 since	 our	 measure	 tracked	 displacement	 as	 a	 scalar	quantity	irrespective	of	the	direction	of	motion.	Although	the	magnitude	of	the	change	in	structure	was	large	(indicated	by	the	coefficient	size),	results	only	reached	statistical	significance	 using	 the	 FDR	 correction	 and	 neither	 Bonferroni	 or	 TFCE/permutation	testing	confirmed	this	association.	FWER	methods	are	conservative,	reducing	statistical	power	 and	 given	 the	 small	 number	 of	 TTNtv	 positive	 subjects	 this	 is	 a	 significant	problem	 here.	 FDR	 is	 commonly	 used	 in	 high-dimensional	 datasets	 such	 as	 these,	tolerating	 a	 prescribed	 proportion	 of	 “false-discoveries”,	 but	 for	 this	 reason	 we	 are	
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cautious	in	the	interpretation	of	the	borderline	significance	values	demonstrated	here.	Combining	a	technique	which	rewards	contiguity	(such	as	TFCE)	with	the	benefits	of	a	pragmatic	multiple-testing	method	is	a	need	which	has	led	to	strategies	combining	both	approaches	[582].	This	may	represent	an	improved	approach.	
Titin	 is	 a	 single	 giant	 protein	which	 stretching	 from	 the	 Z-disk	 to	 the	M-band	 of	 the	sarcomere	 [693].	 The	 region	 spanning	 the	 I-band	 consists	 of	 PEVK11,	 tandem	 Ig	 and	N2B-unique	 segments	 (N2B-Us),	 each	 functioning	 as	 a	 spring	 [712]	 with	 distinct	rigidities	which	change	through	development	[713,	714]	and	disease	[236,	715-717].	As	the	 sarcomere	 stretches,	 links	 between	 these	 domains	 straighten	 and	 define	 the	force/extension	relationship	of	the	sarcomere.	Differential	splicing	in	the	I-band	creates	isoforms	with	different	spring	compositions	[718],	tensions	[719]	and	passive	stiffness	[238,	720]	and	feedback	may	also	occur,	with	mechanical	and	metabolic	challenges	up-regulating	protein	expression	and	gene	expression	 [67,	68].	The	composition	of	 the	 I-band	 region	 is	 therefore	 strongly	 linked	 to	 sarcomeric	 stiffness	which	may	 affect	 the	force/extension	 relationship	 even	 in	 healthy	 subjects.	 Given	 the	 common	 structural	elements,	TTNtv	are	likely	to	have	biventricular	effects	as	have	been	demonstrated	by	volumetry	in	disease	cohorts	[176].	
Our	work	 suggests	 that	 the	global	 systolic	dysfunction	associated	with	TTNtv	 in	DCM	patients	 is	 not	 found	 in	 healthy	 subjects.	Our	method	 replicates	 the	high	 correlations	seen	 by	 point	 displacement	measures,	 such	 as	 TAPSE	 [642,	 721]	 and	 septal-freewall	displacement	 [26],	 with	 global	 systolic	 function	 by	 extending	 the	 concept	 to	 a	 high-resolution	whole-ventricle	assessment	of	displacement.	We	have	validated	this	against	global	function	(Chapter	4)	and	shown	how	this	model	includes	better	point	surrogates																																																									11	So	called	because	it	is	rich	in	proline	(P),	glutamate	(E),	valine	(V)	and	lysine	(K).	
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of	function	(Chapter	6)	suggesting	that	it	is	an	accurate	and	comprehensive	measure	of	RV	systolic	function.	Nonetheless,	the	effects	on	TTNtv	on	global	RV	function	in	disease	cohorts	 do	 not	 appear	 to	 extend	 to	 healthy	 subjects	 [176].	 Several	 reasons	 may	contribute	 to	 this	disparity.	Our	cohort	showed	a	different	distribution	of	TTNtv,	with	significantly	 lower	 PSI	 suggesting	 that	 both	 the	 position	 and	 usage	 of	 TTNtv	 are	significant	 determinants	 of	 the	 RV	 systolic	 phenotype.	 TTNtv	 in	 our	 cohort	predominantly	 affected	 the	 I-band	 region,	 known	 to	 regulate	 sarcomeric	 stiffness,	suggesting	that	markers	of	diastolic	function	may	be	a	more	appropriate	marker	for	this	type	 of	 TTNtv.	 We	 also	 note	 that	 our	 cohort	 were	 younger	 than	 Roberts’	 [176]	(mean/SD	 age:	 42	 ±	 13	 vs	 52	 ±	 14)	 though	 longitudinal	 follow-up	 is	 necessary	 to	understand	whether	this	difference	is	clinically	significant.	
Our	work	has	significant	limitations.	Titin	is	a	rare	variant	which	occurs	in	1-2%	of	the	population	 making	 acquiring	 significant	 numbers	 of	 TTNtv	 cases	 in	 healthy	 subjects	difficult	 and	 risking	 under-powering.	 Although	 data	 pooling	 has	 successfully	 been	applied	 to	TTNtv	 to	 improve	 inferences	 [176],	phenotyping	varies	and	often	does	not	include	CMR.	Titin	is	a	large	protein	with	diverse	functional	domains	and	similar	effects	for	all	variants	are	unlikely	[722].	We	note	that	our	cohort	 included	five	subjects	with	PSI	≤0.11	which	may	confound	the	perceived	effects	of	TTNtv	on	the	phenotype,	though	provides	valuable	data	on	the	nature	of	TTNtv	in	healthy	subjects.	Our	cohort	relied	on	self-reporting	 of	 health	which	 is	 subjective	 and	 healthy	 cohorts	may	 include	 patients	with	mild	disease.		
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10.4. Conclusions	TTNtv	in	a	UK	cohort	show	similar	prevalence	to	other	cohorts,	and	have	characteristic	locations	and	use	patterns	compared	to	disease	groups.	TTNtv	is	associated	with	diffuse	changes	 in	 RV	 structure	 but	 not	 systolic	 function	 in	 healthy	 volunteers,	 which	 are	captured	 by	 3D	 techniques	 more	 clearly	 than	 volumetric	 measures.	 It	 is	 unclear	whether	 voxelwise	 or	 global	 approaches	 to	 3D	 data	 analysis	 are	 preferable	 but	 the	decision	may	depend	on	the	nature	of	the	signal	for	detection.	Further	work	assessing	diastolic	function	and	in	the	pressure-overloaded	right	ventricle	is	justified.		
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11. The	Effects	of	Common	Genetic	Variants	on	the	Right	Ventricle	in	
Healthy	Subjects	
	
Preliminary	Work	
	Knowledge	of	 the	genetic	determinants	of	RV	structure	and	function	centres	around	a	small	number	of	comparatively	rare	acquired	conditions	[176,	237,	723]	and	congenital	structural	 abnormalities,	 both	 chromosomal	 [724-727]	 and	 non-chromosomal	 [728-733].	Despite	 evidence	 from	healthy	 subjects	 [17,	 18]	 and	 several	 diseases	 [1-16,	 99]	that	both	RV	structure	and	function	have	significant	prognostic	value,	 there	remains	a	considerable	 gap	 in	 our	 understanding	 in	 this	 area.	 Some	 genetic	 variants	 have	biventricular	 effects	 [176]	 and	 mechanisms	 may	 be	 extrapolated	 from	 left	 to	 right	ventricle	 [25],	 but	 there	 are	 also	 clear	 differences	 in	 the	 development	 and	 genetic	biology	of	the	ventricles.	Interventions	which	are	beneficial	for	the	left	ventricle	may	be	beneficial	 for	 the	 right	 [734,	 735]	 but	 not	 always	 [736,	 737].	 New	 experimental	approaches	may	 provide	 new	 insights	 into	 this	 problem,	 and	 genomics	 provides	 one	such	approach.	
GWA	studies	offer	an	unrivalled	opportunity	to	detect	novel	molecular	pathways	by	the	association	of	DNA	or	RNA	data	with	phenotype	in	an	unbiased,	comprehensive	manner	[738].	 This	 approach	 has	 had	 considerable	 success	 in	 cardiovascular	 medicine	 [204-206,	 739-743]	 though	 the	 role	 of	 common	 variants	 in	 determining	 RV	 structure	 and	function	has	not	been	examined	to	date.		
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A	 criticism	of	GWA	studies	has	been	non-replication	of	 findings	 [256-258],	which	has	stimulated	the	development	of	several	areas.		
Since	 the	 success	 of	 the	 human	 genome	project	 in	 identifying	new	 loci	 and	pathways	associated	with	disease,	many	workers	have	called	for	the	development	of	 large-scale,	high-dimensional	phenotyping	–	“phenomics”	–	as	a	route	to	advances	in	biology	[744-748].	Large-scale	GWA	studies	 in	cardiovascular	medicine	have	undoubtedly	added	to	our	understanding	of	heritability,	but	many	complex	traits	still	have	a	significant	deficit	in	the	heritability	explained	by	known	variants	[749-751],	in	part	because	variants	are	rare	 or	 their	 effects	 are	 small	 [752].	 Providing	 high-resolution,	 comprehensive	phenotyping	approaches	may	therefore	be	a	more	productive	approach	[746,	747,	753,	754].	 Imaging	 is	 key	 as	 it	 provides	 data	 from	 a	 range	 of	 scales,	 from	 sub-cellular	processes	 to	 whole-organism	 [755]	 and	 from	 anatomical,	 functional	 and	 metabolic	origin.	
A	 second	 fast-developing	 area	 is	 data	 analysis.	 Traditional	 analysis	 methods	 relate	 a	small	 (less	 than	 ten)	 number	 of	 covariates	 to	 a	 single	 dependent	 variable,	 often	 by	regression.	As	discussed	in	section	2.5,	detailed	phenomics	vastly	increases	the	number	of	 parallel	 tests	 promoting	 over-fitting,	multiple	 testing	 and	 dependency	 effects	 all	 of	which	 increase	 the	 risk	 of	 non-validation	 in	 new	 samples.	 Dimensionality	 reduction	[473,	 479-481]	 and	 regularisation	 [395,	 756-760]	 are	 effective,	 easily	 applied	 and	popular	methods	of	reducing	the	feature	load,	but	do	so	on	the	basis	of	statistical	rather	than	biological	information.	Features	may	therefore	be	difficult	to	interpret	biologically,	especially	when	 unvalidated	 [479].	 Supervised	 and	 Bayesian	 approaches	 have	 shown	promise	 in	 feature	 reduction	 while	 retaining	 biological	 relevance	 [488,	 489,	 761].	Frequentist	 statistical	 approaches	 have	 also	 presented	 problems	 in	 multiple	 testing	
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handling	 either	 due	 to	 loss	 of	 power	 or	 false-positive	 acceptance,	 which	 are	 both	undesirable	[259].	Bayesian	approaches	make	use	of	prior	 information	[260,	261]	and	the	probabilistic	estimation	of	expression	residuals	(PEER)	is	one	such	approach	which	has	provided	increased	power	and	interpretability	of	phenotypic	data	[207,	208].	PEER	is	 an	 iterative	 Bayesian	 approach	 to	 understanding	 associations	 between	 sources	 of	variation	in	high-dimensional	phenotypes.	It	aims	to	model	not	only	known	sources	of	variation	 (e.g.	 environmental,	 physiological	 genetic)	 but	 also	 unknown,	 “hidden”	sources	which	may	have	a	strong	effect	on	phenotypic	effects	[762-765].	Failure	to	do	so	may	obscure	the	associations	of	interest	and	has	led	to	several	approaches	including	PEER	 [764,	766].	The	PEER	 framework	accommodates	a	variety	of	 study	designs,	but	can	be	schematically	represented	as	in	Figure	11.1.	
	
	
Figure	11.1.	The	Probabilistic	Estimation	of	Expression	Residuals	(PEER)	method	
PEER is one of a small number of Bayesian probabilistic approaches which aim to estimate the error attributable 
to “hidden factors” as well as accounting for the effects of known factors and the genotype. This has led to 
increased detection of the effects of genetic variation on gene expression, which can equally be applied to the 
detection of genetic effects on phenotype data. “Epistasis” refers to the phenomenon by which the effects of 
one gene depend on the presence of one or more modifier genes. Figure adapted from Stegle et al. [207] 
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In	 this	preliminary	work	we	examined	 the	effect	of	 common	variants	on	RV	structure	and	 function.	 As	 part	 of	 this	 process	 we	 aim	 to	 demonstrate	 the	 additional	 benefit	provided	 by	 3D	 imaging	 over	 traditional	 volumetric	 approaches	 and	 the	 additional	benefit	of	PEER	over	a	standard	frequentist	approach.		
11.1. Methods	1346	 subjects	 were	 taken	 from	 the	 Digital	 Heart	 Study	 in	 whom	 genotyping	 and	phenotype	 data	 were	 available.	 Study	 inclusion/exclusion	 criteria,	 2D	 and	 3D	phenotyping	and	volumetric	and	segmentation	were	as	previously	described.	
11.1.1. Genotyping	of	common	variants	Common	 variants	 were	 genotyped	 on	 the	 Illumina	 HumanOmniExpress-12	 v1.1	 SNP	array	 (Sanger	 Institute,	 Cambridge)	 read	 and	 quality	 controlled	 (Figure	 11.2).	 SNPs	were	called	by	 the	GenCall	 [767]	automated	software	application	which	automatically	clusters,	calls	and	assigns	confidence	scores	to	colour	probe	intensities.	In	this	process	each	SNP	is	considered	 in	turn	 for	all	subjects	and	the	aim	is	 to	convert	raw	intensity	data	into	genotype	calls	at	each	SNP.	This	works	on	the	premise	that	two	possible	alleles	at	each	SNP	(A	and	a)	can	form	three	possible	genotypes	(AA,	Aa	and	aa)	resulting	in	up	to	 three	 different	 clusters.	 An	 individual’s	 genotype	 at	 that	 SNP	 can	 then	 be	 inferred	from	group	membership.	In	cases	where	fewer	than	three	clusters	are	observed,	such	as	in	low	minor	allele	frequency,	locations	and	shapes	of	the	missing	clusters	are	estimated	by	 neural	 networks.	 A	 statistical	 score	 is	 estimated	 based	 on	 the	 confidence	 of	 the	cluster	calling,	(here:	the	GenTrain	score),	and	this	score	together	with	cluster	positions	and	shapes	is	used	to	filter	out	failed	genotypes,	DNAs	or	loci	[768].	Quality	control	(QC)	is	important	since	the	large	number	of	SNPs	tested	will	convert	even	a	low	error	rate	to	
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a	sizeable	number	of	false	calls	and	wasted	effort	in	replicating	the	results	afterwards.	QC	was	performed	by	PLINK	software	[769]	and	can	be	considered	“by	subject”	and	“by	marker”.	
“By	subject”	QC	consisted	of	 four	stages.	Briefly,	 individuals	were	excluded	if	they	had	discordant	 gender	 information	 compared	 to	 self-declared	 gender,	 missing	 genotype	rates	≥1%,	an	extreme	high	or	low	heterozygosity	rate,	related	or	duplicated	individuals	and	 those	with	 divergent	 genetic	 ancestry	were	 all	 excluded	 [770].	 These	 steps	were	undertaken	 for	 the	 following	 reasons.	 Discordant	 gender	 information	 may	 lead	 to	subjects	erroneously	labelled	as	male	to	have	all	heterozygous	X-chromosome	markers	called	 as	 “missing”	 since	 software	 surmises	 that	 heterozygosity	 cannot	 exist	 from	 a	single	chromosome.	Low	DNA	quality	or	concentration	can	result	in	lower	than	average	call	 rates	 and	 genotype	 accuracy.	 Our	 threshold	 for	 excluding	 subjects	 with	 missing	genotypes	was	 ≥1%	 -	 typical	 thresholds	 are	 up	 to	 7%	 [771,	 772].	 Likewise,	 outlying	heterozygosity	may	be	due	to	either	contamination	(high	level	of	heterozygosity)	or	in-breeding	 (low-level	 of	 heterozygosity).	 To	 prevent	 confounding	 by	 underlying	population	differences,	rather	than	the	phenotype	of	interest	“population	stratification”,	the	 genotype	 of	 the	 target	 population	 was	 compared	 to	 reference	 genotypes	 of	 four	known	ancestries	from	the	HapMap	Phase	III	study	using	EIGENSTRAT/smartpca	[773].	Subjects	 identified	 which	 matched	 the	 HapMap	 Phase	 III	 study	 Caucasian	 ancestry	group	were	retained	for	analysis.		
“By	markers”	QC	consisted	of	two	stages.	SNPs	which	deviated	significantly	from	Hardy-Weinberg	 equilibrium	 (HWE)	 (p	 <	 0.001)	 and	 those	with	 low	minor	 allele	 frequency	were	 excluded.	 Deviation	 from	 HWE	 can	 be	 a	 marker	 of	 genotype	 calling	 error	 and	
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similarly	low	frequency	alleles	are	unreliably	called	and	often	represent	false-positives	[770].		
	
Figure	11.2.	Post-sequencing	workflow		
After	subject	QC,	947	subjects	(438	males,	509	females)	remained	in	the	cohort	with	a	genotyping	 rate	 of	 0.997.	 After	 marker	 QC,	 618153	 SNPs	 were	 available	 (99201	excluded).	
After	QC,	phasing	(the	process	of	generating	haplotypes)	and	imputation	(predicting	the	intervening	alleles	based	on	reference	SNP	datasets)	were	performed	by	the	SHAPEIT	(version	2)	and	IMPUTE2	packages	respectively,	based	on	a	combined	reference	panel	from	1000	Genomes	and	UK10K.	SNPs	with	a	certainty	score	≤0.4	were	excluded	from	further	 analysis.	 IMPUTE2	 generates	 posterior	 probabilities	 for	 three	 allele	combinations	(AA,	Aa	and	aa)	at	each	position	and	these	are	converted	to	an	expected	
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genotype	 by	 converting	 to	 the	 codes	 0,1	 and	 2,	 multiplying	 by	 the	 posterior	probabilities	and	summing.	
11.2. Statistical	Analysis	To	 show	 the	 incremental	 benefit	 of	 different	 additions	 to	 the	 methodology,	 three	methods	 for	 analysing	 SNP	data	 are	 proposed.	 Firstly,	 a	 standard	 approach	 assessing	GWA	using	RVEDVI	and	RVEF	and	a	 frequentist	 association	method.	Secondly,	 the	3D	phenotype	will	be	used	in	place	of	volumetric	data	the	first	principal	component	of	the	wall	position	data	(as	an	equivalent	 to	volume)	and	of	 the	wall	displacement	distance	data.	In	both	cases	the	phenotype	will	have	covariates	of	gender,	age,	body	surface	area	and	 activity	 score	 to	 avoid	 confounding	 by	 these	 variables.	 Multiple-testing	 error	 in	both	these	approaches	will	be	corrected	by	the	false-discovery	rate	method	[576].	
Finally,	the	PEER	approach	will	be	applied,	as	described	above.	This	method	uses	the	3D	phenotypic	data	and	a	dimensionality	reduction	process	similar	to	PCA,	though	allows	for	 non-orthogonal	 components.	 The	 number	 of	 hidden	 factors	 is	 pre-specified	(typically	 100)	 though	 the	 influence	 of	 some	 hidden	 factors	 may	 be	 small	 due	 to	 a	rigorous	regularisation	process	in	the	algorithm	[208].		
11.3. Results	After	 quality	 control,	 phasing	 and	 imputation	 as	 described	 above,	 944	 Caucasian	subjects	 with	 9.5	 x	 106	 common	 variants	 were	 identified	 and	 used	 in	 genome-wide	association	tests.	Population	characteristics	are	described	in	Table	11.1.	
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	 Full	Cohort	
(n	=	944)	
Males	
(n	=	437)	
Females	
(n	=	507)	
p	value	
Age	(years)	 42.2	±	13.1	(18-81)	 42.5	±	12.8	(20	–	81)	 42.0	±	13.4	(18	–	75)	 0.55	
Height	(cm)	 171	±	9	 178	±	7	 165	±	6	 <0.001	
Weight	(kg)	 72	±	13	 80	±	12	 66	±	11	 <0.001	
BSA	(m2	)	 1.8	±	0.2	 2.0	±	0.2	 1.7	±	0.1	 <0.001	
BMI	(kg/m2)	 24.7	±	3.7	 25.2	±	3.3	 24.3	±	4.0	 <0.001	
RVEDV	(ml)	 170	±	39	(83	–	312)	 197	±	37	(106	–	312)		 146	±	24	(83	–	239)	 <0.001	
RVESV	(ml)	 72	±	24	(16	–	169)	 87	±	23	(37	–	169)	 59	±	15	(16	–	107)	 <0.001	
RVSV	(ml)	 97	±	20	(11	–	175)	 109	±	21	(11	–	175)	 87	±	14	(53	–	140)	 <0.001	
RVEF	(%)	 58	±	6	(40	–	80)	 56	±	6	(40	–	73)	 60	±	6	(40	–	80)	 <0.001	
RVEDVI	(ml/m2)	 91	±	16	(51	–	145)	 99	±	17	(55	–	145)	 85	±	13	(51	–	132)	 <0.001	
RVESVI	(ml/m2)	 39	±	11	(10	–	76)	 44	±	11	(21	–	76)	 34	±	9	(10	–	66)	 <0.001	
RVSVI	(ml/m2)	 53	±	9	(6	–	101)	 55	±	10	(6	–	101)	 50	±	7	(33	–	76)	 <0.001	
CI	(L/min)	 3.4	±	0.7	 3.4	±	0.7	 3.3	±	0.6	 0.01	
Cardiac	Output	(L)	 6.2	±	1.4	 6.8	±	1.5	 5.7	±	1.2	 <0.001	
Heart	Rate	(BPM)	 64	±	11	 63	±	11	 65	±	10	 0.001	
Activity	score	 64/363/351/164	 27/131/166/112	 37/232/185/52	 <0.001	
Table	11.1.	Digital	Heart	Project	anthropometric,	volumetric	and	haemodynamic	data	by	gender		
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The	results	of	the	first	two	stages	are	given	below:	
(a) RVEDVI (b) RVEF 
	 	
Figure	11.3.	Manhattan	plot	of	GWA	using	a	volumetric	phenotype	from	the	Digital	Heart	Project	
Plots show data from healthy subjects (n=947) in which indexed right ventricular end-diastolic volume (a) and 
right ventricular ejection fraction (b) were associated with common genotypic variants. The threshold for 
positive associations is p = 1 x 10-8 with p = 1 x 10-5 (blue line) “suggestive” of an association. Both analyses 
included control for gender, age, body surface area and activity score. 	
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(a) Wall position (b) Point displacement 
	
Figure	11.4.	Manhattan	plot	of	GWA	using	a	3D	phenotype	from	the	Digital	Heart	Project	
Both plots show data from healthy subjects (n=947) in which the 3D phenotype was summarised using the first 
principal component from principal component analysis. The 3D phenotype used was right ventricular wall 
position in (a) and right ventricular ejection fraction in (b). The threshold for positive associations is p = 1 x 10-8 
(red line) with p = 1 x 10-5 (blue line) “suggestive” of an association. Both analyses included control for gender, 
age, body surface area and activity score. 	
The	data	completing	these	investigations	using	PEER	is	not	available	currently.	
11.3.1. Conclusions	Early	 investigation	 of	 a	 common	 variant	 approach	 to	 understanding	 the	 genetic	determinants	 of	 RV	 structure	 and	 function	 in	 healthy	 subjects	 is	 feasible	 and	 has	demonstrated	 a	 small	 number	 of	 “suggestive”	 variants	 (i.e.	 p	 <	 1	 x	 10-5)	 though	 no	variants	 above	 the	 threshold	 1	 x	 10-8.	 Several	 methods	 may	 be	 used	 to	 increase	sensitivity	to	common	variants	with	small	individual	effects.	Increasing	sample	size,	3D	approaches	 using	 high-dimensional	 data	 and	 Bayesian	 methods	 which	 use	 prior	knowledge	may	improve	inference	on	a	clinically	important	question.	
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Future	 work	 will	 aim	 to	 complete	 the	 Bayesian	 approach	 to	 this	 analysis	 and	demonstrate	 whether	 these	 approaches	 bring	 added	 sensitivity	 to	 the	 detection	 of	common	influential	variants.	
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12. Thesis	Overview	This	 thesis	aims	to	contribute	 to	 the	understanding	of	anthropometric,	environmental	and	genetic	determinants	of	RV	structure	and	 function.	The	novel	 contribution	of	 this	work	 is	 the	 demonstration	 that	 high-resolution	 phenotyping	 methods	 with	 high-dimensional	 statistical	 approaches	 and	 using	 state	 of	 the	 art	 genetic	 sequencing	methods	can	offer	new	insights	to	an	important	clinical	problem.	
We	 initially	 demonstrated	 the	 feasibility	 and	 accuracy	 of	 applying	 3D	 high-resolution	approaches	to	RV	imaging	in	a	large	cohort	of	healthy	subjects	and	developed	the	first	high-resolution	 RV	 atlas	 from	 over	 one	 thousand	 subjects.	 This	 data	 was	 validated	against	 conventional	 2D	 approaches,	 and	 in	 so	 doing	 provided	 references	 ranges,	 a	demonstration	 of	 the	 influence	 of	 age,	 gender,	 exercise	 and	 race	 on	 ventricular	volumetrics	 and	 showed	 that	 allometric	 scaling	 removes	 the	 influences	 of	 body	 size	more	 effectively	 than	 ratiometric	 measures,	 allowing	 more	 subtle	 influences	 on	structure	and	function	to	be	recognised.		
We	 also	 demonstrated	 the	 accuracy	 of	 a	 semi-automated	 segmentation	 technique	against	 manual	 segmentation	 showing	 how	 automated	 segmentation	 techniques	 can	offer	quantification	which	cannot	be	achieved	manually.	This	reveals	the	opportunity	to	provide	 high-resolution	 quantitative	 phenotyping	 of	 the	 right	 ventricle	 on	 which	physiological	 “experiments”	 of	 human	 phenomics	 can	 be	 conducted.	 One	 such	experiment	 is	 to	 understand	 the	 regional	 correlates	 of	 global	 function	 and	 we	demonstrated	how	a	whole-ventricle	approach	allows	natural	optimisation	of	the	point	surrogate	 for	 global	 function,	while	 simultaneously	 demonstrating	 how	 such	markers	are	fundamentally	limited	in	the	extent	to	which	they	can	summarise	the	complexity	of	RV	function.	
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3D	 approaches	 bring	 large	 datasets	 with	 problems	 of	 multiple-testing,	 overfitting,	contiguity	 and	 computational	 burden	 and	 we	 present	 methods	 which	 address	 these	problems.	In	all	cases,	the	approach	taken	will	reflect	what	represent	tolerable	limits	of	approximation,	computational	power	and	statistical	“certainty”	and	as	we	have	seen	in	genomics,	no	doubt	the	rise	of	high-resolution	imaging	will	be	met	with	a	parallel	rise	in	analytical	 approaches.	 These	 are	 the	 first	 applications	 of	 threshold-free	 cluster	enhancement	and	 low-rank	matrix	completion	to	cardiac	datasets,	 though	cardiac	and	neuroimaging	 now	 share	 many	 of	 the	 same	 data	 problems	 so	 this	 transition	 seems	natural.	
We	 showed	 the	 difficulties	 of	 applying	 this	 technique	 to	 patients	with	 PH	 and	 how	 a	combined	approach	using	2D	and	3D	imaging	can	still	provide	accurate	3D	modelling	of	the	right	ventricle.	Given	the	prognostic	relevance	of	the	right	ventricle	and	the	drive	to	provide	 better	 phenotyping,	 an	 obvious	 demonstration	 of	 this	 technique	 was	 to	 test	whether	it	provided	better	prognostication.	We	demonstrated	that	3D	modelling	using	standard	imaging	acquired	at	initial	clinical	presentation	is	a	stronger	and	less	variable	predictor	than	all	current	haemodynamic	and	functional	markers	across	an	unselected	group	 of	 incident	 PH	 patients.	 Our	 3D	 approach	 allows	 mechanistic	 insights	 to	 be	offered	 simultaneously,	 which	 suggest	 that	 deterioration	 of	 longitudinal	 and	 radial	function	with	 compensatory	 increases	 in	 circumferential	 function	 form	a	 signature	 of	poor	survival.	Future	work	may	look	to	use	imaging	surrogates	for	treatment	goals	and	accelerate	clinical	decisions.	
We	 phenotype	 the	 PA	 by	 pulse	 wave	 velocity	 and	 show	 how	 vascular	 stiffness	 is	 a	significant	 contributor	 to	 prognostically	 significant	 changes	 in	 RV	 structure	 by	increasing	afterload.	Although	the	right	ventricle’s	susceptibility	to	increased	afterload	
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is	well	known,	this	work	dissects	out	the	contribution	of	PA	stiffness	and	demonstrates	the	importance	of	work	in	large	healthy	subject	cohorts	in	understanding	early	disease.	
Finally	we	apply	high-resolution	phenotyping	 to	understanding	 the	genetic	 influences	on	the	right	ventricle.	Titin	 truncating	variants	(TTNtv)	have	been	associated	with	RV	dysfunction	 in	 disease	 cohorts	 [176]	 	 but	 it	 is	 unclear	whether	 these	 effects	 are	 also	seen	 in	healthy	subjects.	We	show	a	weak	trend	towards	structural	but	not	 functional	differences	 in	 this	 group	 which	 volumetry	 was	 unable	 to	 demonstrate.	 Collaborative	work	with	pooling	of	 this	 rare	variant,	 coupled	with	3D	diastology	may	provide	more	incisive	answers	in	this	area.	We	contrast	this	with	the	first	genome-wide	approach	to	understanding	 RV	 structure	 and	 function	 and	 present	 preliminary	 data	 using	frequentist	 statistics.	 High-dimensional	 problems	 may	 improve	 sensitivity	 if	 prior	information	 and	 computational	 iterative	 approaches	 are	 applied	 and	 we	 discuss	 one	example	of	such	an	approach.	
12.1. Conclusions	This	thesis	demonstrates	that	3D	whole-ventricle	approaches	offer	significant	advances	on	 current	 phenotyping	 approaches.	 These	 approaches	 require	 appropriate	 analytical	tools	 but	 have	 the	 capacity	 to	 offer	 new	 insights	 to	 understanding	 the	 structure	 and	function	of	the	right	ventricle	in	health	and	its	progression	into	disease.	It	is	hoped	that	these	 insights	can	be	applied	clinically	by	 improving	understanding	of	RV	dysfunction	and	accelerate	the	development	of	treatment	for	an	important	clinical	problem.		
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13. Appendices	
13.1. Appendix	1.	Factors	Affecting	the	Signal-to-Noise	Ratio	
13.1.1. Slice	thickness	and	interslice	gap		The	 received	 signal	 comes	 from	 the	protons	 in	 the	 excited	 slice	plane.	 The	 larger	 the	slice	 plane,	 the	 larger	 the	number	 of	 excited	protons.	Assuming	 the	proton	density	 is	uniform	 across	 the	 region	 in	 question,	 signal	 increases	 proportionately	 with	 slice	thickness.	 In	spin	echo	sequences,	 interslice	gaps	are	necessary	because	the	RF	pulses	are	 imperfect	 causing	excitation	of	protons	 in	adjacent	 slices	 (“cross-talk”).	Cross-talk	produces	saturation	effects	reducing	SNR.	Although	some	interslice	gap	is	necessary	to	avoid	 this,	 it	 also	 reduces	 the	 acquired	 information.	 Multislice	 imaging	 avoids	 this	though	 scan	 times	 are	 longer.	 Alternatively	 gradient-echo	 sequences,	 which	 do	 not	require	 a	 1800	 pulse	 to	 refocus	 spins	 allow	 contiguous	 slices	 to	 be	 acquired	with	 no	interslice	gap.	
13.1.2. Receiver	bandwidth	The	bandwidth	is	the	range	of	frequencies	which	are	collected	by	the	scanner.	Although	a	 narrow	 bandwidth	 improves	 SNR,	motion	 artefacts	 and	 chemical	 shift	 artefacts	 are	worse	and	acquisition	time	is	longer.	
13.1.3. Matrix	and	pixel	size	and	field	of	view	A	matrix	is	a	two-dimensional	grid	consisting	of	picture-elements	(“pixels”).	The	size	of	the	pixels	can	be	calculated	from	the	field	of	view	in	each	direction	(phase-encoding	and	frequency-encoding	directions)	and	from	the	size	of	the	matrix.	Each	pixel	represents	a	
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three-dimensional	 volume	 element	 (“voxel”)	 when	 extended	 over	 the	 whole	 slice-thickness.	
If	the	matrix	size	is	constant	then	decreasing	the	FOV	also	decreases	the	pixel	and	voxel	size.	 This	 improves	 the	 spatial	 resolution,	 but	 reduces	 the	number	of	 excited	protons	which	 can	 be	 detected	 per	 voxel,	 assuming	 uniform	 proton	 density,	 reducing	 SNR.	Conversely,	increasing	the	matrix	size	for	the	same	FOV	improves	spatial	resolution	but	reduces	SNR	and	increases	scan	time.	
In	light	of	the	trade-offs	between	spatial	resolution,	SNR	and	scan	time,	it	is	important	to	consider	methods	which	may	be	primarily	used	to	improve	either	spatial	resolution	or	scan	time	but	which	may	also	impact	on	SNR.	Scan	time	is	affected	by	matrix	size	in	the	phase-encoding	direction,	whereas	spatial	resolution	is	affected	by	matrix	size	in	the	frequency-encoding	 direction.	 Reducing	 the	 FOV	 in	 the	 phase-encoding	 direction	therefore	 provides	 a	 convenient	 way	 of	 reducing	 scan	 time	 without	 affecting	 spatial	resolution,	though	it	also	incurs	a	small	reduction	in	SNR.	This	can	lead	to	wrap-around	artefacts	when	signal	in	the	phase-encoding	direction	is	mapped	backed	to	an	incorrect	location	 within	 the	 ROI	 but	 this	 can	 be	 suppressed	 by	 anti-aliasing	 tools.	 Other	techniques	 which	 acquire	 only	 a	 fraction	 of	 the	 k-space	 data	 (“partial	 k-space	acquisition”)	 in	 order	 to	 reduce	 scan	 time	 also	 reduce	 SNR.	 Partial	 Fourier	 imaging	acquires	 approximately	 half	 the	 k-space	 lines	 in	 the	 phase-encoding	 direction,	 while	partial	 echo	 imaging	 under-samples	 in	 the	 frequency-encoding	 direction.	 Both	technique	rely	on	k-space’s	inherent	symmetry	to	interpolate	the	missing	data	and	both	techniques	reduce	SNR.	
	328		
13.1.4. NEX,	field	strength	and	imaging	parameters	The	number	of	excitations	(NEX)	indicates	the	number	of	times	each	slice	is	measured.	Resampling	from	the	same	slice	increases	the	SNR	proportional	to	the	square	root	of	the	NEX,	though	scan	time	increases	proportionally.	The	static	field	strength	(B0)	affects	the	number	of	excess	spins	in	the	parallel	state	and	has	an	almost	linear	effect	on	the	signal	intensity,	 thus	 increasing	the	SNR.	Echo	time	(TE),	repetition	time	(TR),	 flip	angle	and	the	choice	of	sequence	all	influence	SNR.	Longer	TRs	increase	SNR	though	reduce	the	T1	effect.	Shorter	TEs	increase	SNR	though	reduce	the	T2	effect.		
Finally	the	choosing	a	coil	which	reduces	the	distance	between	transmission,	organ	and	reception	may	also	improve	SNR,	though	the	different	types	of	coil	are	considered	more	fully	elsewhere	[774-776].	
13.2. Appendix	2.	Weighted	Cluster	Norm	The	form	of	the	transformation	is	justified	by	considering	the	extent	values,	e(h)	as	real	vectors	whose	 overall	magnitude	 can	 be	 summarised	 using	 the	 p-norm	 of	 the	 extent	values12	[777].	Treating	h,	and	therefore	e(h),	as	continuous	variables:	
	 𝑝𝑛𝑜𝑟𝑚 =  𝑒(ℎ) !.𝑑ℎ!!!!!
!/!	 (13.1)	
																																																								12	The	“norm”	of	a	mathematical	object,	such	as	a	vector	or	a	matrix,	is	used	to	describe	the	 length,	 size	 or	 extent	 of	 an	 object	 depending	 on	 the	 object’s	 dimensions.	 In	 two-dimensional	 vector	 space	 this	 quantity	 is	 the	 “root	 mean	 square”,	 represents	 the	magnitude	 of	 the	 object,	 and	 is	 given	 by	 𝑥 =  𝑥!! +  𝑥!! +⋯+  𝑥!!	 .	 The	 formula	above	generalises	this	to	p-dimensional	objects.	
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This	equation	can	be	discretized	to	allow	numerical	estimation,	weighting	can	be	added	as	 a	 function	 of	 h,	 and	 p	 can	 be	 substituted	 for	 E.	 Lastly,	 the	 range	 over	 which	 the	discretised	integral	is	assessed	(ℎ! −  ∞)	can	be	represented	by	the	vector	k.	This	gives:		
	 𝑝𝑛𝑜𝑟𝑚 =  𝑤 ℎ!  . 𝑒(ℎ!) !  . 𝛿ℎ!
!/! 	 (13.2)	
The	significance	of	transformed	statistics	is	computed	by	permutation	testing	which	is	a	rank-based	method.	Since	E>0	and	hence	(1/E)>0,	this	term	will	not	affect	the	order	of	the	test	statistics	and	therefore	this	term	can	be	dropped	for	simplicity.	Therefore,	the	transformed	test	statistic	has	the	form:	
	 𝑇𝐹𝐶𝐸 𝑡 = ℎ! 𝑒(ℎ!)!!  .𝑑ℎ	 (13.3)	
13.3. Appendix	3.	Fisher’s	P-value	Combining	Theory	and	Random	Field	Theory	The	 form	 of	 the	 TFCE	 transformation	 is	 based	 on	 combining	 theory	 from	 Fisher’s	 P-value	 combining	 theory	and	 from	Random	Field	Theory.	The	 former	 is	used	 to	 justify	summing	the	values	calculated	from	each	subdivision,	δh,	to	form	an	overall	significance	level.	The	latter	is	used	to	justify	the	coefficients	E	and	H.		
13.3.1. Fisher’s	P-value	Combining	Theory	Several	methods	of	combining	P-values	have	been	proposed	[778],	though	the	optimal	method	may	 vary	 depending	 on	 whether	 signal	 is	 confined	 to	 one,	 or	 spread	 across	many,	subdivisions	 [779].	Fisher’s	method	may	be	particularly	appropriate	 for	signals	which	 are	 spread	 across	 a	 large	 number	 of	 subdivisions	 [779].	 When	 combining	 K	
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independent	tests,	the	joint	probability	of	event	occurrence	under	the	null	hypothesis	is	given	by:	
	 𝑝 =  −2 𝑙𝑜𝑔!𝑃!!!!!  ∝  𝜒!! 	 (13.4)	
Although	independence	is	violated	in	our	data	so	the	result	cannot	be	approximated	to	a	𝜒!,	 this	 approach	 suggests	 that	 summating	 –log	 p-values	 is	 a	 sensible	 approach	 to	combining	 individuals	 significance	 results	 [439].	 Thus,	 if	 we	 could	 chose	 coefficients	which	allow	the	numerical	method	to	replicate	the	–log	P-values	of	clusters	under	the	null	 hypothesis	 at	different	 thresholds,	 then	a	numerical	method	 for	 each	 subdivision	could	conclude	with	summating	these	values	into	an	overall	probability.	
13.4. Appendix	4.	Test-statistic	Cumulative	Distribution	Function	and	
Incremental	Significance	The	 shape	 of	 the	 cumulative	 distribution	 function	 may	 be	 used	 to	 motivate	 the	incremental	statistical	significance	for	each	subdivision	of	the	test	statistic.	For	Gaussian	distributed	statistics,	the	P-Value	at	a	z-value	of	h	is	given	by:	
	 𝑃 𝑇 ≥ ℎ =  1−  Φ h 	=  𝜙!! ℎ  𝑑𝑡	 (13.5)	
Hence:	
	 − log𝑃 𝑇 ≥ ℎ =  −log (1−Φ(h))	 (13.6)	
By	Mill’s	ratio,	[!! !(!)]!(!) 	has	an	upper	limit	of	!!	for	h>0		[780]	and	can	therefore	provide	the	following	approximation:	
	331		
-log	P	(T≥h)	 =  − log 1−  Φ h 	 (13.7)	
	 ≈  − log𝜙 ℎℎ 	 (13.8)	
	 = 12 log 2𝜋 +  ℎ!2 + log (ℎ)	 (13.9)	
Hence,	 ignoring	 the	 lower	 order	 terms,	 -log	 P	 values	 are	 roughly	 proportional	 to	 the	square	 of	 the	 test	 statistic,	 h.	 This	 suggests	 that	 hH	 is	 an	 acceptable	 form	 for	 the	relationship	 between	 –log	 P	 and	 h	 and	 that	 H=2	 is	 a	 sensible	 choice	 of	 power.	 To	illustrate	the	accuracy	of	 these	approximations,	Figure	13.1	shows	the	–log10	P-Values	produced	by	a	Gaussian	CDF	and	by	the	CDF	using	Mill’s	ratio.	
	
Figure	13.1.	Gaussian	Cumulative	Distribution	Function	and	an	Approximation	Using	Mills'	Ratio	
Red line indicates the cumulative distribution of the –log10 P-Values calculated from a Gaussian distribution as 
the z-values given. Blue line indicates the –log10 P-Values calculated from an approximated cumulative Gaussian 
distribution using the Mill’s ratio. 
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13.5. Appendix	5.	Random	Field	Theory	Random	Field	Theory	 (RFT)	 is	 an	 area	 of	mathematics	 developed	 to	 identify	 discrete	significance	 levels	 from	 manifolds	 with	 high,	 or	 important,	 spatial	 correlations.	 The	theory	 estimates	 the	 probability	 of	 different	 sized	 clusters	 appearing	 above	 different	threshold	for	a	given	type	of	statistic	(e.g.	z-,	t-,	F)	based	on	image	smoothness,	which	is	a	surrogate	for	spatial	correlation	(Figure	13.2).	
(a) (b) (c) 
	 	 	
Figure	13.2.	Spatial	correlation	and	manifold	smoothness		
Images	 of	 two-dimensional	 image	 fields	with	 test	 statistics	 highly	 correlated	 (R=0.98,	p<0.001),	 moderately	 correlated	 (R=0.68,	 p<0.001)	 and	 uncorrelated	 with	 spatial	coordinates	 (R=0.02,	 p=0.74).	 Highly	 correlated	 datasets	 correspond	 to	 high	smoothness	surfaces.		
RFT	predicts	 the	 frequency-distribution	of	 cluster	 size,	S,	 based	on	 the	distribution	of	the	cluster	volume	above	a	given	threshold,	T,	and	the	number	of	clusters	in	this	search	volume,	L.	The	expected	value,	E,	of	this	distribution	under	the	null	hypothesis	is	given	by:	
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	 𝐸 𝑆 =  𝐸(𝑁)𝐸(𝐿) 	 (13.10)	
The	numerator	and	denominator	can	be	calculated	here	as	follows.	E(N),	the	expected	value	from	the	distribution	of	search	volume	above	the	threshold	is	given	by:	
	 𝐸 𝑁 = 𝑉 . 1− 𝐹 𝑇 	 (13.11)	
where	V	 is	 the	 search	 volume	 above	 the	 threshold,	 T,	 and	F(T)	 is	 the	CDF	of	 the	 test	statistic	under	the	null.	For	TFCE,	this	 is	assumed	to	be	a	Gaussian	variable,	so	F(T)	is	equal	to	a	Gaussian	CDF.	
E(L),	 the	 expected	 number	 of	 clusters	 above	 the	 threshold,	 T,	 can	 be	 calculated	 from	two	quantities:	 the	RESEL	 count	 and	 the	Euler	Characteristic	 (EC)	of	 the	 surface.	The	RESEL	 count	 (RESolution	 ELements)	 is	 an	 estimation	 of	 the	 number	 of	 independent	spatial	 elements	within	 a	 voxel-space,	 and	 is	 therefore	 less	 than	 the	 total	 number	 of	voxels	 in	 surfaces	 which	 have	 spatial	 correlation	 between	 voxels.	 The	 number	 of	RESELs	 therefore	 is	 dependent	 on	 the	 number	 of	 voxels	 and	 the	 smoothness	 of	 the	surface	(Equation	(13.12))	smoother	surfaces	have	a	lower	RESEL	count.		
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑅𝐸𝑆𝐸𝐿𝑠 =  𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑉𝑜𝑥𝑒𝑙𝑠𝐹𝑢𝑙𝑙 −𝑊𝑖𝑑𝑡ℎ 𝐻𝑎𝑙𝑓 𝑀𝑎𝑥𝑖𝑚𝑢𝑚 𝑒𝑠𝑡𝑖𝑚𝑎𝑡𝑒 	 (13.12)		
Several	 methods	 of	 defining	 the	 smoothness	 of	 a	 surface	 have	 been	 suggested	 [588,	781]	and	summarised	[782]	of	which	the	Kiebel	method,	which	defines	smoothness	by	the	 Full-Width	Half	Maximum	estimate,	 is	 used	 for	 comparison	 by	 Smith	 and	Nichols	[439].	 However,	 the	 exact	 method	 of	 estimating	 smoothness	 is	 not	 relevant	 to	 this	discussion	and	the	 interested	reader	 is	referred	to	other	references	 for	 further	details	[439,	603,	782].	We	can	therefore	say:	
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	 𝐸 𝑆 ∝ 𝐸𝐶	 	(13.13)	
After	work	by	Worsley	[783],	EC	has	been	described	for	z-,	t-,		χ2	and	F-	statistics	for	up	to	 three	 dimensions.	 These	 definitions	 can	 be	 substituted	 into	 (13.13)	 –	 here	 for	 a	Gaussian	field	in	three	dimensions	-	to	give:	
E(S)	 ∝  𝑉 . (1−  Φ h )ℎ! − 1 .  𝑒!!.!!! 	 (13.14)	
	 ∝  𝜙 ℎ ℎℎ! − 1  . 𝑒!!! !. 2𝜋 !!	 (13.15)	
	 ∝  𝜙(ℎ)ℎ! − 1  . ℎ . 𝑒!!! !. 2𝜋 !!	 (13.16)	
	 ∝ (ℎ! − ℎ)!!	 (13.17)	
Lastly,	we	use	 the	 result	 that	 for	a	Gaussian	random	 field,	 at	high	 threshold	 level,	 the	probability	 distribution	 of	 cluster	 size	 to	 the	 power	 2/D	 follows	 an	 exponential	distribution	[784],	i.e.	
	 𝑓 𝑡;  ψ =  𝜓𝑒!!"  𝑥 ≥ 00         𝑥 < 0   	 (13.18)	
with	mean	=	1/ψ	where	ψ	is	defined	as:	
	 𝜓 =  Γ . D2 + 1 .𝐸 𝐿𝐸 𝑁
!!	 (13.19)	
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This	approximation	 is	 convenient	as	exponential	distributions	have	a	CDF	of	1-e-tψ,	P-Value	of	e-tψ	and	therefore	–log	P	=	tψ.	Therefore	the	–log	P-value	for	a	cluster	of	size	s	in	a	Gaussian	field,	which	is	given	by:	
	 − log𝑃! = 𝑠! ! Γ . D2 + 1 .𝐸 𝐿𝐸 𝑁
!!	 (13.20)	
which	in	3	dimensions	(D=3)	is:	
-log	Ps	 =   𝑠! ! Γ . 32+ 1ℎ! − ℎ !! ! !	 (13.21)	
	 ∝   𝑠ℎ! − ℎ !! ! !	 (13.22)	
	 ∝  𝑠 . (ℎ! − ℎ) ! !	 (13.23)	
Assuming	h3	>>	h	:	
	 ∝ 𝑠! ! . ℎ!	 (13.24)	
so	under	the	null	hypothesis	the	–log	P	values	increase	with	cluster	size	indexed	to	2/3.	this	 suggests	 that	 the	parameter	 labelled	E	 in	 the	original	 formulation	 should	 also	be	2/3.	 This	 value	 is	 influence	 by	 the	 level	 of	 the	 test	 statistic,	 h,	 and	 this	 derivation	suggests	that	–log	P	values	are	proportional	to	the	squared	value	of	h.	Therefore,	H=2	in	the	original	formulation.	
Smith	and	Nichols	aimed	to	optimise	these	parameters	using	simulated	signal	data	from	several	 test	 image	 shapes,	 and	 data	 from	 structural	MR	 images	 from	 a	 schizophrenia	
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study	 [785].	 Their	 work	 applied	 a	 Gaussian	 smoothed	 kernel	 to	 the	 images	 before	analysis	 and	 then	 compared	 voxelwise,	 cluster,	 TFCE	 and	wavelet	methods.	 For	 each	method	a	range	of	parameters	were	compared.	They	concluded	that	the	most	accurate	results,	by	receiver-operating	characteristics,	were	obtained	with	a	Gaussian	smoothing	kernel	with	 full	width	half-maximum	length	of	1.5	voxels,	and	with	E=0.5,	H=2.	These	values	have	therefore	been	suggested	for	future	analyses.		
13.6. Appendix	6.	Heteroscedasticity-Consistent	Estimators	This	 appendix	 describes	 several	 suggested	 diagonal	 components	 (ω1,	 …	 ,	 ωn)	 of	 the	matrix	omega,	which	can	be	used	to	derive	the	variance	of	coefficients,	from	which	the	standard	 error	 	 can	 be	 calculated	 and	 inferences	 me	 for	 heteroscedastic	 data.	 All	normalise	 the	 squared	 residuals	 for	 each	 observation,	 𝜖!! 	 using	 combinations	 of:	 the	number	 of	 observations,	 N,	 the	 number	 of	 covariates,	 k,	 and	 the	 leverages	 of	 each	point13,	 hi.	 Some	 formulations	 limit	 the	 degree	 of	 normalisation	 to	 prevent	 excessive	influence	of	outlier	values	using	𝜕! 	which	 is	 set	 as	 the	 smaller	value	of	4	and	hi/ℎ,	 or	more	succinctly	:	𝜕! = 𝑚𝑖𝑛 4, ℎ!/ℎ .	
const.	 𝜔! =  𝜎!	 (13.25)	
HC0:	 𝜔! =  𝜖!!	 (13.26)	
HC1:	 𝜔! =  𝑁𝑁 − 𝑘  𝜖!!	 (13.27)	
HC2:	 𝜔! =  𝜖!!1− ℎ!  	 (13.28)	
																																																								13	Defined	as	the	diagonal	of	the	matrix:	X	.	(XT	X)-1	.	XT	
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HC3:	 𝜔! =  𝜖!!1− ℎ! !	 (13.29)	
HC4:	 𝜔! =  𝜖!!(1− ℎ!)!! 	 (13.30)	
HC4m:	
𝜔! =  𝜖!!1− ℎ! !! 	
𝛿! = 𝑚𝑖𝑛 1.0,𝑛ℎ!𝑝
+𝑚𝑖𝑛 1.5,𝑛ℎ!𝑝 	
(13.31)	
	HC0	is	the	“White	estimator”	and	is	perhaps	the	most	commonly	used	[596].	HC1-3	are	suggested	 to	 be	 more	 accurate	 for	 small	 sample	 sizes	 (N	 <	 250)	 [594],	 with	 some	suggestion	 that	 HC3	 may	 provide	 the	 best	 performance	 in	 small	 sample	 sizes	 as	 it	reduces	 the	 impact	of	 single	 influential	 observations	 [597].	HC4	may	 further	 improve	this	 performance	 by	 setting	 an	 upper	 bound	 on	 the	 denominator’s	 index	 of	 4	 [598].	HC4m	 provides	 incremental	 accuracy	 on	 HC4	 with	 coefficients	 empirically	 identified	[786].	
13.7. Appendix	7.	Voxelwise	Sample	Size	Calculations	To	 simplify	 calculations	 the	 11,262	 points	 across	 the	 right	 ventricle	were	 considered	independently	 and	 sample	 size	 calculations	 were	 performed	 at	 each	 point.	 From	 the	cohort	of	20	healthy	subjects	who	were	scanned	twice,	the	differences	in	point	position	between	 the	 two	 scans	 were	 compared	 and	 a	 segmentation	 error	 estimated	 at	 each	point.	Thus	each	point	have	20	error	estimations	which	were	assumed	to	be	normally	
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distributed	of	mean	0,	 from	which	 the	standard	deviation	of	 the	distribution	could	be	estimated.	From	this,	the	sample	size	needed	to	detect	a	difference	in	point	position	of	∂	(we	used	5mm)	can	be	calculated	as:	
𝑆𝑎𝑚𝑝𝑙𝑒 𝑠𝑖𝑧𝑒 =  2 . 𝑓 𝛼,𝑝 𝜎!!𝜕! 	
where	f(𝛼,p)	=	 (𝑢! +  𝑢! !!! )	where	𝑢! 	is	the	value	of	the	normal	distribution	(mean	0,	variance	1)	such	that	the	probability	of	lying	between	−𝑢! 	and	+𝑢! 	is	1-𝛼.	Alpha	and	p	can	 be	 set	 as	 necessary.	 We	 chose	 𝛼=0.05	 and	 p=0.9.	 To	 account	 for	 multiple	comparisons,	𝛼was	corrected	using	the	Bonferroni	correction,	i.e.	𝛼	/	number	of	tests.		
The	 sample	 size	was	calculated	at	each	point	and	 the	percentage	 reduction	 in	 sample	size	 at	 each	 point	 for	 3D	 segmentation	 over	 2D	 segmentation	was	 calculated	 at	 each	point	as:	
!"#$%& !"#$!!! !"#$%& !"#$!!!"#$%& !"#$!! × 100		 	
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